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Abstract 
This is the fifth in the series of reviews developed as part of the Biomarkers of Nutrition for Development (BOND) pro- 
gram. The BOND Iron Expert Panel (I-EP) reviewed the extant knowledge regarding iron biology, public health implica- 
tions, and the relative usefulness of currently available biomarkers of iron status from deficiency to overload. Approaches 
to assessing intake, including bioavailability, are also covered. The report also covers technical and laboratory considera- 
tions for the use of available biomarkers of iron status, and concludes with a description of research priorities along with 
a brief discussion of new biomarkers with potential for use across the spectrum of activities related to the study of iron 
in human health. The I-EP concluded that current iron biomarkers are reliable for accurately assessing many aspects of 
iron nutrition. However, a clear distinction is made between the relative strengths of biomarkers to assess hematological 
consequences of iron deficiency versus other putative functional outcomes, particularly the relationship between mater- 
nal and fetal iron status during pregnancy, birth outcomes, and infant cognitive, motor and emotional development. The 
I-EP also highlighted the importance of considering the confounding effects of inflammation and infection on the inter- 
pretation of iron biomarker results, as well as the impact of life stage. Finally, alternative approaches to the evaluation of 
the risk for nutritional iron overload at the population level are presented, because the currently designated upper limits 
for the biomarker generally employed (serum ferritin) may not differentiate between true iron overload and the effects 
of subclinical inflammation. 
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Introduction 
TheBiomarkers of Nutrition for Development (BOND) project 
is designed to provide evidence-based advice to anyone with an 
interest in the role of nutrition in health. Specifically, the BOND 
program provides state-of-the-art information with regard to 
the selection, use, and interpretation of biomarkers of nutrient 
exposure, status, function, and effect (1). To accomplish this 
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 objective, Iron Expert Panel (I-EP) members were recruited to 
evaluate the literature and draft comprehensive reports on the 
current state of the science with regard to specific nutrient bi- 
ology and available biomarkers for assessing nutrient status at 
clinical and population levels. 
Phase I of the BOND project included the evaluation of 
biomarkers for six nutrients: iodine, iron, zinc, folate,  vita-  
min A, and vitamin B12. The reviews for iodine,  zinc,  vita-  
min A, and folate have been published previously (2–5). Read- 
ers interested in obtaining information on iodine or folate 
biomarkers that might be of use to their specific needs are 
encouraged to utilize the interactive BOND Query-Based Sys- 
tem located on the BOND website: http://www.nichd.nih.gov/ 
global_nutrition/programs/bond/Pages/index.aspx 
This review represents the fifth in the series of reviews and 
covers all aspects of iron biology relevant to the discovery, selec- 
tion, use, and interpretation of biomarkers. The paper is orga- 
nized to provide the reader with a full appreciation of the back- 
ground history of iron as a public health issue, its biology, and 
an overview of available biomarkers. Specific considerations for 
the use and interpretation of biomarkers of iron nutrition across 
a range of clinical and population-based applications are de- 
scribed. The paper also highlights priority research needs for 
moving this important global health agenda forward. 
 
The biological importance of iron 
Iron is the fourth most abundant element in the earth’s crust 
and an essential component of almost all biological systems. 
 
the EP may not endorse all statements in this report. The original EP consisted 
of SL (chair), CMP, MG, GB, SFT, RFH, HJM, and DJR. The BOND project thanks 
the European Recommendations Aligned (EURRECA) program, the Micronutri- 
ent Genomics Project (MGP), the WHO and the CDC for their partnership. 
Author disclosures: SL, CMP, MKG, GB, SF-T, RFH, HJM, and DJR, no conflicts 
of interest. 
Supplemental Table 1 is available from the “Supplementary data” link in the 
online posting of the article and from the same link in the online table of contents 
at https://academic.oup.com/jn/. 
Address correspondence to DJR (e-mail: raitend@mail.nih.gov). 
Abbreviations used: ACD, anemia of chronic disease; ACT, α1-antichymotrypsin; 
AGP, α1-acid glycoprotein; AOAC, Association of Official Analytical Chemists; 
APP, acute-phase protein; APR, acute-phase response; BMP, bone morpho- 
genetic protein; BOND, Biomarkers of Nutrition for Development; BRINDA, 
biomarkers reflecting inflammation and nutrition determinants of anemia; CHr, 
reticulocyte hemoglobin content; CNPase, cyclic nucleotide 3-phophohydrolase; 
CRP, C-reactive protein; DCYTB, duodenal cytochrome b; DMT-1, divalent metal 
transporter 1; DR, dietary record; EFSA, European Food Safety Authority; EP, 
erythrocyte protoporphyrin; ERFE, erythroferrone; EuroFIR, European Food In- 
formation Resource; EURRECA, European Recommendations Aligned; FAO, 
Food and Agriculture Organization of the United Nations; FEP, free erythro- 
cyte protoporphyrin; FPN, ferroportin; GAIN, Global Alliance for Improved Nu- 
trition; HAMP, gene encoding hepcidin; HbE, hemoglobin E; Hct, hematocrit; 
HFE, human hemochromatosis; HIF-1, hypoxia inducible factor 1; HIF2α, hypoxia 
inducible factor 2α; HJV, hemojuvelin; ICSH, International Council for Standard- 
ization in Haematology; IDA, iron-deficiency anemia; I-EP, Iron Expert Panel; 
INSPIRE, Inflammation and Nutrition Science for Program/Policy and Interpreta- 
tion for Research Evidence; IRIDA, iron-refractory iron-deficiency anemia; IRE, 
iron-responsive element; IRP, iron-regulatory protein; MCH, mean corpuscular 
hemoglobin; MCV, mean corpuscular volume; mTOR, mechanistic (mammalian) 
target of rapamycin; NaFeEDTA, sodium iron ethylene diamine tetraacetic acid; 
NRAMP2, natural resistance-associated macrophage protein 2; PSC, preschool 
children; PT, proficiency testing; QA, quality assessment; QC, quality control; 
RAS/RAF MAPK, rapidly accelerated fibrosarcoma mitogen-activated protein ki- 
nase; RDW, red blood cell distribution width; Ret He, reticulocyte hemoglobin 
equivalent; RNI, recommended nutrient intake; SF, serum ferritin; sHJV, soluble 
hemojuvelin; sTfR, serum (soluble, plasma) transferrin receptor; SMAD, sons 
of mothers against decapentaplegic; TB, tuberculosis; TfR, transferrin receptor; 
TIBC, total iron-binding capacity; TSAT, percentage transferrin saturation; T3, tri- 
iodothyronine; T4, thyroxine; TTSP, type-two transmembrane serine protease; 
UIBC, unsaturated iron binding capacity; WRA, women of reproductive age; ZPP, 
zinc protoporphyrin; ZPP/H, zinc protoporphyrin/heme ratio. 
 
Humans require iron for energy production, oxygen transport 
and utilization, cellular proliferation, and pathogen destruction. 
Some of the seminal events in the evolution of our understand- 
ing of iron in human health are outlined in Text Box 1 (6–21). 
 
 
Text Box 1 
Historical landmarks in iron biology 
• Hippocrates (c 460 BC–c 370 BC) is credited as the 
first physician to use iron as a topical therapeutic styptic. 
• 1574: Nicolas Bautista Monardes (1493–1588) 
published on the use of iron to treat a variety of systemic 
illnesses (http://www.library.nd.edu/rarebooks/exhibits/ 
durand/indies/monardes.html) (6, 7). 
• 1681: Sydenham is credited with first recognizing the 
value of iron therapy for treatment of chlorosis (“green 
sickness”), a commonly recognized disorder prevalent 
among young women in in the 18th and 19th centuries  
(6, 7). 
• 1713: Nicolas Lemery and Etienne Geoffroy first 
demonstrated the presence of iron in blood. 
• 1831: Pierre Blaud, reported successful treatment of 
the chlorosis with a combination of ferrous sulfate and 
potassium carbonate (“Blaud’s pill”) (8). 
• Amand Trousseau (1801–67) documented the use of 
oral iron compounds and was the first to report the po- 
tential risk of giving therapeutic doses of iron to patients 
suffering from tuberculosis (9, 10). 
• 1919: George Washington Carey recognized the im- 
portance of iron for oxygen transport: “It is not simply the 
heat that causes distress in a fever patient, but it is the lack 
of oxygen in the blood due to a deficiency in iron, the car- 
rier of oxygen” (11). 
• 1925: Fontes and Thivolle discovered that there are 
small quantities of iron in the plasma and the concentration 
is decreased in experimentally induced anemia. 
• 1932: Heath, Strauss and Castle provided incontro- 
vertible evidence that parenterally administered iron im- 
proved hemoglobin levels in patients with hypochromic 
anemia. They also recognized the importance of iron for 
the normal function of other tissues although most of their 
attention was focused on what could be observed clin- 
ically, i.e., abnormalities of the nails, skin and mucosae 
(12). 
• 1925: The plasma iron transport protein transferrin 
was identified during the subsequent two decades (13). 
• 1937: Laufberger crystalized the iron storage protein 
ferritin from a horse’s spleen (14). 
• 1937: McCance and Widdowson (15) concluded that: 
1) iron is stored in the body and there are significant sex 
differences; 2) healthy adults maintain iron balance despite 
differences in dietary intake; 3) unlike some other minerals 
very little iron is excreted in the urine; 4) the amount of iron 
in the feces varies but is approximately equal to the amount 
consumed in food, implying that only a small proportion 
of dietary iron is absorbed; however, 5) because their meth- 
ods were insufficiently sensitive to demonstrate that iron 
absorption is highly regulated, they concluded that there 
was no mucosal control. 
• 1943: Hahn and Whipple demonstrated that: 1) iron 
absorption is highly regulated and affected by anemia, hy- 
poxia, and recent antecedent intake (16); and 2) to account 
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The unique biological properties of iron stem from the 
marked variability of the Fe2+/Fe3+ redox potential which al- 
lows iron sites to have redox potentials from –0.5 V to  0.6 
V, encompassing virtually the entire biologically relevant range. 
Protein ligands adapt these redox potentials to meet biologi- 
cal requirements (22). The Micronutrient Genomics Project (23) 
provides a comprehensive list of iron-requiring proteins, includ- 
ing enzymes, controlling factors, transporters, and storage pro- 
teins, with the relevant genetic information. The GWAS web- 
site (24) catalogues single nucleotide polymorphisms associated 
with iron overload and iron deficiency (22, 25). A classification 
system for iron-containing proteins based on biochemical func- 
tion in humans was proposed by Crichton (22) and is outlined 
in Text Box 2. 
 
Food sources and iron bioavailability 
Foods that have relatively high iron content include liver, red 
meat, beans, nuts, green leafy vegetables, and fortified breakfast 
cereals, but iron absorption is very variable. For the purposes of 
this review, bioavailability is the term used to describe the ex- 
tent to which iron is absorbed from the diet and used for normal 
body functions, which include incorporation into hemoglobin, 
ferritin, and iron enzymes (26, 27). Throughout this review we 
always use the nutritional definition of iron bioavailability. This 
includes both the absorption and utilization of iron. Iron, unlike 
other minerals, has no regulated excretion pathway, so absorbed 
iron is more or less completely utilized for functional or storage 
proteins. Bioavailability includes the iron used for storage, and 
absorption and bioavailability are used synonymously. The his- 
tory of the landmark observations that provided the basis for 
our understanding of bioavailability is summarized in Text Box 
3 (28–46). 
 
 
 
 
Text Box 2 
Classification scheme for functional iron-containing pro- 
teins in human biology 
Hemoproteins 
The iron atoms in hemoproteins are bound to the four 
pyrrole rings of protoporphyrin IX (heme) and to one or 
two axial ligands in the protein. There are three types of 
hemoproteins: 
• Oxygen carriers: 
-Hemoglobin is the oxygen transporter in red blood 
cells. Hemoglobin binds oxygen in the lung and transports 
it throughout the body where it is used in aerobic metabolic 
pathways. 
-Myoglobin is found in muscle tissue where it tem- 
porarily stores oxygen making it readily available during 
episodes of oxygen deprivation. 
• Activators of molecular oxygen: 
-Cytochrome oxidase 
-Peroxidases 
-Catalases 
-Cytochrome P450s 
• Electron transport proteins: 
-Cytochromes transfer electrons from substrate oxida- 
tion to cytochrome c oxidase. 
Iron-sulfur proteins 
• Iron-sulfur proteins mediate one electron redox pro- 
cesses as integral components of the respiratory chain in 
mitochondria. 
• They are also involved in many other metabolic pro- 
cesses including the control of gene expression, DNA dam- 
age recognition and repair, oxygen and nitrogen sensing, 
and the control of cellular iron acquisition and storage. 
Other iron-containing proteins 
• Mononuclear non-heme iron enzymes 
• Dinuclear non-heme iron enzymes 
• Proteins involved in iron transport and storage 
for the regulation of iron balance they proposed that a 
“mucosal block” occurs when the absorbing surface is ex- 
posed to large quantities of iron limiting further absorp- 
tion. Subsequent experiments revealed that the mucosal 
block is not absolute and that body iron status has an im- 
portant regulatory role in modulating iron absorption (17). 
• 1963: Conrad and Crosby (18) demonstrated that: 1) 
radioactive iron administered to rats enters mucosal cells; 
and 2) when iron requirements are high, the iron is ex- 
ported to the portal circulation; when low, the iron remains 
in the mucosal cells, as these cells are sloughed from the villi 
absorption. 
• 1997–2000: A mucosal iron transporter, respon- 
sible for nonheme iron absorption, divalent metal 
transporter 1 (DMT-1, also known as divalent cation 
transporter), natural resistance-associated macrophage 
protein (NRAMP2) (19), and the cellular iron exporter, 
ferroportin (20) were identified. 
• 2001: Park et al. (21) coined the name “hepcidin” to 
describe a peptide that we now understand to be a major 
regulator of iron absorption and homeostasis. 
after ∼48 h taking the iron with them and thereby limiting 
 
Text Box 3 
Landmarks in the study of iron bioavailability 
• McCance, Edgecombe and Widdowson initiated the 
study of dietary zinc and iron bioavailability and the in- 
hibitory effect of phytate (28). 
• Iron bioavailability studies were facilitated in the late 
1940s and 1950s by the availability of two radioisotopes of 
iron, 55Fe and 59Fe (29, 30). Iron absorption and bioavail- 
ability are synonymous and were estimated based on the 
measured incorporation of iron isotopes into hemoglobin. 
• Observations by Dubach et al. (31) and Moore and 
Dubach (30) simplified the methodical approach to mea- 
suring food iron absorption and bioavailability, demon- 
strating that 2 wk after the ingestion of radio iron, a mean 
of 80% of the amount absorbed is present in the circulat- 
ing red blood cells in healthy human volunteers, making it 
unnecessary to undertake whole body counting. 
• Layrisse et al. (32) demonstrated that absorption and 
bioavailability from a food item in a meal is a property of 
the composition of the meal, not of the specific food item, 
which led to the “common pool” concept of iron absorp- 
tion and removed the necessity to tag individual food items 
(intrinsic labeling) when measuring nonheme iron absorp- 
tion. A soluble isotopic tracer can be added to the meal. Its 
  
 
The two major forms of food iron are heme iron in meat 
products (10–15% of daily dietary iron intake in populations 
that eat meat) and non-heme iron in both plant foods and ani- 
mal source foods, including meat (47). Ferritin iron, present at 
fairly high levels in liver and legume seeds such as beans, and the 
various forms of iron used for food fortification, are important 
sources of non-heme iron. Heme iron is always well absorbed. 
On the other hand, the absorption of non-heme  iron, includ- 
ing ferritin iron, depends on the iron status of the individual 
consuming the meal as well as its composition. Text Box 4 (44, 
47–55) contains some key points regarding the various sources 
of iron. 
 
 
 
Factors which influence  non-heme  iron  bioavailability.  
Food components influence iron bioavailability by influencing 
iron absorption but have no influence on iron utilization. Food 
components that are inhibitors of non-heme  iron absorption  
in general bind iron in the gastrointestinal tract and prevent  
its absorption, whereas enhancers of iron absorption are food 
components that weaken or prevent iron binding by inhibitory 
compounds by reducing the more reactive ferric iron to its less 
reactive ferrous state or additionally by binding iron in bioavail- 
able complexes, thus preventing its binding to the inhibitor. 
Table 1 contains descriptions of the most common factors af- 
fecting iron absorption (26, 42, 44, 46, 52, 56–75). 
 
Fortification iron. Iron bioavailability in relation to fortifi- 
cation compounds refers to both absorption and utilization, 
although the properties of the iron fortification compounds 
influence only iron absorption. The properties, including 
relative bioavailability, of iron compounds used in food fortifi- 
cation have been extensively reviewed (76). The order of pref- 
erence for use in food fortification is as follows (77): 1) ferrous 
sulfate; 2) ferrous fumarate; 3) encapsulated ferrous sulfate or 
encapsulated ferrous fumarate; 4) electrolytic iron (a pure form 
of small particle size iron powder produced by an electrolytic 
processe) or ferric pyrophosphate; 5) sodium iron ethylene di- 
amine tetraacetic acid (NaFeEDTA) (78) is preferred for phytic- 
acid-containing foods; 6) iron amino acid chelates, particularly 
iron-glycinate chelates, have also been used as iron supplements 
and as food fortificants for liquid milk, dairy products, wheat 
rolls, and multinutrient beverages (79, 80). However, more 
rigorous trials are required to establish their potential utility. 
Text Box 5 (57, 58, 76–79, 81–83) contains some general 
caveats about the use of iron fortificants and enhancers of iron 
absorption). 
 
Nutrient-nutrient interactions.  Iron,  iodine,  and  vitamin  A 
are the most common micronutrient deficiencies and often 
occur concurrently in infants, women, and children in resource- 
constrained settings. Deficiencies are most often due to higher 
requirements of these risk groups, low dietary intake, and poor 
bioavilability in food sources (84). In addition to the multiple 
 
Text Box 4 
Relative absorption of dietary sources of iron 
Heme iron 
• Muscle tissue contains heme iron in the form of 
hemoglobin and myoglobin. 
• Heme iron is estimated to contribute 10–15% of the 
total iron in meat-eating populations, but because of its 
higher and more uniform absorption (estimated at 15– 
35%), it may contribute up to 40% or more of the total 
absorbed iron (47). 
• The proportion of heme iron in lean meats ranges from 
∼30% in white meats to ∼70% in red meats (48). 
Ferritin iron 
• Liver is rich in ferritin iron. 
• Legume seeds such as beans may also contain up to 
30% of their iron as ferritin iron (49). 
• Recent studies indicate that iron in plant ferritin is 
readily released during cooking and digestion (50). 
• In humans, ferritin iron is absorbed to the same extent 
as ferrous sulfate when consumed in a meal (51). 
Nonheme iron 
• Present in plant and animal foods. 
• Varies widely in absorption from <1% to >90% de- 
pending on the iron status of the consumer and the pres- 
ence of iron absorption inhibitors or enhancers in the food. 
-The iron in beans and leafy vegetables, for example, is 
poorly absorbed due to the presence of phytate and phe- 
nolic compounds (44, 52). 
-When these foods are consumed in composite meals 
together with foods providing iron absorption enhancers, 
such as ascorbic acid and muscle tissue, absorption may be 
increased to nutritionally useful levels (53, 54). 
Fortification iron (e.g., ferrous sulfate, ferrous fumarate; 
for full list see below) 
• Added to foods including cereal products, infant foods, 
condiments, milk and dairy products, and meal replace- 
ments. 
• Iron compounds that are soluble in water or dilute 
acid enter the common nonheme iron pool in the gastroin- 
testinal tract and are absorbed to the same extent as native 
nonheme iron compounds in the meal. 
• Some iron fortification compounds, however, are not 
soluble in the gastric acid, so do not fully enter the common 
iron pool, and are poorly absorbed (48, 55). 
absorption and bioavailability will reflect the overall ab- 
sorption and bioavailability from the meal (33, 34). 
• This model was expanded to recognize the indepen- 
dent absorption of heme iron and the existence of contam- 
inant iron, i.e., insoluble nonfood iron derived from dust, 
processing machinery, and cooking utensils (35) in the diet 
that is not available for absorption (36). 
• Radio-isotope methodology has now been largely re- 
placed by stable isotopes (37). 
• The important enhancers and inhibitors of iron ab- 
sorption have been identified. 
-Ascorbic acid (38), and, to a lesser extent, other organic 
acids (39) and animal tissue (40, 41) are the most effective 
enhancers of nonheme iron absorption. 
-Phytate (42, 43) and polyphenols (44, 45) are the most 
important inhibitors; calcium reduces iron absorption in 
single-meal studies (46). 
 TABLE 1 Common factors affecting iron absorption 
Factor Description 
 
Inhibitors 
Phytic acid (myo-inositol 
hexaphosphate) 
• The main inhibitor of nonheme iron absorption from plant-based diets 
• Relatively high levels are found in whole grain cereals and legume seeds 
• A dose-dependent effect on iron absorption that starts at very low concentrations (42, 56) 
• At phytic acid:iron molar ratios >6, iron absorption is greatly inhibited from composite meals containing small amounts of enhancing 
components, whereas in cereal or soy meals with no enhancers, iron absorption is greatly inhibited by a molar ratio >1 (26) 
• Food-processing methods, such as milling, germination, fermentation, and the addition of phytase enzymes, can be used to degrade phytic 
acid and improve iron absorption from traditional or processed foods (57) 
• Ascorbic acid reverses the inhibitory effect of phytate 
• Ascorbic acid:iron molar ratio of 2:1 or 4:1 is recommended to overcome phytic acid inhibition of iron absorption in cereal foods that can be 
packaged to avoid ascorbic acid losses during storage (58) 
• EDTA will also overcome phytate inhibition in fortified foods such as wheat flour (59) 
Polyphenols • Inhibit iron absorption in a dose-dependent way, although the strength of the binding depends on the structure of the phenolic compound 
• Sources include: beverages (tea, coffee, cocoa, red wine) (60), vegetables (spinach, aubergine) (61), legumes (colored beans) (52), and 
cereals such as sorghum (44) 
• Polyphenol compounds vary widely in structure and extent of polymerization 
• The gallate-containing tea polyphenols appear to be most inhibitory (60) 
• Sorghum polyphenols are also very inhibitory 
• Although colored bean and sorghum varieties containing high levels of phytate and polyphenols are strongly inhibitory (48), the polyphenol 
inhibition is small relative to phytate inhibition (62). 
• Ascorbic acid, and to a lesser extent EDTA, will overcome the polyphenol inhibition of iron absorption (63) 
Calcium • Calcium is a relatively weak iron absorption inhibitor causing a dose-dependent inhibition in simple meals but little or no inhibition in 
complex meals containing absorption enhancers (46) 
• In a small bread meal, inhibition of iron absorption was dose related ≤ 300 mg Ca, with 165 mg Ca causing ∼50% inhibition whether added 
as calcium chloride or 150 mL milk (64) 
• The same quantity of milk added to a meal of steak, carrots, French fries, Camembert cheese, apple, bread, and water had no effect (65) 
• Ascorbic acid readily overcomes the calcium inhibition of iron absorption (66) 
Protein • Peptides from partially digested food proteins can inhibit iron absorption depending on their nature 
• Peptides from legume proteins and some milk proteins are inhibitory 
• The inhibitory nature of soy protein may be due to the peptides formed on digestion of the conglycinin fraction (67) 
• The inhibitory nature of casein is thought to be due to nonabsorbable complexes formed between iron and casein phosphopeptides (68) 
Enhancers 
Ascorbic acid (vitamin C) • Ascorbic acid is the best-known and most potent enhancer of iron absorption either when present in fruits and vegetables (69) or added to 
fortified foods as the pure compound 
• Its facilitating effect is due to its ability to convert ferric to ferrous iron at low pH and to its chelating properties (70) 
• Its effect is dose dependent and it can overcome much or all of the inhibition related to other food components as well as enhance the 
absorption of all currently available iron fortification compounds (71) except NaFeEDTA (72) 
• Its main disadvantage is that it is sensitive to losses during food processing, storage, and cooking because of oxidation 
Muscle tissue • Muscle tissue from beef, lamb, chicken, pork, and fish, as well as liver tissue, enhance iron absorption from inhibitory meals (73) 
• The mechanism is currently presumed to be linked to partially digested peptides 
• Cysteine-containing peptides could potentially reduce ferric iron to the ferrous form and chelate iron in the same way as ascorbic acid; the 
facilitating effect of enzymatically digested beef extract can be removed by oxidizing the cysteine residues (74) 
• Unlike other food proteins, muscle proteins are rapidly digested by pepsin; conceivably, the infusion of small peptides in the jejunum could 
be responsible for solubilizing iron and improving absorption (75) 
 
exposure scenarios, it is also important to recognize that 
nutrients do not function in isolation and often interact within 
common pathways and biological systems. Examples of these 
types of interactions include the influence of iron deficiency on 
iodine utilization and the role of vitamin A, riboflavin, folic 
acid, vitamin B12, and ascorbic acid as potential causes of ane- 
mia (85). These complex interactions demand a more integrated 
approach to nutritional assessment in the global health context. 
Text Box 6 (84, 86–96) contains some examples of iron- 
nutrient interactions. It is not a comprehensive list, but focuses 
on some of the best characterized of these interactions. Although 
uncertainty remains with regard to the implications of these 
interactions, the intent is to highlight both the need for more 
research and for awareness of their relationships, particularly 
in the context of nutritional assessment at both individual and 
population levels. 
 
Text Box 5 
General caveats regarding commonly used iron fortificants 
• WHO/FAO (2006) provided recommendations for 
iron compounds to be added to specific foods, including ce- 
real products, condiments, milk, and cocoa products (78). 
• Iron absorption from electrolytic iron and ferric py- 
rophosphate added to foods is only half the iron absorp- 
tion from ferrous sulfate. In order to ensure an adequate 
iron absorption from a fortified food, the iron fortification 
level when using electrolytic iron and ferric pyrophosphate 
should be twice the fortification level when using ferrous 
sulfate (76, 77). 
  
 
 
Criteria for categorizing bioavailable iron intake (dietary 
reference intakes). Nutritional requirements for iron are 
markedly affected by the life stage of the individual (age, sex, 
and in the case of women, pregnancy). Various reference values 
for iron intake at the population level have been published, tak- 
ing bioavailability into consideration (27, 47, 97). Several cat- 
egories that have specific applications are summarized in Text 
Box 7. Detailed guidelines describing the appropriate applica- 
tion of these parameters are available (47, 97). 
 
 
peasants when vitamin A was added to iron-fortified wheat 
and maize breads (88), the results could not be confirmed in 
Swiss and Swedish students (89). The addition of vitamin A 
to an iron-fortified maize porridge resulted in a reduction 
in iron absorption by vitamin A-deficient Ivorian children 
(90). 
Iodine 
• Extensive data from animal studies indicate that  
iron deficiency with or without anemia impairs thyroid 
metabolism. This is supported by two recent intervention 
studies which showed that provision of both iron and io- 
dine to iron-deficient, goitrous Ivorian and Moroccan chil- 
dren decreased goiter rates more effectively than did the 
provision of iodine alone (91, 92). 
• It has been suggested that iron deficiency can lead to al- 
terations in the thyroid hormone feedback system, reduce 
deiodinase activity and lower the transformation of thy- 
roxine to triiodothyronine in the peripheral tissue, and re- 
duce thyroid hormone synthesis. 
• Thyroperoxidase, a heme enzyme that plays a key role 
in thyroid hormone synthesis by catalyzing the iodination 
of thyroglobulin, is markedly decreased in iron-deficient 
rats (93). 
Zinc 
• Due to similarities in absorption and transport, there 
has been a long-standing concern about the potential neg- 
ative interaction between iron and zinc (94). 
• The study of this interaction is complicated not only by 
shared chemistry, absorption, and transport but also study 
design (e.g., single supplements compared with food ma- 
trices, presence or absence of common enhancers and in- 
hibitors). 
• A debate exists with regard to the implications of this 
potential interaction to public health interventions with an 
emerging consensus that obviates concerns about joint ad- 
ministration of these essential elements (95, 96). 
• Particular care is recommended when adding elemen- 
tal iron powders; only electrolytic iron powder is judged 
useful. 
• Other commonly used iron powders, such as atomized 
or hydrogen-reduced iron powders, are judged to be too 
poorly absorbed and are not recommended. 
• Ascorbic acid, phytase treatment, NaFeEDTA, and 
amino acid chelates can be used to enhance iron absorp- 
tion from food vehicles rich in inhibitors. 
-Ascorbic acid is recommended to be added at a 2:1 
molar ratio in relation to fortification iron for low-phytate 
products and 4:1 for high-phytate products (58). 
-Ascorbic acid’s instability during processing, storage, 
and cooking is its main disadvantage. 
-Phytases can be used to degrade phytic acid in high- 
phytate foods either during processing (57) or during 
digestion by addition to in-home fortification powders 
added to cereal gruels at the time of consumption (81). 
-NaFeEDTA is specifically recommended for high phy- 
tate cereals such as whole-grain  wheat  flour  (82)  as  
well as for sauces rich in peptides such as soy and fish 
sauces. 
-NaFeEDTA is particularly useful in the presence of 
phytate. 
-Na2EDTA is also effective in combination with ferrous 
sulfate at molar ratios <1 with low-phytate cereals such as 
rice (83). 
-Na2EDTA does not appear to increase the absorption 
of ferrous fumarate or ferric pyrophosphate. 
-The amino acid chelate ferrous bisglycinate also pro- 
tects iron from inhibitors and is especially useful in liquid 
products such as milk (79). 
 
Text Box 7 
Dietary Reference Intake categories 
Estimated average requirement or average requirement: 
• The average daily intake needed to meet the estimated 
requirements of 50% of the individuals in the population 
being evaluated. 
• The Institute of Medicine values for the United States 
and Canada assume a bioavailability of 18%. 
RDA 
• The average daily intake needed to meet the estimated 
requirements of 97.5% of the individuals in the population 
being studied. 
 
Text Box 6 
Examples of iron-nutrient interactions 
Vitamin A 
• An interaction of vitamin A in iron metabolism which 
results in less incorporation of iron into red blood cells is 
supported by animal studies in which long-term admin- 
istration of vitamin A-deficient, but iron-sufficient diets, 
leads to anemia which can be corrected with vitamin A 
(86). 
• In chronically inflamed/infected populations in low- 
resource settings, it is also possible that vitamin A defi- 
ciency induces anemia via its negative influence on the im- 
mune defense, leading to more infections and more anemia 
of infection and inflammation (87). 
• The science regarding the interaction of vitamin A and 
iron at the metabolic level is evolving. Some examples of 
the impact of vitamin A deficiency include: impaired ery- 
thropoiesis, poor red blood cell differentiation, impaired 
incorporation of iron into hemoglobin, increased break- 
down of malformed red blood cells, and impaired mobi- 
lization of iron from reticuloendothelial macrophages and 
liver iron stores (84). 
• There is no agreement on the influence of vitamin A 
on iron absorption. Although there was a report of stud- 
ies demonstrating enhanced iron absorption by Venezuelan 
 ∼ 
∼ 
∼ 
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Alterations in erythropoiesis therefore have a dominant effect 
on the regulation of iron absorption, transport, and storage (99). 
 
Systemic iron homeostasis 
Iron is transported through the systemic circulation and extra- 
cellular fluid bound to transferrin. Text Box 8 (22, 98, 100–107) 
contains a summary of some key elements of systemic iron trans- 
port. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Iron homeostasis 
The requirement for iron in a multitude of biological processes 
emphasizes the importance of an uninterrupted iron supply for 
cellular turnover. This demand and the need to avoid the poten- 
tial toxic effects of free iron are met by a rigorously regulated 
system that controls the rate of iron absorption, maintains a 
store of readily available iron and recycles iron derived from 
cells at the end of their life spans. 
The cells that constitute the various body organs are being 
renewed constantly. Iron requirements change dramatically dur- 
ing cell growth and maturation. The overall requirement also 
changes because of physical growth in children, pathophysio- 
logical changes in organ function, and pregnancy. Iron impor- 
tation must be controlled precisely and continuously to supply 
physiological needs and avoid potential toxicity. This is achieved 
by maintaining a readily available, highly regulated iron store. 
Considerable quantities of iron are rapidly mobilized if there is 
a sudden increase in physiological requirements. An adult with 
a 1000-mg store can extract 40 mg daily (98). On the other 
hand, maximal bioavailability from a high bioavailability West- 
ern diet is only 2–4 mg/d. It is convenient to review iron biology 
relevant to the selection of biomarkers of nutritional iron sta- 
tus by first dealing with systemic and cellular iron homeostasis. 
This is followed by a description of absorption and finally sec- 
tions dealing with placental iron uptake and iron transfer into 
the nervous system. 
Iron homeostasis is achieved by the coordinated opera-  
tion of two systems. Iron supply is regulated by keeping the 
plasma iron level within a fairly narrow range (systemic iron 
homeostasis). Individual cells have the ability to adjust the 
amount of iron they import and to store any excess (cellular 
iron homeostasis). Almost two-thirds  of  body  iron  is  found 
in the erythroid compartment (circulating red blood cells). 
Text Box 8 
Key elements of systemic iron transport 
Transferrin 
Transferrin is the major vehicle for iron delivery to cells 
and is present in the circulating plasma and extravascular 
fluid, and has the following characteristics: 
• Apotransferrin (transferrin without attached iron) is 
a single-chain glycoprotein with two lobes, each of which 
can bind one ferric ion. It is synthesized in the liver and has 
a half-life of 8 d. 
• Iron is tightly bound under physiological conditions 
in the plasma with an effective stability constant of 1026– 
1030  M−1. Iron bound to transferrin remains soluble, but  
is prevented from generating toxic free radicals. 
• Binding is markedly affected by pH, being maximal 
above pH 7.0. Dissociation of the iron occurs if the pH is 
lowered, becoming virtually complete below pH 4.5 (22, 
100, 101). 
• Duodenal enterocytes, macrophages in the spleen, 
liver, and bone marrow, and hepatocytes are the major 
sources of iron that binds to transferrin. 
• About 35% of the iron-binding sites on plasma trans- 
ferrin are occupied at any one time; it is customarily ex- 
pressed as percentage of transferrin saturation (TSAT); this 
corresponds to a plasma or serum iron concentration of 
115 µg/L. 
• A diurnal variation exists in both the plasma iron con- 
centration and the TSAT, with higher levels in the morning 
in most individuals (100, 102). The pattern is usually re- 
versed in in people who are awake at night and sleep during 
the day. 
• The iron is removed by target cells and the apotrans- 
ferrin returned to the plasma or extracellular fluid. 
• This cycle is completed >10–15 times each day. Thus, 
the circulating transferrin pool contains only 3 mg Fe at 
any one time, but 10 times as much iron (  35 mg), most   
of it destined for developing red blood cells ( 24 mg), 
moves through this transport system each day in a normal 
adult (98). However, the potential capacity of the system 
to respond to an increased demand for iron is remarkable. 
It is exemplified by patients suffering from thalassemia 
major with severe ineffective erythropoiesis. Rapid iron 
recycling may supply sufficient iron to sustain erythroid 
marrow production levels that are 6–10 times normal 
(103). 
Ferroportin 
Ferroportin is expressed on the surfaces of cells and is 
the only known cellular iron exporter (104, 105), trans- 
porting iron across the plasma membrane for its subse- 
quent binding by transferrin in the plasma and extracel- 
lular fluid, and has the following traits: 
 
• The Institute of Medicine values for the United States 
and Canada assume a bioavailability of 18%. 
Adequate intake 
• For populations in which the estimated average re- 
quirement cannot be specified and is usually  the  aver- 
age daily intake based on observed or experimentally 
determined approximations in apparently healthy indi- 
viduals who are assumed to have an adequate  iron  
intake,  e.g.  full  term  during  the  first  six  months  of  
life. 
Upper level 
• The highest continuous daily iron intake considered 
unlikely to pose any risk of adverse health effects for al- 
most all individuals in the specified life stage and sex 
group. 
WHO/FAO: recommended nutrient intake (RNI) 
• Conceptually equivalent to the RDA, the RNI is the 
value used by WHO/FAO. 
• Expanded stipulated values make adjustments for 
bioavailability providing separate levels for 15%, 10%, 
and 5% bioavailability. 
Population reference intake 
• Conceptually equivalent to the RDA, this is the value 
used by the European Food Safety Authority (EFSA). 
• EFSA uses an absorption value of 16% for men and 
18% for women to convert physiological requirements into 
dietary intakes. 
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Most of the iron entering the plasma pool ( 22 mg/d) is 
derived from the reprocessing of heme in red blood cells that 
have reached the end of their 100–120-d life spans by special- 
ized macrophages in the spleen, liver (Kupffer cells), and bone 
marrow (98, 100, 108). These old red blood cells are phago- 
cytosed and the heme is rapidly catabolized by cytosolic heme 
oxygenase-1 to yield biliverdin, carbon monoxide, and iron. The 
iron is either returned to the plasma via ferroportin within a 
mean  transit time of 86 min or stored in ferritin (109, 110). 
When iron status is in the normal range, 64% is transferred 
to transferrin. In iron-deficient individuals, almost all the iron 
is released immediately, but as much as 80% may be retained 
and incorporated into ferritin in patients suffering from aplastic 
anemia when requirements are minimal because erythropoiesis 
is severely impaired. This intracellular ferritin iron pool is in 
dynamic equilibrium with the iron circuit. The half-time of res- 
idence in the pool is 6 d in an individual with a normal iron 
store. Smaller quantities of iron are exported by other cells, par- 
ticularly hepatocytes. Absorption from the diet contributes only 
1 mg/d in an iron-sufficient adult man. During their childbear- 
ing years, women absorb a little more, 1.5 mg/d, to compen- 
sate for menstrual blood losses (100). 
 
Regulation of systemic iron homeostasis. Systemic iron 
homeostasis depends on the regulation of the rate of iron de- 
livery to circulating transferrin. This is achieved by adjustments 
to the amount of ferroportin on cell membranes through the 
action of circulating hepcidin (111). Hepcidin binds to ferro- 
portin, causing the complex to be ubiquinated, internalized and 
degraded (112, 113). Hepcidin is therefore the central regula- 
tor that controls iron absorption, iron recycling, and the size of 
the iron store in adults and children >6 mo (114–116). While 
hepcidin is detectable in the newborn infant (117), further stud- 
ies are necessary to determine whether its regulation is similar 
to that demonstrated in older children and adults. Text Box 9 
(111, 118–120) contains some salient features of hepcidin bi- 
ology. The following is a brief summary of the key interacting 
pathways involved in control of hepcidin and iron concentra- 
tions. 
 
 
 
 
 
 
 
 
 
 
Hepatocellular iron stores. The regulation by hepatocellular 
iron is a multifactorial process. Increasing hepatocellular iron 
stores promote the expression of BMP-6. In the presence of 
hemojuvelin (HJV), a membrane-bound protein, BMP-6 acts as 
an autocrine signal by binding to hepatocyte cell surface BMP-6 
receptors. In this scenario, HJV acts as a co-receptor augment- 
ing BMP-6 binding (39, 43). Transcription of the gene encoding 
hepcidin (HAMP) is regulated by the SMAD and signal trans- 
ducer and activator of transcription 3 (STAT3) pathways (121). 
HJV expression is regulated by iron and hypoxia; both act  
by inducing cleavage of HJV by furin to yield a soluble prod-  
uct (sHJV). sHJV acts as an antagonist to BMP-6-induced hep- 
cidin synthesis. In response to acute iron deprivation, HJV is 
cleaved by matriptase-2 (type-two transmembrane serine pro- 
tease, TTSP, also known as TMPRSS6), thereby attenuating the 
BMP-6 signal, which then leads to decreased hepcidin produc- 
tion. Hypoxia exerts control on hepcidin production by stabi- 
lizing liver-specific hypoxia inducible factor 1 (HIF-1) which in- 
creases the synthesis of matriptase-2. Hypoxia therefore reduces 
hepcidin synthesis by decreasing BMP-6 by two mechanisms: 
HJV antagonism by sHJV, and augmentation of martriptase-2 
cleavage (122). 
 
Erythropoiesis. The rate of production of red blood cells 
(erythropoiesis) exerts an important effect on hepcidin produc- 
tion. Increased erythropoiesis suppresses hepcidin synthesis. 
The effect usually overrides the control exerted by iron stores. 
It is therefore an important contributor to the iron overload, 
which may be severe, in patients suffering from conditions 
such as thalassemia major (122, 123). A putative regulator 
called erythroferrone which suppresses hepcidin expression 
was identified recently by Kautz et al. (124) in a mouse model. 
It is produced by erythroblasts in response to erythropoietin. 
Hepcidin suppression appears to require activation of the 
JAK2-STAT5 signaling pathway and to be independent of the 
canonical BMP-SMAD pathway (124). In patients who require 
blood transfusions, iron overload is a consequence of both 
• It is a transmembrane protein that transports ferrous 
iron. 
• It is encoded by the SCL40A1 gene (solute carrier fam- 
ily 40 member 1). 
• It binds ferrous iron. Iron transfer to transferrin re- 
quires oxidation by copper oxidases, ceruloplasmin in 
macrophages and hepatocytes, hephaestin in duodenal en- 
terocytes (106), and zyklopen in the placenta (107). 
DMT1 
• DMT1 represents a large family of orthologous metal 
ion transporter proteins that are highly conserved from 
bacteria to humans (22). 
• DMT1 can bind a variety of divalent metals, but is 
primarily an iron transporter in mammals. 
 
Text Box 9 
Salient features of hepcidin 
• Synthesized primarily in hepatocytes as an 84-amino- 
acid propeptide that is processed to the active 25-amino- 
acid peptide in the Golgi apparatus before being secreted 
into the circulation. 
• Subsequent amino-terminal processing produces two 
smaller peptides with 22 and 20 amino acids that can be 
measured in urine, but are not detectable in plasma or 
present at only very low concentrations in healthy humans. 
• These smaller peptides appear to lack ferroportin reg- 
ulatory function. 
• Circulating hepcidin is bound to α2-macroglobulin 
(118). 
• Unregulated renal excretion is the major pathway for 
hepcidin clearance from the circulation, in addition to the 
quantity removed by receptor-mediated endocytosis pri- 
marily in hepatocytes and the macrophages of the liver, 
spleen, and bone marrow (119, 120). 
• Circulating hepcidin concentrations are primarily reg- 
ulated by the interaction of four interrelated pathways: 
-hepatocellular iron stores [bone morphogenic protein 
(BMP)/sons of mothers against decapentaplegic (SMAD)] 
-erythropoietic rate 
-circulating iron concentration [human hemochromato- 
sis (HME)/transferrin receptor (TfR)2] 
-inflammatory cytokines [the janus kinase signal trans- 
ducer and activator of transcription 3 (JAK/STAT)] (111) 
 the additional iron administered parenterally in the transfused 
blood and excessive absorption from the diet. 
 
Circulating iron. Hepatocytes and developing erythrocytes ex- 
press transferrin receptor 1 as well as a second transferrin re- 
ceptor that is encoded by a separate gene, TfR2 (105, 125, 126). 
The function of both TfR1 and TfR2 are affected by HFE pro- 
tein. Transferrin carrying iron binds to  both  TfR1  and  TfR2. 
It displaces the HFE molecule from TfR1. The HFE molecule     
is then available to interact with TfR2, producing a complex 
that induces hepcidin transcription by BMP/SMAD signaling. 
TfR2 functions as a sensor of iron bound to transferrin. TfR2    
is expressed in hepatocytes, regulating hepcidin expression, and 
in erythroid precursors, coordinating erythropoiesis with iron 
availability (105, 127). 
 
Iron, inflammation, and hepcidin. The reciprocal re- 
lationships between nutrition and iron homeostasis, and 
inflammation have been described recently (128). Text Box 10 
(105, 111, 129, 130) provides a brief outline of the specifics of 
this relationship as it pertains to iron homeostasis regulated by 
hepcidin. 
 
 
FIGURE 1 Factors regulating hepcidin. Fpn, ferroportin. Repro- 
duced with permission from reference 131. 
 
 
 
set of processes with multiple compensating factors, which be- 
comes particularly relevant in pregnancy and development (see 
below). 
 
Cellular iron homeostasis 
Individual cells possess an independent complex system for reg- 
ulating iron import and export, and intracellular iron economy 
and storage (99, 105, 129, 133). Iron uptake closely matches 
physiological requirements. The steps for getting iron into and 
transported within cells are outlined in Text Box 11 (99, 105, 
126, 129, 130, 133–136). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1 is a graphic representation of our current un- 
derstanding of the factors regulating hepcidin (131). Recent 
studies have found that yet other signal transduction path- 
ways are involved in the control of hepcidin synthesis, includ- 
ing mammalian target of rapamycin (mTOR) and proliferative 
rat sarcoma/rapidly accelerated fibrosarcoma mitogen-activated 
protein kinase (RAS/RAF MAPK) signaling, linking hepcidin 
regulation to nutrient metabolism, cytokines, growth factors, 
and cellular proliferation (132). 
It is evident from this brief summary of our current un- 
derstanding of systemic iron homeostasis that hepcidin is the 
final common pathway for signals that orchestrate the control 
of iron absorption and the delivery from stores. It is also clear 
that hepcidin secretion is regulated by a complex, finely tuned 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Text Box 11 
Iron transport at the cellular level 
Getting in 
• Transferrin-receptor 1 (TfR1) provides high-affinity 
uptake of diferric transferrin by cells and is the dominant 
route of iron uptake in immature erythroid cells and per- 
haps most other cells (124, 126). 
o Low-affinity cellular uptake of diferric transferrin by 
other mechanisms in nonerythroid tissues has also been de- 
scribed and its relative importance remains under investi- 
gation. 
o Transferrin binds to TfR1, with diferric transferrin 
having a higher binding constant (105, 126, 129, 130) 
than the monoferric form at the pH of extracellular fluid 
(7.4). 
• Apotransferrin does not compete significantly. 
• The transferrin-TfR1 complex enters the cell by endo- 
cytosis in clathrin-coated vesicles. 
• The endosome is acidified by an ATP-dependent pro- 
ton pump, reducing the pH to ∼5.5. 
• The iron is released from transferrin and reduced 
by 6-transmembrane epithelial antigen of the prostate 3 
(STEAP3). 
• The ferrous iron is transported across the endosomal 
membrane into the cell by the DMT1. 
 
Text Box 10 
Iron homeostasis, hepcidin, and inflammation 
• Hepcidin contributes to innate immunity and is a ma- 
jor component of the anemia of chronic disease (ACD) and 
inflammation (129). 
• Inflammatory cytokines, IL-2 and IL-6, stimulate hep- 
cidin synthesis. 
• IL-6 activates the JAK/STAT which stimulates the hep- 
cidin promoter (105, 111). 
• Endoplasmic reticulum stress also increases hepcidin 
expression. 
• ACD is characterized by: 
-moderate severity 
-stability over the course of the illness 
-hypoproliferativ, and morphologically normocytic ery- 
throcytes without an increase in the red blood cell distri- 
bution width (RDW) (130) 
-a modest decrease in erythrocyte survival 
-sequestration of iron in the reticuloendothelial cells as- 
sociated with a low serum iron and low total iron-binding 
capacity (TIBC), considered to reflect the primary role of 
increased hepcidin production (111) 
 ∼ 
 
 
Regulation of cellular iron homeostasis. Erythroid precur- 
sors have been the focus of much research on cellular iron 
uptake. However, it is assumed that all cells employ similar 
regulatory mechanisms (137), although erythroid cells express 
additional controlling factors that are related specifically to 
hemoglobin synthesis (137). Iron acquisition is matched to cel- 
lular requirements by control of cell surface TfR1 expression 
by the iron regulatory protein (IRP)–iron responsive element 
(IRE) system. IRP 1 and 2 sense the cell’s immediate iron re- 
quirements. When there is a need for additional iron they be- 
come bound to stem loop structures (IREs) in the 31 untranslated 
region of TfR mRNA, thereby preventing constitutive mRNA 
degradation and increasing the quantity of TfR expressed on 
the cell surface. More iron is imported. At the same time ferritin 
synthesis is suppressed by the binding of the IRPs to IREs on 
the 51 untranslated region of ferritin mRNA. Less iron is incor- 
porated into the cellular ferritin store. When iron in the cell is 
sufficient, the process is reversed with downregulation of TfR 
expression and increased storage in ferritin. Additional details 
on iron homeostasis in erythroid cells are provided in Text Box 
12 (138–141). 
 
 
Specific role of macrophages. Dedicated macrophages in the 
spleen, liver (Kupffer cells), and bone marrow have a special- 
ized role in the body’s internal iron economy (142). After a life 
span of 100–120 d in the circulation, red blood cells are re- 
moved from the circulation by these macrophages. This pro- 
cess involves the following two steps: 1) entry into an ery- 
throphagolysosome where the red blood cell membrane is lysed; 
and 2) catabolism of the heme by an enzymatic complex con- 
taining NADPH-cytochrome c reductase, heme oxygenase 1, 
and biliverdin reductase to yield iron, carbon monoxide, and 
bilirubin. 
Depending on the body’s immediate needs, iron is trans- 
ported across the plasma membrane by FPN, oxidized from the 
ferrous to the ferric state by ceruloplasmin, and then bound to 
apotransferrin in the plasma, or incorporated into ferritin in the 
cytosol for temporary storage. 
Some erythrocytes are damaged in the circulation (intravas- 
cular hemolysis) even in healthy individuals. This intravascular 
hemolysis may be markedly accelerated in hemolytic anemias 
and diseases that cause ineffective erythropoiesis. Hemoglobin 
released into the plasma is rapidly bound to haptoglobin, a gly- 
coprotein synthesized in the liver to form a complex  that is  
too large to be filtered by the kidneys. The iron is conserved. 
The hemoglobin-haptoglobin complex binds to CD163 recep- 
tors on macrophages and hepatocytes, and is then endocytosed 
and degraded in lysosomes, releasing heme that is catabolized 
as described above. Heme may be separated from globin in the 
plasma. If this occurs, it is bound to another plasma protein, 
hemopexin. The complex is again too large to be filtered by the 
kidney. It is removed by macrophages in the liver and spleen 
expressing the CD91 receptor and catabolized (143). 
 
Iron storage and recycling by hepatocytes. In the liver, hep- 
atocytes have a central role in controlling the body’s iron econ- 
omy and are the main site for iron storage. They acquire iron 
from both the systemic and the portal (newly absorbed iron) 
circulations. Moreover they have the capacity to obtain iron via 
• Globin synthesis is coordinated with heme synthesis 
through translational control by the heme-regulated tran- 
sitional inhibitor. 
• Additional mechanisms [e.g., effect of TfR2 on ery- 
thropoiesis (138), aconitase-associated control of erythro- 
poieisis (139)] may have important roles. 
• Reduced responsiveness of erythroid progenitors to 
erythropoietin in iron deficiency (139). 
• Developing erythroblasts synthesize ferroportin (FPN) 
and can export iron. There are two FPN transcripts 
(FPN1A and FPN1B). 
o Unlike FPN1A, the transcript that is expressed by all 
cells, FPN1B lacks an IRE in its 51 untranslated region. 
o FPN derived from both transcripts are responsive to 
hepcidin and systemic iron requirements. 
o It has been hypothesized that FPN1B expression en- 
hances sensing of systemic iron status and facilitation 
of restricted erythropoiesis in response to systemic iron 
deficiency (140, 141). FPN1A predominates once cells 
begin to produce hemoglobin. 
• The developing red blood cell’s requirements are pri- 
oritized. Ferroportin expression is suppressed and an ade- 
quate iron supply for heme synthesis is ensured (140). 
• The apotransferrin-TfR1 complex is returned to the 
plasma membrane where apotransferrin dissociates from 
TfR1 at the extracellular pH of 7.4 and re-enters the 
plasma pool. 
• Hepatocytes also import iron by TfR1-independent 
pathways (99). 
Once in 
• Most of the cytosolic iron is transported across mito- 
chondrial membranes by the transmembrane protein mito- 
ferrin encoded by SLC25A37, for synthesis of heme by 
incorporation into protoporphyrin IX (134). 
• Smaller quantities enter iron-sulfur clusters in both the 
mitochondrion and the cytosol. 
• Iron is also incorporated into nonheme cytosolic en- 
zymes or stored as ferritin. 
• Emerging evidence indicates that there are complex 
mechanisms that facilitate the distribution of iron within 
the cell (135, 136). 
• Some experimental evidence indicates that iron is 
transferred from endosomes to the mitochondria by direct 
contact rather than transfer through the cytoplasmic com- 
partment (133). 
 
Text Box 12 
Iron homeostasis in erythroid cells: iron supply and 
hemoglobin synthesis 
• The precise matching of iron supply to erythropoietic 
requirements is a critical element of red blood cell matura- 
tion presumably because of the potential for iron-induced 
oxidative toxicity. Protoporphyrin IX synthesis is coordi- 
nated with iron availability by the IRPs. 
• The mRNA for δ-aminolevulinic acid synthetase 2, the 
initial and rate-limiting enzyme in the heme synthetic path- 
way, has an IRE in the 51 region of its mRNA; IRP binding 
inhibits heme synthesis. 
 ∼ 
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both TfR1- and TfR1-independent pathways (99). In addition, 
iron derived from hemoglobin-haptoglobin, heme-hemopexin, 
ferritin, lactoferrin, or non-transferrin-bound iron is recycled 
through hepatocytes. The liver is also the primary source of 
hepcidin. 
 
Iron absorption 
Body iron is controlled rigorously by the regulation of ab- 
sorption in the duodenum and proximal jejunum. Iron excre- 
tion is minimal and unregulated in human beings. It results 
from loss from the gastrointestinal tract (putatively due to bil- 
iary iron excretion, cellular desquamation, and perhaps micro- 
scopic bleeding), in the urine and by the desquamation of skin 
cells (144). In women additional losses occur as a result of 
menstruation and the demands of pregnancy. The usual North 
American diet contains  7 mg Fe/1000 kcal (98). A healthy  
man with adequate iron stores utilizes   1 mg/d, but this can   
be increased to 2–4 mg/d in iron deficiency and reduced to 
0.5 mg/d if iron stores are high. Much more iron can be utilized 
if supplemental iron is consumed (98). The rapidity with which 
these adjustments occur is remarkable. Absorption of a second 
dose of iron is blocked within 2–4 h of an initial dose (145). It is 
convenient to describe the process of absorption by considering 
four interrelated stages, which are described in Text Box 13 (18, 
32, 34, 50, 104, 146–153). 
 
• Food fortification with iron nanoparticles could enter 
the mucosal cell by mechanisms not available to the com- 
mon nonheme pool iron (147). 
2. Enterocyte uptake 
• All forms of iron are predominantly absorbed in the 
duodenum and upper jejunum. 
• Heme iron crosses the brush-border membrane as the 
intact iron porphyrin, although the transporter has not yet 
been identified. 
• Almost all of the nonheme iron is taken up by the 
DMT1, which is a transmembrane protein encoded by the 
Slc11a2 gene that mediates proton-coupled ferrous iron 
uptake (148). 
• Because most of the iron in the diet is ferric, reduction 
to the ferrous form is required for binding to DMT1. 
-Dietary components, such as ascorbic acid, promote 
absorption in part by this mechanism. 
-In addition, a brush-border membrane ferrireductase, 
duodenal cytochrome b (DCYTB), may play some role 
in facilitating reduction by electron transfer from intra- 
cellular ascorbate (149). DCYTB is markedly upregu- 
lated in iron deficiency and hypoxia and is thought to 
play a major role under these conditions. 
• Observations in both rodents and  humans  indi-  
cate that DMT1 transports most of the  nonheme  iron  
that enters mucosal cells (148, 150). However, other 
systems may exist, because inactivation of intestine- 
specific Slc11a2 causes severe iron deficiency, but is not 
lethal. 
3. Storage within the enterocyte and transport to the 
basolateral membrane 
• The processes responsible for the transport of intra- 
cellular enterocyte iron are unknown. 
• However, it is evident that all absorbed iron enters    
a common pathway after the iron in heme is released by 
heme oxygenase (151). 
• The iron is then distributed as follows: 
-to meet the requirements of intracellular compart- 
ments, such as mitochondria, transferred to the baso- 
lateral membrane for absorption into the portal circu- 
lation; or 
-to be stored within the enterocyte as ferritin when the 
body’s demands are low. Most of the iron ferritin is lost 
due to exfoliation of enterocytes (18). 
4. Efflux across the basolateral membrane and binding 
to transferrin 
• Ferrous iron is transported out of the enterocyte 
across the basolateral membrane by FPN1 (encoded by the 
Slc40a1 gene). Like DMT1, intestine-specific inactivation 
of this gene in mice causes severe iron deficiency but is not 
lethal (104). 
• Binding to transferrin in the interstitial fluid requires 
that the iron be in the ferric form. Oxidation is mediated 
largely by hephaestin, a membrane-bound multicopper fer- 
roxidase (152). Ceruloplasmin in the interstitial fluid also 
appears to play a role in this process (153). 
 
 
Systemic regulators of iron absorption. In the absence of 
infection or inflammation, iron absorption is stimulated when 
body stores are low or erythropoiesis is increased. Finch (123) 
 
Text Box 13 
Stages of iron absorption 
1. The luminal phase 
• Most of the dietary iron is present in one of three 
forms: 
-Heme derived from hemoglobin and myoglobin in 
meat and fish 
-Soluble nonheme iron that is derived from all the other 
iron in food and behaves as a common pool for absorp- 
tion 
-Iron that is insoluble in gastric juice and therefore not 
absorbed (32, 34) 
• Heme iron is well absorbed and enters mucosal cells 
as the intact heme moiety. 
• The absorption of all other forms of dietary iron 
present in both meat and plant foods depends on their sol- 
ubilization in gastric juice and reduction from the ferric to 
the ferrous state. 
• Absorption is markedly affected by meal composition. 
Unidentified components of meat (thought to be partially 
digested peptides), ascorbic acid, and to some extent other 
organic acids promote absorption, whereas phytates, cer- 
tain polyphenols, and some plant and milk proteins are 
inhibitory. 
• The mechanism of absorption for two types of iron, 
ferritin and nanoparticulate iron, remains uncertain. 
-Some investigators have suggested that ferritin iron, 
an important iron source in both meat and vegetables, 
crosses the brush border membrane as an intact and is 
highly bioavailable molecule (146). 
-Other studies suggest that iron is released from ferritin 
in the stomach to join the nonheme common pool (40). 
 coined the terms “store regulator” and  “erythroid  regulator” 
to describe these two processes. The “erythroid regulator” has 
the dominant role and accounts for the nontransfusional iron 
overload that occurs in such conditions as thalassemia major  
in which absorption may continue to be enhanced despite a 
progressive increase in the size of the iron store. Both mecha- 
nisms are now known to be mediated by circulating hepcidin. 
The relationship between iron stores, hepcidin concentrations, 
and physiologic control of iron status by the “store regulator” 
are described elsewhere. Hepcidin production is suppressed by 
increasing storage iron. Hepcidin binds to FPN1 on the baso- 
lateral surface of duodenal enterocytes, leading to its internal- 
ization and degradation (113). 
A new hormone named erythroferrone (ERFE) has been 
identified that increases iron absorption by suppressing hepcidin 
during stress erythropoiesis in mice (124). ERFE is secreted by 
human erythroblasts in response to erythropoietic stimulation 
by erythropoietin and appears to be a component of the “ery- 
throid regulator.” 
The overriding importance of the hepcidin/FPN1 axis in 
preventing excessive iron absorption is illustrated by two sets 
of observations. Virtually all inherited primary iron overload 
disorders result from mutations that affect hepcidin or ferro- 
portin (154). The recent discovery of ERFE suggests that iron- 
loading anemias are also the result of hepcidin suppression in 
the face of iron overload. Hepcidin has also been shown to 
reduce enterocyte iron uptake by inhibiting DMT1 expression 
(155) through ubiquitin-dependent proteasome degradation of 
DMT1 in Caco-2 cells (156). In experimental animal models, 
iron absorption has been shown to be increased in response to 
oxygen deprivation (157). Hypoxia inducible factor 2α (HIF2α) 
has been identified as a key transcription factor in this response 
(158, 159). DMT1, Dcytb, and FPN1 have hypoxia response 
elements within their promoters that activate transcription in 
response to hypoxia (158–160). 
 
Cellular regulators of iron absorption. Enterocytes also have 
the complex cellular machinery found in erythroid precursors 
that control their internal iron economy. These mechanisms en- 
sure the safe handling of iron necessary for cellular metabolism 
and regulate the transfer of iron to the systemic circulation, and 
in particular afford protection against sudden iron surpluses in 
the duodenal lumen. This protection may occur by downregula- 
tion of DMT1 and incorporation of iron that crosses the brush 
border membrane into ferritin (161). The control of iron im- 
port and storage by the IRE/IRP system is described in detail 
elsewhere in this review. 
The regulatory mechanisms that control iron absorption, 
storage, and export described for erythroid cells,are similar in 
enterocytes but with the additional involvement of some specific 
proteins, as  follows:  1)  the  31 IRE  of  DMT1  mRNA  stabilizes 
the mRNA, leading to increased protein levels in iron deficiency 
(162); 2) the IRE in the 51 region of FPN 1 mRNA binds IRPs, 
thereby inhibiting protein translation (145, 161); and 3) DcytB 
and hephaestin mRNAs do not appear to contain IREs. 
Control mechanisms are, however, even more complicated 
as two splice variants of both the FPN 1 and DMT1 mRNAs    
are present, one with and one without an IRE. Furthermore, 
transcriptional regulation is also important. For a more detailed 
description see references (145, 163). 
There is debate regarding how well regulated iron absorp- 
tion is in the neonate and infant.  Animals  models  suggest  
that DMT-1 and FPN-1 are developmentally regulated (164) 
with achievement of full expression at the time of weaning (in 
rodents). Whether this is present in humans is unknown. Several 
stable isotope studies of iron absorption in term and preterm 
infants have shown a surprisingly consistent 35–40% rate, a 
finding that would suggest relatively limited active regulation 
given the wide range of iron status found in this population 
(114–116). 
 
Placental iron transport 
The placenta is a complex organ, which has many  roles  to  
play, including nutrient transfer and waste disposal, and en- 
docrine functions that are integral to its role as a regulator      
of fetal growth and differentiation. The study of the placenta    
is complicated by the available resources that can be used. 
Most studies in humans utilize placentas from full-term infants. 
The use of animal models presents a range of challenges, from 
species differences in anatomy to differences in iron transport 
and metabolism. These differences have been reviewed recently 
(165). Text Box 14 (107, 148, 166–172) contains a summary of 
the current understanding of placental iron transport and po- 
tential adaptations to iron deficiency. 
 
Text Box 14 
Mechanisms of placental iron transport 
• Diferric transferrin binds to the TfR on the apical sur- 
face of the placental syncytiotrophoblast membrane (166). 
This is a high-affinity binding process, with the Kd for di- 
ferric transferrin being ∼10−9 M−1 (167). 
• Following binding, the complex is internalized and is 
incorporated into coated vesicles. 
• The vesicles are acidified (168) and the affinity of di- 
ferric transferrin for iron decreases. 
• Although in most cells, iron is released and exits the 
endosome through DMT1, in the placenta, DMT1 may not 
be essential for this purpose (148). 
• Recent studies suggest that other metal transporters, 
such as ZIP8, may fulfill this function (169). 
• Following release into the cytoplasm of the syncy- 
tiotrophoblast, iron is transferred to the basolateral side. 
How this is accomplished is not known. It is unlikely to be 
as a freely diffusible moiety, since ferrous (III) iron is very 
insoluble at neutral pH, and ferric (II) iron is biologically 
very active. Specific iron chaperones, e.g., PCBP1 which is 
reportedly highly expressed in the placenta, have been sug- 
gested. 
• At the basolateral membrane of the syncytium, iron 
effluxes through ferroportin in a similar fashion to that de- 
scribed for the duodenal cell. It moves through the mem- 
brane as Fe(II) and is oxidized by a copper ferroxidase 
termed zyklopen (107). 
• It then binds to fetal transferrin, and is carried to the 
fetal liver and to the erythropoietic tissues. 
• Irreversible changes in brain occur following prenatal 
iron deficiency (170). 
Adaptation to iron deficiency 
• An increase in TfR expression at the apical surface of 
the placental syncytium membrane results in increased iron 
uptake. 
-Increases have been observed in DMT1 and zyklopen 
expression, but no change in ferroportin mRNA levels. 
The mechanism of regulation appears to be governed 
 ∼ 
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Fetal iron 
Fetal iron requirements change throughout pregnancy. In the 
early stages of pregnancy, iron is needed to maintain growth 
and differentiation of the fetus, so that although the amounts of 
iron may not be very high, iron deficiency can result in signifi- 
cant changes. It has been shown that the mid-pregnancy period 
is particularly important (173). Using cultured embryos, iron 
deficiency resulted in delayed growth and differentiation, and 
an increase in malformations. Providing iron over the 10.5- to 
12.5-d period in rats reversed these changes (term is 22.5 d in 
the rat). Extending the work to in vivo studies, it was demon- 
strated that restoring iron status in the mother following iron 
deficiency in the early part of pregnancy only partly reversed 
the developmental effects (174). 
During early development, the fetus is entirely dependent 
on maternal supplies to meet its iron requirements. In order to 
maintain iron status in the fetus, at least to the maximum ex- 
tent possible, the placenta has developed a series of adaptive 
mechanisms, regulated partly by the same system as operates in 
other cell types. In humans, most of the iron delivered to the fe- 
tus comes from maternal transferrin (175), though recent data 
suggest that heme may also be a source (176). Because of its im- 
portance in the delivery of iron during pregnancy, the placenta 
has been studied fairly extensively, so that the transfer has been 
reasonably well elucidated. 
The fetus will accumulate iron to the detriment of the mother 
(176, 177). For example, in early studies, reducing iron in the 
maternal diet of rats resulted in a significantly lower maternal 
iron status as reflected by lower hemoglobin and hematocrit 
(Hct) compared with control animals receiving iron-adequate 
diets. In contrast, levels in the fetal liver dropped only by 30% 
(174). Interestingly, this effect is strain specific, and other breeds 
of rat are less capable of maintaining iron levels in the face of 
nutritional stress (178). Other studies have shown different win- 
dows of sensitivity for other physiological parameters. For ex- 
ample, postnatal iron deficiency has been shown to result in per- 
manent changes in hippocampal function in mice (179, 180), 
although restoration at the end of pregnancy can reverse the 
changes. 
 
Iron homeostasis in the developing brain and nervous 
system 
Iron is essential for normal brain development and function 
(181). The core functions of iron in the brain are listed in Text 
Box 15 (182–188). Disruption of these processes by iron defi- 
ciency lead to predictable and consistent structural, electrophys- 
iological, and behavioral abnormalities both during the period 
of iron deficiency and long after iron repletion (170, 188–191). 
Brain iron transport. The transport of iron across the blood- 
brain barrier is not completely understood. Figure 2 shows an 
overview of iron transport in the brain (192). 
Some of the details of our current understanding of iron 
transport in the brain are outlined in Text Box 16 (193–196). 
 
 
The mechanisms of iron transport to the central nervous sys- 
tem remain areas of intensive investigation to better understand 
the etiologies of deficiency as well as overload states (197). Even 
as our understanding of neuronal iron transport evolves, it is 
 
 
 
 
Text Box 15 
Roles of Iron in the Brain 
• Energy metabolism (182) 
• Neuronal and oligodendroglial cell migration (183) 
• Myelination (184) 
• Monoamineregic and glutamatergic neurotransmitter 
metabolism (185, 186) 
• Regulation of genes related to myelin, synaptic plas- 
ticity, and growth factors (187, 188) 
by the fetus. Fetal liver hepcidin correlates strongly with 
iron levels, and also with TfR levels in the placenta. 
• In contrast, maternal liver iron and hepcidin do not 
correlate (171), suggesting that another signaling system 
may be operating between the placenta and the maternal 
liver. 
• Recent suggestions for the signaling system have in- 
cluded GDF15 and soluble hemojuvelin (172), but much 
work remains to be done to demonstrate this. 
 
Text Box 16 
Evolving view of brain iron transport 
Early view 
• Early studies suggested that the transferrin-iron com- 
plex was transcytosed intact across the vascular endothe- 
lium (193). 
• By this mechanism, ferric iron bound to transferrin 
would be available to bind TfR-1 located on the neuronal 
membrane with uptake via the Tfr-1/DMT-1 mechanism 
present in red blood cells (and any other “terminal” cell). 
• In this mechanism, one or two molecules of ferric 
(Fe3+) iron are bound to serum transferrin. 
• This mono- or diferric saturated transferrin binds to 
TfR-1, a transmembrane homodimer, whose binding affin- 
ity is greater for saturated holo(diferric)transferrin than for 
unsaturated apotransferrin. 
Evolving view 
• Ferric iron is reduced and then transferred via the clas- 
sical TfR-DMT-1 mechanism into the endothelial cell and 
then extruded across the basal membrane via a ferroportin 
and the multicopper oxidase mechanism to transferrin syn- 
thesized in the brain (194, 195). 
• At the basal (brain-facing) surface, ferrous iron is 
transported to the brain via ferroportin. 
• A multicopper oxidase (e.g., ceruloplasmin or hep- 
haestin) is needed to convert ferrous iron back to its fer- 
ric state so that endogenous brain transferrin will bind it 
and deliver it to TfR-1 located on the neuronal membrane 
for incorporation via the TfR-1-DMT-1 uptake mechanism 
described above. 
• The possibility that oligodendrocytes do not obtain 
their iron via a transferrin mediated mechanism, but rather 
by via ferritin binding of the Tim-2 receptor, has been pro- 
posed (194, 196). 
 ∼ 
 
 
 
 
FIGURE 2 Diagrammatic portrayal of the BBB 
and the iron transport proteins believed to play 
a role in iron movement into the brain. BBB, 
blood-brain barrier; CSF, cerebrospinal fluid; 
DMT1, divalent metal transporter 1; Frt, ferritin; 
FrtR, ferritin receptor; MTP, metal transport pro- 
tein or ferroportin; Tf, transferrin; TfR, transfer- 
rin receptor. Reproduced with permission from 
reference 192. 
 
 
 
 
 
 
important to note that the uptake of iron via TfR-1-DMT-1 is 
developmentally controlled during the late fetal/early neonatal 
time period. For example, in the rat, hippocampal TfR-1 expres- 
sion is minimal at postnatal day 5 (human developmental equiv- 
alent of 32 wk of gestation) and increases to adult levels by post- 
natal day 15 (human equivalent of 2–4 mo postnatal age) (198). 
This increased expression coincides with a burst of hippocampal 
metabolic activity characterized by increased glucose uptake, 
neuronal differentiation (199), maturation of electrophysiology 
(190), and upregulation of growth factors  (200). The  finding 
of increased iron uptake during this time period underscores 
the importance of iron in supporting neuronal metabolism and 
mitochrondrial integrity, most likely through its direct role in 
cytochromes (201). 
 
Iron needs during critical periods of  brain  development.  
The brain consists of multiple regions that have different de- 
velopmental trajectories (202). The risk to any brain region or 
nutrient-dependent process will be a function of the timing of 
the nutritional insult (203, 204). The following will summarize 
what is known about iron’s role in brain development from the 
perspective of 1) brain monoamine metabolism, 2) brain energy 
metabolism, and 3) myelin formation. 
 
Iron and monoamine metabolism. In humans,  the  
monoamine neurotransmitter system begins its  develop-  
ment in mid-gestation and continues to have a period of rapid 
development until  3  y  of  age. The  multiple  feedback  loops 
in the dopamine and serotonin systems make it difficult to 
determine primary compared with secondary effects of iron.    
A summary of the impact of iron on monoamine metabolism    
is found in Text Box 17 (170, 205, 206). The observations 
outlined point to a critical period during which iron is necessary 
for normal brain monoamine metabolism development that 
occurs at the developmental equivalent of late gestation in the 
human. If correct, the information strongly supports the notion 
that maintenance of maternal iron status is key to offspring 
brain health and that post-hoc treatment of the iron-deficient 
newborn or child will not result in normal development of this 
neurotransmitter system, which is important for reward and 
mood/affect. 
 
 
 
 
 
Iron and brain energy metabolism. Iron is found at the active 
enzymatic core of cytochromes, which mediate electron trans- 
port and oxidative phosphorylation. Energy availability is es- 
sential for normal neuronal dendritic growth and differentia- 
tion, as evidenced by increases in glucose metabolism and iron 
uptake by brain regions during their growth spurt. A summary 
of the evidence for iron’s role in brain energy metabolism is pro- 
vided in Text Box 18 (179, 182, 185, 189–191, 200, 207–210). 
 
 
 
Text Box 17 
Iron, monoamine metabolism, and brain development 
• The most direct effect of iron is likely to be on the 
synthesis of all three monoamine neurotransmitters, i.e., 
dopamine, serotonin and norepinephrine. 
• Iron acts through alteration of the iron-containing en- 
zymes tyrosine hydroxylase and tryptophan hydroxylase 
(205). 
• Gestational and lactational iron deficiency alters as- 
pects of dopamine and serotonin metabolism acutely dur- 
ing the period of iron deficieny and long term after iron 
repletion (170). 
• Specifically, alterations are seen in the following: 
-The neurotransmitters themselves 
-Neuronal postsynaptic neurotransmitter receptors 
-Neuronal presynaptic neurotransmitter reuptake 
mechanisms (170) 
• Timing is important in terms of preventing the long- 
term sequelae. 
-Treatment at or after postnatal day 7 (equivalent to 
36–40 wk of human gestation) fails to prevent long- 
term changes in monoamine metabolism (170). 
-Treatment at postnatal day 4 (equivalent to 30 wk ges- 
tation) appears to reverse the acute findings (206). 
 (which may be undetected unless appropriate laboratory tests 
are carried out) and malabsorption due to diseases of the stom- 
ach and proximal small bowel account for most of the other 
cases (100). Genetic mutations of the TMPRSS6 gene are rare 
causes, giving rise to the clinical entity called iron-refractory 
iron-deficiency anemia (IRIDA), which is reviewed in reference 
(212). At the individual level, especially in populations where 
the prevalence of nutritional iron deficiency is low, establishing 
the cause is essential (e.g., occult bleeding in the gastrointesti- 
nal tract). In populations with a high prevalence of iron defi- 
ciency, evaluation of bioavailable iron intake is most important, 
although it may be necessary to assess the risk of exposure to 
parasitic helminths that cause bleeding such as hookworm and 
schistosomiasis. 
 
 
 
 
 
 
 
 
 
As with the role of iron in monoamine development, a 
critical period exists when iron  is  essential  for  hippocam-  
pal neuronal development (postnatal day 10–25), after which 
provision of iron does not completely prevent long-term gene, 
metabolism, or structural and behavioral abnormalities (179). 
The hippocampus has been extensively studied from the per- 
spective of neuronal metabolism as a way of understanding the 
role of iron sufficiency in learning and memory behavior. How- 
ever, it is likely that other areas of the brain have different de- 
velopmental trajectories and critical periods. 
 
Iron and myelination. Myelination in the human begins in the 
late fetal period and extends at a rapid pace through the first 
2–3 y (202). Myelin is the fatty sheath found on nerves that in- 
creases conduction speed and efficiency, properties that are in 
turn related to speed of processing for behavioral tasks. Hy- 
pomyelination increases the latency between peaks of electro- 
physiological activity in the auditory and visual systems. The 
role of iron can be summarized as follows (211): 1) iron is 
present in delta 9-desaturase as well as fatty acid elongases, 
important enzymes in the synthesis of fatty  acids  found  in  
the myelin sheath; and 2) oligodendrocytes are highly active 
metabolic cells when they are synthesizing myelin and thus are 
dependent on adequate cytochrome activity. 
In the rat model, iron-deficiency anemia (IDA) during gesta- 
tion/lactation results in hypomyelination with significant alter- 
ations in the fatty acid profile of the myelin and reductions in 
myelin basic protein expression (187, 211). 
 
 
Disorders of iron balance 
Iron deficiency 
The causes of iron deficiency are summarized in Text Box 19. 
An inadequate intake of bioavailable iron (nutritional iron de- 
ficiency) is the most common cause of iron deficiency and the 
most prevalent disorder of iron balance worldwide. It occurs 
primarily in individuals with increased requirements, especially 
in early childhood, the adolescent growth spurt, the childbear- 
ing years, and pregnancy. Pathological blood or hemoglobin loss 
The primary focus of the following sections will be nutri- 
tional iron deficiency, which occurs when an individual con- 
sumes insufficient bioavailable iron on a daily basis over an 
extended period to meet requirements, despite maximal upregu- 
lation of the physiological mechanisms for accelerating absorp- 
tion. Iron deficiency is the only disorder of iron balance in which 
nutrition has the primary role. Systemic iron overload occurs 
as a result of pathological disorders that impair the regulation 
of iron absorption, parenteral iron administration, or repeated 
blood transfusion. Conditions that lead to organ-specific iron 
accumulation are beyond the scope of this review. 
 
 
Text Box 19 
Causes of iron deficiency 
• Inadequate intake due to: 
-Habitual/discretionary inadequate intake of bioavail- 
able iron 
-Nutritional iron “insecurity,” i.e., inadequate access or 
availability of bioavailable dietary iron (e.g., poor di- 
etary diversity) 
• Iron malabsorption due to: 
-Celiac disease (hluten enteropathy) 
-Chronic Helicobacter pylori gastritis 
-Autoimmune atrophic gastritis 
-Some surgical procedures involving the stomach or the 
upper small bowel 
-Iron-refractory iron-deficiency anemia (IRIDA) 
• Accelerated physiological requirements. 
• Increased requirements for growth: 
-Premature infants 
-Early childhood 
-Adolescent growth spurt 
• Menstruation. 
• Pregnancy. 
• Pathological blood loss: 
-Bleeding from the gastrointestinal and genitourinary 
tracts 
-Parasitic infections notable helminth infections such as 
hookworm and schistosomiasis 
-Menorrhagia 
-Intravascular hemolysis 
• Blood donation. 
 
Text Box 18 
Iron and brain energy metabolism 
• Maintenance of brain energy status is affected by iron 
deficiency via reduced cytochrome c concentrations (182) 
and reduced cytochrome c oxidase activity (207), a reliable 
marker of neuronal activity (208). 
• Gestational/lactational iron deficiency anemia as well 
as nonanemic neuronal iron deficiency alters phosphorus 
utilization for ATP and lactate metabolism in the develop- 
ing hippocampus (185, 209), suggesting significant effects 
on neuronal energy metabolic balance. 
• Disruption of energy metabolism in iron deficiency re- 
sults in abnormal dendritic arborization, synapse forma- 
tion, and expression of synaptic plasticity and growth fac- 
tor genes (185, 189, 200, 209). 
• Form follows function in that these abnormal den- 
dritic arbors (in the hippocampus) have reduced electro- 
physiologic function (190) and the animals exhibit altered 
learning and memory behavior (179, 191, 209, 210). 
 TABLE 2 Prevalence of anemia in infants and young children 
(birth to 5 y of age) by region, 20051 
 
 
Global region Prevalence (%) 
Africa 64.6 
Asia 47.7 
Europe 16.7 
Latin America 39.5 
North America 3.4 
Oceania 28.0 
 
 
1Adapted with permission from reference 216. 
 
 
Anemia. Anemia is the most evident consequence of iron defi- 
ciency. It is associated with significant morbidity and has been 
the focus for evaluating iron status. Pallor is often noted as a pri- 
mary sign of anemia and patients may complain of symptoms 
that result from the diminished oxygen-carrying capacity of the 
blood, including weakness, fatigue, decreased physical work ca- 
pacity, shortness of breath, and palpitations (100). However, the 
body’s compensatory mechanisms for improving oxygen deliv- 
ery to tissues are very effective if the onset of anemia is grad- 
ual and symptoms may not be noticeable until the hemoglobin 
is <80 g/L (213). Nevertheless, anemia is associated with sig- 
nificant morbidity. Iron-deficiency anemia is correlated with an 
increased risk for preterm delivery, low birth weight, and ma- 
ternal and child mortality (214). Mental, motor, and emotional 
development is adversely affected in children, and IDA may be 
a contributory factor to heart failure (215). 
The risk is particularly high in low-resource settings 
(Table 2)  (216).  However,  iron  deficiency  remains  a  pub-  
lic health challenge in parts of the population even in the 
United States. The data in Table 3 are based on NHANES 
(2003–2006) (217). The global prevalence of anemia in 2010 
was estimated to be 32.9%. Iron deficiency was the most preva- 
lent cause (215). 
The historically accepted model of nutritional iron deficiency 
(218) proposed by Bothwell et al. (100) is based on the severity 
of iron deficiency categorized by its impact on the erythron.     
It emphasizes the need to recognize the early stages of iron 
deficiency—before the appearance of frank anemia. In the event 
of a sudden increase in iron requirements—e.g., as the result of 
pathological blood loss—iron in stores can be mobilized within 
a few days. On the other hand, if there is little storage iron avail- 
able it may take months to repair the deficit by increasing ab- 
sorption from a nonsupplemented diet. Three stages in the evo- 
lution of uncomplicated nutritional iron deficiency are described 
as follows (100): 
— Storage iron depletion: iron stores are exhausted, but there 
are no erythropoietic consequences, absent stainable bone 
marrow iron, low serum ferritin (SF); normal values for 
TSAT, red blood cell protoporphyrin, serum transferrin re- 
ceptor (sTfR), and hemoglobin. 
— Iron-deficient erythropoiesis: there is evidence of inade- 
quacy in the iron supply for erythropoiesis, but no decrease 
 
TABLE 3 Percentage of persons with iron deficiency (based on 
the body iron model) from NHANES (2003-06) (217) 
in the hemoglobin concentration sufficient to be detected 
by the standards used to differentiate normal from anemic 
states, absent stainable bone marrow iron, low SF, low TSAT, 
increased red blood cell protoporphyrin and sTfR, and nor- 
mal hemoglobin 
— Iron-deficiency anemia: measurable functional iron defi- 
ciency (reduced circulating red blood cell mass), absent 
stainable bone marrow iron, low SF, low TSAT, increased red 
blood cell protoporphyrin and sTfR, and low hemoglobin. 
This model has played a critical role in developing our 
approach to improved iron nutrition and the prevention of 
iron-deficiency anemia. It appropriately focuses on anemia as 
the overriding functional consequence of progressive iron defi- 
ciency. The currently available biomarkers have been selected 
to characterize the three stages in the evolution of uncompli- 
cated nutritional iron-deficiency anemia. They provide a means 
of establishing an accurate assessment of the severity of iron 
deficiency at both the individual and population level. How- 
ever, they may fail to identify other potentially important func- 
tional consequences of iron deficiency that may or may not be 
associated with anemia. Such nonspecific symptoms as muco- 
cutaneous clinical findings such as koilonychia, angular stom- 
atitis, and glossitis, as well as sideropenic dysphagia, have been 
described in the past (100). However, these symptoms are rarely 
encountered now and may well have resulted from the com- 
bined effect of iron deficiency and other nutritional or environ- 
mental factors. Pica is still encountered in some populations and 
iron deficiency may be a contributing factor in patients suffering 
from restless legs syndrome (219, 220). 
The following sections are reviews of five other high-priority 
functional outcomes including: 1) pregnancy outcome; 2) fetal 
and infant neurologic development; 3) exercise capacity; 4) thy- 
roid function; and 5) morbidity related to infectious disorders. 
The effect of iron deficiency on the maturation of the cen- 
tral nervous system has been considered in the greatest detail 
because of the potential long-term consequences of iron depri- 
vation during this critical period of the life cycle. 
 
Effects of iron deficiency on pregnancy outcome. The eval- 
uation of maternal iron status during pregnancy relies on the 
same biomarkers described in the preceding section, but their 
interpretation requires consideration of the evolving changes in 
the amount and distribution of body iron during the course of 
gestation. In this section, the underlying changes in iron home- 
ostasis during pregnancy will be summarized for each trimester 
and the corresponding effects on the principal biomarkers of 
iron status described. 
During pregnancy, iron is needed for the following: 1) the 
growth of the fetus and placenta; 2) the increase in the maternal 
red blood cell mass; 3) replenishing blood losses at parturition; 
and 4) restoring basal iron losses. 
The total iron requirement during pregnancy is of the order 
of 1000 mg, with the exact amounts depending, in part, on body 
weight, fetal and placental size, and the extent of the expansion 
of red blood cell mass (221, 222). 
The mother may remain iron replete if the iron requirement 
can be met from the combination of the stores present at con- 
ception and the amounts of dietary iron that can be absorbed 
during pregnancy. Iron requirements in excess of these amounts 
can lead first to maternal iron depletion, then to iron-deficient 
erythropoiesis and finally to IDA. To avoid the development of 
iron deficiency, a storage iron reserve of some 300–500 mg is 
likely to be needed, in conjunction with a diet with abundant 
Children (age 1–2 y) 14% 
Children (age 3–5 y) 4% 
Females (age 12–19 y) 9% 
Females (age 20–49 y) 9% 
 
 
 
 
 ∼ 
∼ 
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bioavailable iron (223, 224). After delivery, the iron that was 
used in the expansion of the red blood cell mass, 400–500 mg, 
gradually becomes available for erythropoiesis or for replenish- 
ment of stores. 
Most of the evidence for the relation of biomarkers to body 
iron status is indirect; bone marrow examination is seldom used 
to assess iron status during pregnancy. However, one study ex- 
amined marrow iron stores in Swedish women with uncom- 
plicated pregnancies who were not anemic during their first 
trimester. At about 12 wk of gestation, marrow iron stores were 
present in almost 90% of the women. By 35 wk of pregnancy, 
marrow iron stores were absent or present in only trace amounts 
in >60% of the women who had been given 200 mg Fe as fer- 
rous sulfate daily and in all the women who had been given 
placebo (225). 
The patterns of changes in the principal biomarkers of iron 
status during pregnancy and postpartum are shown graphically 
in Figure 3, derived from a study of apparently healthy Dutch 
women (226). It should be noted that because pregnancy is an 
inflammatory state (227–229), the potential confounding effects 
of inflammation on the interpretation of these biomarkers must 
be considered. In addition, the influence of obesity and weight 
gain during pregnancy on iron homeostasis and biomarkers of 
iron status has not been well characterized (230, 231). Gener- 
ally, studies in initially iron-replete women given adequate iron 
supplementation during pregnancy have been used to assess the 
effects of pregnancy on biomarkers in the absence of iron defi- 
ciency and to estimate iron requirements (223, 225, 232). 
 
First trimester. A number of changes occur that affect iron 
physiology, absorption, and status after conception and dur- 
ing the first trimester. Text Box 20 (223, 233) contains a list of 
some the key events. Using data derived from the Dutch study 
described above (226), median concentrations of the principal 
biomarkers of iron status in healthy women during the first 
trimester of pregnancy are shown in Figure 3. The following 
highlights what is known about specific biomarkers. 
 
 
Hemoglobin. 
— In the absence of iron deficiency, the circulating hemoglobin 
concentration declines by 10 g/L during the first trimester 
(234). 
— The threshold for  anemia  decreases  from  120  to  110  
g/L  in  guidelines  from  the   CDC   (235)   and   WHO 
(236). 
— Modifications to the threshold are needed to account for the 
effects of altitude and smoking (236). 
— Other corrective adjustments (e.g., adjusting cut-offs, 
different intervention strategies) have been proposed 
(237). 
— The  optimal   hemoglobin   concentrations   for   func- 
tional outcomes have not been determined (221,  222,  
238). 
 
Serum iron, ferritin, sTfR, and iron stores. 
— During the first trimester, with expansion of the plasma vol- 
ume, the serum iron begins to fall whereas the serum trans- 
ferrin concentration, shown as TIBC in Figure 3, begins a 
steady increase, resulting in a decrease in the serum transfer- 
rin saturation (226). 
— By the end of the first trimester, the SF concentration, an 
indicator of body iron stores, begins a steady decline (239). 
— SF concentrations are reduced as a result of hemodilution 
in pregnancy and exhibit considerable day-to-day intraindi- 
vidual variability (240). 
— An SF concentration >70 µg/L before pregnancy or early in 
the first trimester has been proposed as a means of identify- 
ing women who will not need iron supplementation during 
gestation (241). However, a variety of guidelines have been 
published with respect to the concentration of SF that is best 
to identify iron deficiency (242). 
— The sTfR concentration remains stable (243–246) whereas 
the sTfR index (the sTfR concentration divided by log SF) 
begins to increase. The distribution of body iron stores, 
estimated from SF and serum transferrin receptor concen- 
trations (247, 248) among pregnant women examined in 
NHANES, 1999–2006, was reported by Mei et al. (249). 
During the first trimester, 6.9% of these women were iron 
deficient, using the criterion of body iron index <0 mg/kg. 
(Body iron index is defined as the logarithm of the ratio of 
sTfR/ferritin. It provides a quantitative estimate of the size 
of the body iron store; discussed in greater detail later in this 
review.) 
 
Erythrocyte protoporphyrin. 
— Zinc protoporphyrin (ZPP) is reputed to be “the most 
established biomarker of iron-deficient erythropoiesis” 
(250). 
— Measured as the ZPP/heme ratio (ZPP/H) by a hematoflu- 
orometer, erythrocyte protoporphyrin is unaffected by the 
hemodilution of pregnancy (251). 
— With an adequate iron supply, erythrocyte protoporphyrin, 
unlike sTfR, is also unaffected by increased erythropoiesis 
during pregnancy (252). 
— Erythrocyte protoporphyrin remains within the reference 
range in iron-replete women during the first trimester (235, 
246, 251–253). 
 
Second trimester. A number of changes occurring in iron 
homeostasis as gestation progresses are highlighted in Text Box 
21 (223, 233). Median concentrations of the principal biomark- 
ers of iron status during the second trimester of pregnancy are 
again shown in Figure 3. 
 
duce the circulating red blood cell mass and increase iron 
stores (223). 
• In the latter portion of the first trimester, fetal and pla- 
cental growth accelerate and expansion of the plasma vol- 
ume begins. 
• Initially, a reduction in erythropoiesis may slightly re- 
∼0.4 mg/d (233). 
• With a highly bioavailable diet, total (heme and 
nonheme) iron absorption has been estimated at only 
• The iron requirement falls to ∼0.8 mg/d (223) and iron 
absorption may decline. 
Text Box 20 
Basics of iron biology in pregnancy: first trimester 
• After conception, the arrest of menstruation decreases 
iron losses to a basal level for much of the first trimester 
(Figure 1). 
  
FIGURE 3 Biomarkers of iron status during pregnancy and 6 wk postpartum in 31 apparently healthy Dutch women. The participants in this 
study were >18 y old with an expected normal pregnancy based on a normal hematologic blood count, renal function, and liver enzymes at their 
first visit. Iron supplements were not routinely prescribed and were reserved for those with hemoglobin concentrations <105 g/L and reduced 
mean cell volume (<80 fL) in accordance with national guidelines. Data are shown as medians with the IQR. Asterisks represent the significance   
in relation to first trimester values; analyzed with linear mixed models, *P < 0.05, **P < 0.001, ***P < 0.000. sTfR, soluble transferrin receptor; 
sTfR-index, sTfR divided by log ferritin; TIBC, total iron-binding capacity. Reproduced with permission from reference 226. 
 
 
 
 
 
Hemoglobin. 
— In the absence of iron deficiency, the circulating hemoglobin 
concentration continues to decline, with the threshold for 
anemia decreasing from 110 g/L in the first trimester to 105 
g/L in guidelines from the CDC (235). 
— WHO guidelines (236) continue to use a threshold for ane- 
mia of 110 g/L. 
 
Serum iron, ferritin, sTfR and iron stores. 
— During the second trimester the serum iron continues to fall 
as the transferrin concentration rises, and a further decrease 
in the serum transferrin saturation is the result (Figure 3) 
(226). 
— Serum ferritin concentrations continue to decrease during 
the second trimester in British women not receiving iron sup- 
plements (232). 
— In the available studies of sTfR during the second trimester, 
concentrations remained stable or rose somewhat (226, 243, 
244, 246). Because both functional iron deficiency and in- 
creased erythropoiesis raise sTfR concentrations, the rela- 
tive contribution of the two processes during pregnancy is 
uncertain. 
— In some studies, the increase in sTfR during pregnancy 
seems more closely associated with erythropoietic activity 
(244), but others suggest that iron deficiency is the predom- 
inant factor (243, 246). With the decrease in SF, the sTfR 
• Total iron absorption rises to an estimated 1.9 mg/d 
from a highly bioavailable diet (233). 
• Iron requirements steadily increase to ∼4 mg/d by the 
end of the second trimester (223). 
Text Box 21 
Basics of iron biology in pregnancy: second trimester 
• Fetal and placental growth increase throughout the 
second trimester. 
• Both the red blood cell mass and plasma volume ex- 
pand steadily with a greater proportional increase in the 
plasma volume. 
 index increases during the second trimester (226, 246). In 
the pregnant women examined in NHANES  1999–2006,  
the proportion with body iron index <0 mg/kg increased to 
14.3% in the second trimester (249). 
— In iron-replete women, erythrocyte protoporphyrin re- 
mained within the reference range during the second 
trimester (235, 246, 250–253). 
 
Third trimester. As pregnancy moves toward its conclusion, a 
number of processes continue with regard to the maternal and 
fetal physiology to meet iron needs; these are highlighted in Text 
Box 22 (223, 233). Again, median concentrations of the princi- 
pal biomarkers of iron status in Dutch women during the third 
trimester of pregnancy are shown in Figure 3. The following de- 
scribes aspects of physiology relative to specific iron biomarkers. 
 
 
Hemoglobin. 
— The circulating hemoglobin threshold for anemia during the 
third trimester is 110 g/L in guidelines from both the CDC 
(235) and the WHO (236). 
— In women given iron supplements, the hemoglobin concen- 
tration in the third trimester rises from a nadir near the end 
of the second trimester but is appreciably lower in those who 
receive no supplemental iron (254). 
 
Serum iron, ferritin, sTfR and iron stores. 
— During the third trimester, the serum iron falls further as 
the transferrin concentration continues to  rise,  resulting 
in a continued decline in the serum transferrin saturation 
(Figure 3) (226). 
— In the Dutch study, SF decreased during the third trimester 
(Figure 3) (226) as sTfR increased, resulting in a marked 
increase in the TfR index. 
— As in the second trimester, the relative contributions of func- 
tional iron deficiency and erythropoietic activity to the in- 
crease in sTfR have not been determined (226, 243, 244, 
246). 
— In the pregnant women examined in NHANES, 1999–2006, 
the proportion with body iron index <0 mg/kg rose to 
29.5% in the third trimester (249). 
— In women supplemented with iron, erythrocyte protopor- 
phyrin remains within the reference range during the third 
trimester but increases in those with iron deficiency (251, 
252). 
Postpartum. Median concentrations of the principal biomark- 
ers of iron status in Dutch women postpartum are shown in 
Figure 3. Key points relative to iron biomarkers include the fol- 
lowing: 1) at 24 h postpartum, the median hemoglobin concen- 
tration was little changed from the third-trimester level but both 
fluid shifts and the extent of blood loss at delivery will determine 
individual values; 2) Delivery-associated inflammation is associ- 
ated with increased concentrations of C-reactive protein (CRP), 
hepcidin, ferritin, and the sTfR index (226, 228, 255–257); 3) 
At 24 h postpartum, serum iron, transferrin, transferrin satu- 
ration, sTfR, and erythrocyte protoporphyrin are little changed 
from values in the third trimester (Figure 3); and 4) by 6 wk 
postpartum, all the biomarkers of iron status in Figure 3 had 
returned to levels not significantly different from those in the 
first trimester, with the exceptions of sTfR and the sTfR index, 
which remained elevated (226). 
 
Potential biomarkers for maternal and fetal iron status. In 
summary, the interpretation of iron status biomarkers at various 
stages of pregnancy are derived from measurements in healthy 
Western women considered to be iron sufficient. In general they 
reflect maternal rather than infant iron status (177, 258). De- 
termining iron needs by using functional criteria based on the 
health of the infant and mother has been advocated as an al- 
ternative approach (221, 222, 238). It is important to note that 
the putative beneficial effects of improved iron status for the in- 
fant have been based on comparisons between mothers receiv- 
ing supplemental iron (usually with folic acid) and those given a 
placebo. The results of this series of observations have been in- 
consistent in different settings. Nevertheless some studies have 
shown critical functional benefits for the infant (259, 260). It 
will be important to correlate the results of current biomarker 
measurements during the various stages of pregnancy with the 
survival and health of the baby to determine whether they have 
predictive value. The evaluation of newer, currently experimen- 
tal biomarkers such as serum hepcidin and novel red blood cell 
parameters will also be very valuable. 
 
Effects of iron deficiency on fetal and infant neurological 
development. Three periods of pediatric development are at 
increased risk for iron deficiency; the fetus/newborn, children 
aged between 6 mo and 2.5 y, and female adolescents, particu- 
larly if they become pregnant. Although each show a wide range 
of motor and cognitive deficits, the first two are the most vul- 
nerable, with iron deficiency resulting in neurodevelopmental 
alterations that persist despite iron repletion (261). Early stud- 
ies demonstrated that deficits occur in iron deficiency without 
anemia (262) or by fetal conditions that are characterized by a 
shift of available iron into a polycythemic red blood cell mass at 
the expense of maintaining brain iron sufficiency (263). These 
findings in humans, supported by animal research in sheep, rats, 
and monkeys, suggest that iron is prioritized to red blood cells 
over other organs, including the brain, during fetal and early 
postnatal life (264–266). Thus, screening for iron deficiency by 
assessing anemia likely means that the brain has already been 
affected prior to diagnosis (267). 
In humans, behavioral deficits map directly onto the abnor- 
mal brain processes (and their interactions) elucidated from 
the animal models (181). These include general reductions in 
intelligence, motor abnormalities, including activity levels and 
coordination, disrupted sleep patterns, slower speed of process- 
ing, altered affect and social interactions, and reduced learning 
and memory capacity (181). Long-term persistence of some of 
these abnormalities has been documented to adulthood (268). 
even higher, 10 mg/d, during the last 6–8 wk of pregnancy 
(223). 
• Total iron absorption from a highly bioavailable diet 
also increases to an estimated 5.0 mg/d (233), but is still 
far below the calculated daily iron requirement. 
• The iron requirement rises to 6–7 mg/d and may be 
• The overall increase in the red blood cell mass is ∼35% 
and in the plasma volume, ∼50%. 
Text Box 22 
Basics of iron biology in pregnancy: third trimester 
• Fetal and placental growth, together with expansion 
of the red blood cell mass and plasma volume, steadily in- 
crease to a peak in the latter portion of the third trimester. 
 Because these long-term abnormalities exist in spite of relatively 
prompt diagnosis and treatment of anemia, biomarkers that 
index brain health independent of red blood cell iron status are 
critically needed. 
Establishing the functional consequences of the effects of a 
nutrient deficiency on brain development can be challenging for 
the following reasons: 1) nutrient deficiencies frequently have 
their most profound effects on the brain when it is in its most 
rapid growth trajectory, during the late fetal period and from 0 
to 3 y of postnatal age (202, 203, 269); 2) functional assessment 
of the brain at these ages is difficult because of the limited behav- 
ioral repertoire of the fetus and young child; 3) the effects can 
be relatively subtle, often affecting specific neurologic domains 
and behaviors rather than global function; and 4) common nu- 
trient deficiencies are rarely fatal and thus tissue-level “proof of 
effect” is often not an option. 
The features of the two general approaches typically used to 
assess the brain consequences of early-life nutrient deficiencies 
are highlighted in Text Box 23. 
beyond the scope of this paper.  However, several reviews of  
the subject are worth considering in order to appreciate the 
body of evidence that early-life iron deficiency is detrimental to 
long-term brain health (77, 181, 270–272). 
In considering nutritional interventional studies in children, 
the following four key developmental neuroscience principles 
must be followed in order to optimize the chances of obtaining 
accurate information: 1) timing of the intervention; 2) clarity 
regarding level of risk in target populations; 3) use of age- 
appropriate testing tools; and 4) ensuring linkage between in- 
terventions and assessment. The key features of these principles 
are summarized in Text Box 24 (273–274). The following is a 
summary of some additional details about the implications of 
iron deficiency during development. 
 
 
 
Human and animal studies strongly support the hypothesis 
that early-life iron deficiency  alters  the  brain,  both  acutely,  
as long as iron deficiency persists, and chronically, well after 
iron repletion. A comprehensive review of this topic is well 
 
Text Box 23 
Approaches to evaluating the impact of nutritional insults 
on development 
• Use of multidisciplinary assessments ranging from 
molecular neuroscience through behavior to construct a 
plausible biological proof. 
-This approach can be driven top-down (i.e., from be- 
havior to bench science) or bottom up. 
-In either case the following are required: 1) develop- 
mentally appropriate preclinical models; 2) physiologi- 
cally appropriate degrees of nutrient deficiency; and 
3) a certainty as to the equivalency of animal 
behaviors to human behaviors. 
• Clinical studies: can be either observational/treatment 
or prevention/supplementation studies. 
-Observational studies evaluate developmental out- 
come when a population with a specific nutrient 
deficit is compared to a population without that 
specific nu- trient deficit. 
• The assumption is that all confounding variables that 
can affect brain development (including other nutrient de- 
ficiencies) will be equal between groups. 
• Given that nutrient deficiencies tend to co-occur, this 
goal can be difficult to achieve. 
-Prevention/supplementation studies: the nutrient in 
question is supplemented in one group and outcomes 
are compared to a nonsupplemented control. 
• This approach can be problematic due to issue af- 
fecting rigor and reproducibility including, lack of base- 
line status assessment, lack of sensitive and specific nutrient 
biomarkers, and types and expectations regarding outcome 
measures and their relevance to nutrition or nutrient-brain 
interactions. 
 
Text Box 24 
Key principles for evaluating neurological outcomes 
Timing 
• The nutritional intervention must occur at a time when 
there is a demonstrably high demand for the nutrient in the 
developing brain or brain region. 
• The optimal timing for a particular nutrient is most of- 
ten elucidated from developmentally appropriate preclini- 
cal models. 
• Must consider whether administration of a supple- 
ment to a mother eventually results in accretion in the 
developing fetal brain (e.g., in considering iron supple- 
mentation during pregnancy, the driving force would be 
demonstration of an effect on iron-dependent fetal re- 
gional brain development) rather than influencing ma- 
ternal hematologic status (although the two may well 
coincide). 
Level of risk in target population 
• The target population in the study must have a signif- 
icant rate or risk of deficiency. 
• There is no evidence in developmental neuroscience 
that further supplementation of any environmental factor 
(including nutrients) beyond a state of sufficiency results in 
“enhanced” brain development. 
• Study populations cannot have a degree of deficiency 
that is so great that a relatively low dose intervention has 
no effect (273) 
• Study populations should not have deficits of multiple 
nutrients that affect brain development such that it is im- 
possible to assess the role of a single nutrient such as iron 
(274). 
Age-appropriate testing tools 
• Use neurodevelopmental test batteries that are appro- 
priate to the proposed nutrient’s role in the brain at the 
time that the supplement was administered. 
• Global tests (i.e., Bayley Scales of Infant Development, 
IQ tests) are often too generic and fail to detect neurodevel- 
opmentally important differences in higher brain process- 
ing, speed of performance, and subtle memory problems. 
• Nevertheless, global tests are typically utilized in large- 
scale studies because they are easily performed across mul- 
tiple enrollment sites. 
• More specific neural domain tests tend to be techni- 
cally difficult and may also be expensive even though they 
may be better designed to assess the specific nutritional 
deficit-induced pathology. 
 ∼ 
Preclinical models of gestational/lactational iron 
deficiency 
The degree of brain iron deficiency seen in human autopsy spec- 
imens has been achieved in rat models of gestational/neonatal 
dietary iron deficiency (186, 187, 191, 285, 286). Similar evi- 
dence has been provided by genetic mutant nonanemic mouse 
models that isolate the iron deficiency to single brain regions 
(209). The totality of this evidence demonstrates the negative 
effects of gestational/neonatal iron deficiency on regional brain 
anatomy and function and is summarized in Text Box 25 (170, 
184–191, 209, 210, 285, 287–292). 
 
 
 
 
 
 
 
 
The vulnerable period of pregnancy, through infancy and 
toddlerhood (181) will be considered separately because the 
etiologies of iron deficiency and neurodevelopmental conse- 
quences differ. In each case the pathophysiology leading to in- 
creased risk of iron deficiency, the animal models that support 
the hypothesized effects, and the human evidence for the dele- 
terious neurodevelopmental effects will be examined. 
 
 
Pathophysiology of iron deficiency in the fetus and 
neonate 
As detailed above, much is known about the maternal-fetal 
transfer of iron. Evidence in humans points to prioritization of 
iron to the fetus at the expense of the mother (176, 177). In   
the fetus, evidence from humans (275, 276) and animal models 
(264) indicate that interorgan prioritization favors red blood 
cells over other organs, including the brain, the heart, and the 
liver—in that order (264, 276). 
A number of gestational conditions lead to a disruption of 
the balance of fetal iron supply and demand and thus to fetal 
brain iron deficiency (277–279). These include the following: 1) 
severe maternal iron deficiency; 2) placental insufficiency (usu- 
ally due to maternal hypertension); 3) maternal diabetes melli- 
tus; and 4) maternal smoking. 
The first two reduce available iron to the fetus, whereas the 
chronic fetal hypoxemia associated with poorly controlled ma- 
ternal diabetes increases fetal iron demand for compensatory 
erythropoeisis beyond the capacity of the placenta’s transport 
ability (166, 275, 280); for a review, see Nold and Georgieff 
(281). 
Studies have shown that brain iron concentrations are re- 
duced by 40% in newborn iron-deficient infants of diabetic 
mothers (276) and by 33% in newborn intrauterine growth- 
restricted infants (282). Looking at ferritin concentrations, 65% 
of infants of diabetic mothers and 50% of growth-restricted 
newborns have a cord SF concentration <60 µg/L (277). 
Iron in the liver is predominantly in the form of ferritin and 
serves as a storage buffer for the fetus during periods of reduced 
iron supply. Nevertheless, in humans, once liver iron concentra- 
tions are <1500 µg/g dry tissue weight, brain iron concentration 
falls precipitously (276). Based on data presented by Saarinen 
and Siimes (283), a cord SF concentration of 40 µg/L in the 
child (275, 284) would reflect liver iron concentration indicative 
of potential risk for fetal/neonatal brain risk. 
 
The affected behaviors of gestational/lactational iron defi- 
ciency include abnormalities in hippocampus-based learning 
and memory (170, 191, 209, 210, 293) and dopaminergically 
driven behaviors (170, 294) as would be predicted by the 
time/dose/duration paradigm (203). These preclinical studies 
have demonstrated that the hippocampal, dopaminergic, and 
myelin effects persist beyond the initial neonatal deficiency into 
adulthood. It is also clear that only treatment at a time that is de- 
velopmentally consistent with the third trimester of pregnancy 
is effective in preventing those long-term effects. 
Gestational/lactational dietary iron-deficiency anemia in the 
rat has provided a convincing pathophysiologic model of the 
human condition. Although the pathology evinced by this model 
is due to reduced iron exposure, these models have been unable 
to specifically distinguish the role of iron from that of anemia 
(or the combination) in neurodevelopment (209). 
The essentiality of iron to neurodevelopment was elu- 
cidated recently through generation of  two  nonanemic  
genetic mouse models: 1) transgenic mice that express 
tetracycline transactivator-regulated, dominant negative 
transferrin receptor (DNTfR1) in hippocampal neurons; 
2) nonanemic Slc11a2(hipp/hipp) [double mutant, hippocam- 
pal neuron-specific knockout of Slc11a2(hipp/hipp)] mice (72, 
91). In these models iron uptake is disrupted in specific sites 
(hippocampus) and at specific time  (late  gestation). The  use 
of these models demonstrated both a structural vulnerability  
in the hippocampus and a critical period for the provision of 
iron, which if missed, results in irreversible long-term neu- 
rocognitive, structural, and genomic abnormalities (179, 209). 
Functionally, these models show that the loss of learning and 
memory capacity results specifically from the loss of hippocam- 
pal neuronal iron uptake (179,  209).  The  fundamental  role  
of iron availability in learning and memory is also supported  
by  a  dose-dependent  increase  in  expression  of hippocampal 
• The degree of neurodevelopmental deficit must be con- 
sistent with the effect size seen in the developmentally ap- 
propriate preclinical models in order not to misattribute a 
large effect size to a nutrient that is likely, in fact, to have  
a small effect. 
Linkage between interventions and assessment 
• Neurodevelopmental assessment batteries must be ad- 
ministered as close to the intervention as possible in order 
to avoid post-treatment confounding factors. These include 
the following: 
-Negative environmental (including nutritional) factors 
-Positive factors such as neural plasticity in the brain 
areas that were initially negatively impacted by the de- 
ficiency 
 
Text Box 25 
Preclinical evidence of effect of iron deficiency on the brain 
• Electrophysiology (190). 
• Structure (189, 287). 
• Metabolism (185, 288, 289). 
• Neurotransmitter concentrations (170, 185, 186, 285, 
290, 291). 
• Myelination (184). 
• Gene expression (187, 188, 209, 292). 
• These regional cellular abnormalities are particularly 
concentrated in the developing hippocampus and stria- 
tum and result in abnormalities in behaviors dependent on 
those regions (170, 191, 209, 210). 
 ∼ 
neuronal iron transporters with increasingly difficult memory 
tasks (209). These models have also been used to demonstrate 
that nonanemic iron deficiency, which is more prevalent in 
humans than IDA, also disrupts brain development. Thus, the 
available evidence indicates that iron is essential for fetal and 
early postnatal brain development and function, and that iron 
deficiency leads to abnormal brain development and function. 
 
Human studies 
The abnormalities documented in preclinical animal models 
map directly onto the human behavioral and electrophysiologi- 
cal abnormalities in iron-deficient newborns, thereby providing 
a multilayered plausible biological proof for the important role 
of iron in neurodevelopment. The challenge of such studies in 
humans is linking measures of the myriad of structural and func- 
tion components of the developing nervous system to biomark- 
ers of iron nutrition. The former may be referred to as “bioindi- 
cators,” reflecting perturbations of specific structures/neural 
systems as compared to sensitive and specific biomarkers of iron 
nutrition/status (295). 
Although data on the behavior of the iron-deficient new- 
born humans is limited, the existing literature strongly impli- 
cates nonanemic and anemic iron deficiency in the fetal and 
neonatal period as neurodevelopmental risks to precisely the 
systems that were rapidly developing at the time of the defi- 
ciency (284, 296–299). Text Box 26 (177, 273, 294, 296, 297– 
307) highlights some of the extant evidence as well as some of 
the bioindicators that have been used. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Effects of iron deficiency on infants and toddlers. Accord- 
ing to the 2007–2010 NHANES survey, in  the United States, 
7% of children aged 1–5 y have iron deficiency (308) com- 
pared to rates of IDA in regions of sub-Saharan Africa and 
Southeast Asia that exceed 50%. The high rate of infant and 
toddler iron deficiency and IDA around the world is due to 
multiple coinciding and mutually exacerbating factors (181). As 
with the fetus and neonate, iron requirements are high because 
of the rapid rate of somatic growth. The red blood cell mass con- 
tinues to increase with somatic growth and accounts for the vast 
majority of total body iron demand (as hemoglobin), and also 
myoglobin in growing muscles. In addition, any rapidly grow- 
ing and differentiating organ, such as the brain, will continue to 
have high demands. To meet this demand, the child relies on mo- 
bilizing iron present as ferritin and the (relatively) expanded red 
blood cell mass at birth, and from postnatal dietary iron intake. 
Infants with low iron stores at birth are at greater risk for lower 
stores at 9 mo of age; that risk is directly proportional to the 
rate of growth between birth and 9 mo (309). The gestational 
conditions that lead to low neonatal iron stores are discussed 
elsewhere. 
During the postnatal and infancy period the sources of di- 
etary iron include various infant feeding options (e.g., human 
milk, formula, animal milk), complementary foods (e.g., animal 
meat protein, wet- and dry-pack cereals), leading eventually to 
a mixed diet as available within the household. Throughout this 
period infants/children may also be exposed to iron supplements 
with or without micronutrients (310). 
As in adults, iron utilization from these sources can be 
enhanced by ascorbic acid and inhibited by phytates and 
 
Text Box 26 
Impaired newborn iron status and neurodevelopment 
• Infants with low cord ferritin (<76 µg/L) were almost 
5-fold more likely to score poorly on fine  motor  skills, 
and almost 3-fold more likely to have poorer tractability, 
poorer language ability, and score worse on every subtest 
than children with normal ferritin concentrations at age   
5 y (296). 
• Suggests a critical period for multiple brain processes 
in the fetus and neonate. 
• Several studies have evaluated the impact of maternal 
iron intervention on general developmental outcome. 
-Multiple studies show significant positive findings, 
e.g., (299–302). 
-Null studies have been reported with iron supplemen- 
tation in pregnancy (273). 
• Positive findings highlight the following: 
-The importance of an appropriate dose of  iron  for 
the degree of iron deficiency of the maternal-fetal dyad 
(302). 
-The importance of timing of the intervention was ap- 
parent in a subsequent large placebo-controlled supple- 
mentation trial in Nepal (302). 
• Children of women originally randomized to placebo 
during pregnancy had poorer outcomes (300). They subse- 
quently received supplemental iron/folic acid (with or with- 
out zinc) from 1 to 3 y of age. 
• No effect was seen at age 7–9 y of age on neurocogni- 
tive (including frontal lobe) testing (302). Thus, postnatal 
iron supplementation was unable to counteract the prena- 
tal effects of lower iron status. 
• Studies of targeted brain areas and functions have used 
several “bioindicators” (i.e., high-end techniques to target 
functions in rapidly developing iron-dependent neural cir- 
cuitry) including the following: 
-Development of the hippocampus [rapidly developing 
in the late fetal/early neonatal period in humans and 
subserves recognition, e.g., discriminative memory be- 
havior (303)], ID was associated with poor vocal recog- 
nition (304). 
-The persistence of learning and memory problems at 
age 3.5 y. Performance was inversely proportional to 
iron status at birth (305). 
-Monoamine metabolism as reflected by increased risk 
to infant temperament, potentially mediated by the de- 
veloping dopaminergic system, has been documented 
(297). The findings are important because temperament 
is closely related to monoamine status (306). At birth, 
infants with iron deficiency without anemia (294) show 
profound short- and long-term changes in monoamine 
metabolism. 
-Myelin formation/function: auditory brainstem 
responses  were  assessed  as  a  reflection  of  speed  
of  processing  and  a  potential  index  of  myeli-  
nation in infants at birth  (298,  307).  Results 
indicated  that  iron  deficiency  early  in   the   pe-   
riod of myelination of the central nervous system 
causes slower speed of processing along myelinated 
circuits. 
 polyphenolic compounds (e.g., tea, coffee) in the diet. World- 
wide, two significant pathologies contribute to the common 
occurrence of negative iron balance: blood loss from intesti- 
nal (usually parasitic) infections and the hepcidin-mediated 
ACD/inflammation which limits iron absorption during periods 
of infection and inflammation (181). 
Unlike the fetus and neonate, there are no studies that quan- 
tify the degree of brain iron deficiency in iron-deficient anemic 
infants or toddlers. Similarly, no studies address whether iron is 
prioritized to red blood cells over the developing brain as occurs 
in the fetus and neonate. The presence of behavioral abnormali- 
ties in nonanemic iron-deficient children suggests, however, that 
this may well be the case (262). 
 
Preclinical models of postnatal dietary iron deficiency. Vir- 
tually all preclinical studies that induce iron deficiency in the 
postweaning period (i.e., 21 d after birth in the rat) are designed 
to simulate IDA in humans after 1 y of age. These models have 
been used to demonstrate long-term effects on the monoamin- 
ergic and myelin systems that persist into adulthood even af- 
ter remediation of iron deficiency. Alterations in these systems 
have been linked to functional abnormalities in neural circuits 
that regulate mood, affect, social behavior, motor behavior, and 
speed of processing (181). In summary, preclinical models pro- 
vide mechanistic evidence to explain how postnatal dietary iron 
deficiency affects brain development and related functional out- 
comes. Text Box 27 (181–183, 186, 189–191, 298, 307, 311– 
325) contains a summary of knowledge gained from preclinical 
studies of iron deficiency. 
 
 
 
 
 
 
 
 
Human studies. A number of systematic review and data anal- 
yses have been reported recently (270–272). Of particular rel- 
evance is the series on risk factors to early childhood develop- 
ment in The Lancet, originally published in 2007 and updated  
in 2011 (271, 272). 
Studies of the effect of postnatal iron deficiency’s effects on 
neurodevelopment fall into two categories; 
1) Larger-scale population-based studies that typically as- 
sess general outcome of observation/treatment trials and 
prevention/supplementation trials irrespective of initial 
iron status. 
• Prevention/supplementation trials are more likely to 
have null or small effect-size results with respect to an- 
swering the question of whether early life iron deficiency 
causes neurodevelopmental abnormalities because the 
sample populations are unselected. 
• Small effect-sizes in such an unselected group of subjects 
should be considered as evidence for a biologically rele- 
vant effect. 
2) Smaller-scale studies designed to elucidate the role of 
iron in specific neurobehavioral abnormalities predicted 
from preclinical models. 
Overall, 20 of the 22 studies reviewed in the two Lancet 
papers showed poorer functioning on general tests of cog- 
nition, motor, and social-emotional capacity in children with 
 
Text Box 27 
Preclinical evidence of functional consequences: infants 
and toddlers 
Monoamine 
• Through its role in the activity of tyrosine hydrox- 
ylase and tryptophan hydroxylase, iron is responsible for 
the synthesis of dopamine and serotonin, respectively (186, 
311). 
• Iron deficiency reduces the concentration of dopamine 
D2 receptors in the ventral midbrain and prefrontal cortex 
(312). 
• Studies have suggested that nonanemic iron deficiency 
is a risk to brain development and function (313). 
• Behavioral abnormalities in preclinical models are 
consistent with disruptions of dopaminergic pathways and 
map well onto the behavioral findings in humans (181, 191, 
312, 314, 315). 
• Studies in nonhuman primate models have docu- 
mented the following differences in outcomes based on the 
timing of iron deficiency: 
-Prenatal iron deficiency in the rhesus monkey results 
in a behavioral phenotype of hyperactivity and lack of 
inhibitory control. 
-Postnatal iron deficiency results in a hesitant, wary 
phenotype (316–318). 
• Given the role of specific iron-sensitive areas of the 
brain and the role of the dopamine system in mediating 
activity and anxiety (319), the preclinical studies strongly 
support the hypothesis that an iron-dopamine link under- 
lies the motor activity and anxiety behaviors seen in iron- 
deficient children (315, 320, 321). 
Myelin 
• Iron is an essential factor in myelination and oligoden- 
drocyte function via its role in: 
-Fatty acid incorporation into myelin 
-Oligodendrocyte proliferation (183, 322, 323) 
• Iron deficiency may affect oligodendroglia synthesis 
of myelin via cellular mitochondrial dysfunction caused by 
reduction of cytochrome concentrations (182, 323). 
• Iron deficiency in the preweaning and postweaning pe- 
riods alters myelination in the rat, as demonstrated by: 
-Reduced 2,3-cyclic nucleotide-3-phophohydrolase 
(CNPase) activity 
-25–35% reduction in myelin basic protein concentra- 
tions (324) 
• Abnormalities in myelination observed in these rat 
models may be the underlying abnormalities in neural 
speed of processing that can explain the auditory brainstem 
evoked responses (298, 307) and visual evoked responses 
(325) reported in iron-deficient children. 
Cellular energetics and mitochondrial health 
• Studies have established that iron exerts its influence 
through its incorporation into cytochromes (182). 
• Neurons (and glia) have high metabolic rates during 
development, and thus are sensitive to reductions in iron 
supply (286, 323). 
• Neuronal iron deficiency results in changes in dendrite 
structure (189) and lower electrical output (190)—both 
are associated with poorer synaptic efficacy and memory 
deficits. As noted above, iron-deficient oligodendrocytes 
generate less myelin and also myelin with abnormal fatty 
acid profiles (323, 324). 
 iron-deficiency anemia (271–272). The consistency of this find- 
ing across many study designs from multiple populations 
around the world suggests a robust effect. 
In infants, toddlers, and young children, general functioning 
is typically assessed with broad-based standardized tests such as 
the following: 1) Bayley Scales of Infant Development—these 
provide information about mental and motor outcomes, each 
normed to a mean of 100 with an SD of 15; 2) neuropatho- 
logically specific tests can be behavioral or involve some type 
of neuroimaging, and can include electrophysiology to assess 
social-emotional function, speed of central neural processing, 
learning and memory, and complex behaviors. 
Both approaches can assess acute (i.e., while iron deficient) 
and long-term (ie, after treatment and resolution) effects. 
A number of studies have explored the effect of IDA on gen- 
eral function. Some of the key findings are summarized as fol- 
lows: 1) six observational/treatment studies of otherwise well- 
nourished infants with IDA showed that iron-deficient infants 
scored 6–15 points lower on mental developmental indexes 
compared to iron-sufficient, nonanemic controls (326–331); 2) 
five of the studies showed a lower motor index with a similar 
effect size (326–329, 331); 3) recovery of neurobehavioral func- 
tion with treatment was seen in two of the six studies (326, 328), 
but not in the others; 4) in one of the cohorts followed for the 
longest period of time (19 y), loss of IQ was noted over time 
from 1 y to age 19. The slope of this loss was greater in children 
who were chronically iron deficient between 12 mo and 3 y or 
who did not correct their hematology within 3 mo of therapy 
(181); 5) the results imply that critical periods of neurodevel- 
opment exist that are dependent on iron sufficiency, a finding 
supported by the preclinical models. 
Selected studies of the effect of acute IDA on pathophysiolog- 
ically plausible regional brain circuitry are highlighted in Text 
Box 28 (209, 211, 262, 332–336). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Prevention and supplementation trials. Results from pre- 
vention/supplementation trials indicate a modest, but positive 
effect of iron supplementation on neurodevelopment. As noted 
above, a systematic review of these types of trials would be 
expected to show variability in response because of several 
factors that determine nutrient-brain interactions during devel- 
opment. When enrolling unselected (for iron deficiency) sub- 
jects, the baseline rate of iron deficiency, the severity of iron 
deficiency, the timing of intervention, the dose of the interven- 
tion relative to the degree of deficiency and the selection of the 
proper bioindicator of neurodevelopment relative to the stage 
of brain development when the deficiency occurred, all become 
relevant factors in whether an effect will or will not be seen. 
At least seven trials of postnatal iron supplementation of- 
fer useful data and are characterized as follows: 1) two were 
conducted in developed countries (337, 338); 2) five were con- 
ducted in developing countries (339–343); 3) the  trials  did 
not have the same study designs, in that other risk factors to 
 
Text Box 28 
Effect of iron deficiency and IDA on regional brain circuitry 
• Dopaminergic systems: spontaneous eye blink rate, a 
dopaminergic function, was assessed in 19 iron-deficient 
anemic 10-mo-olds (332). 
-Compared to iron-sufficient controls and nonanemic 
iron-deficient infants, the iron-deficient anemic infants 
had significantly slower eye blink rates, consistent with 
reduced dopamine function. 
-A significant dose-response relationship between 
social-emotional behavioral abnormalities and the de- 
gree of iron deficiency exists. Infants with IDA have 
poorer soothability, less positive affect, and less social 
engagement than iron-sufficient infants, with nonane- 
mic iron-deficient infants demonstrating intermediate 
degrees of abnormalities (262). 
• Hippocampus: electrophysiological evidence of hip- 
pocampal dysfunction was provided in a study of 9- to 12- 
mo-old infants with IDA and iron-sufficient controls (333). 
-In a maternal face recognition paradigm, iron-deficient 
anemic infants showed a maturational delay in recog- 
nition memory (333). 
-Part of the effect was mediated by social-emotional 
status of the infants, consistent with the role of 
dopamine in hippocampus-dependent memory func- 
tion. These effects suggest that iron deficiency causes 
hippocampal dysfunction during a period of rapid hip- 
pocampal development that extends from birth to 18 
mo of age in the human. 
-These observations are consistent with preclinical 
model studies that demonstrated that iron is essential 
for normal hippocampal neuronal development, and 
normal learning and memory function (209). 
• Behavioral tasks were used to assess recognition mem- 
ory. 
-In 28 IDA, 28 iron-deficient and 21 iron-sufficient 9- 
mo-olds (334). 
-IDA infants showed poorer object permanence and 
short-term memory than iron-sufficient infants. 
-Iron-deficient infants demonstrated intermediate per- 
formance to the other two groups, suggesting a dose- 
response effect based on iron status. 
• Electrophysiology: auditory brainstem evoked re- 
sponses were utilized to assess the effect of IDA on speed 
of central neural processing in 29 IDA 6-mo-olds and 26 
iron-sufficient controls (325). 
Central conduction time was longer in the iron-deficient 
infants, indicating slower processing speed. 
Because the delays were more prominent at 1-, 2-, and 
4-y follow up (325), the authors concluded that the effect 
likely was a permanent alteration in a primary process such 
as myelination, rather than a developmental delay. 
• Electrophysiology: visual evoked potentials were used 
in 25 IDA compared to 25 iron-sufficient toddlers aged 6 
to 24 mo (335). 
Demonstrated longer latencies on visual evoked re- 
sponses in IDA infants 
A dose-response effect was shown between the dura- 
tion of latency delay and the degree of IDA. The data from 
the preclinical studies confirm significant alterations in the 
myelination process with iron deficiency (211). 
Because a period of rapid myelination exists between 
36 wk gestation and 2 y in humans, the findings suggest a 
vulnerable period precisely at the time that infants are at 
risk of iron deficiency (336). 
 neurodevelopment (stunting, other micronutrient deficiencies, 
etc.) were present in four of the five trials set in developing 
countries; 4) supplementation in some trials was with a multi- 
micronutrient preparation, making isolation of the role of iron 
in any findings more problematic; and 5) the risk of iron defi- 
ciency also varied widely, even in the two trials in the developed 
country settings. 
In spite of these differences, all the trials in developing coun- 
tries (where in some cohorts the risk of iron deficiency was 
high and the degree of iron deficiency when present was large) 
reported improved motor outcomes with iron supplementation 
(339–343), as did one trial in a high-risk population in a de- 
veloped country, England (338). Better cognitive/language out- 
comes were present in two studies (342, 343), whereas improved 
social-emotional development was seen in three (340, 341, 343). 
Long-term follow-up of these cohorts will determine whether 
these benefits are sustained. 
Given its important roles in cellular metabolic processes, it 
should not be surprising that an iron-deficient brain does not 
perform optimally. Of greater concern are the long-term mor- 
bidities conferred by early-life iron deficiency and the consis- 
tent finding that prompt treatment of early-life iron deficiency 
does not prevent long-term disability (in humans or in ani- 
mal models). This failure to completely recover from brain iron 
deficiency is unlike the finding in red blood cells, where 
treatment resolves anemia with no apparent long-term conse- 
quences. Additional aspects of the impact of early iron defi- 
ciency on brain biology and human behavior are addressed be- 
low. 
From a neurodevelopment perspective, the failure to achieve 
normal development after early iron deficiency suggests that 
critical periods of brain development have been missed and 
structure is permanently altered. Moreover, long-term dysreg- 
ulation of critical synaptic and myelin gene expression in dam- 
aged areas suggests the possibility that early-life iron deficiency 
may exert epigenetic effects (187, 292). The long-term behav- 
ioral abnormalities of formerly iron-deficient humans are com- 
plex and confirm the ultimate interaction of altered major cen- 
tral nervous system processes and brain regions affected by iron 
status during development. 
Iron is likely involved in many more biological processes in 
the developing brain than are currently recognized. One exam- 
ple might be the role of iron in the regulation of long-term gene 
expression (187, 292). While future research will undoubtedly 
add further evidence to the importance of iron, our current un- 
derstanding presents an undeniable picture of its essentiality to 
healthy brain development. The key task from both a clinical 
and programmatic perspective is to use this knowledge to de- 
velop better tools for providing care and programs that address 
the importance of iron not just from a survival perspective but 
with an acknowledgment of its critical role in human develop- 
ment (344). “There is no convincing evidence that iron treat- 
ment of young children with IDA has an effect on psychomotor 
development or cognitive function within 30 days after com- 
mencement of therapy. The effect of longer-term treatment re- 
mains unclear” (344). The lack of a consistent response to iron 
therapy once IDA is present is consistent with the premise that 
prevention of IDA in the first place or earlier identification and 
treatment may be necessary to recover neural function acutely 
and prevent long-term effects. 
 
Potential biomarkers for iron status  during  fetal  and  in- 
fant development. As discussed in detail above, iron dis- 
tribution is markedly different in early human development 
compared to toddlers, children, and adults. Some key features 
of fetal/neonatal iron as they pertain specifically to assessment 
are highlighted in Text Box 29 (278, 345, 346). 
 
 
The biomarkers employed for evaluating iron status in adults 
have been measured in the umbilical cord blood of premature 
and full-term infants (Table 4) (277, 278, 346–348). However, 
the studies contain relatively limited sample sizes and the val- 
ues reported, although qualitatively similar, are generally not 
consistent. Thus, infants are relatively polycythemic and have 
high iron stores at birth, but become critically dependent on an 
adequate supply of dietary iron by 4–6 mo. This dynamic flux 
between the red blood cells and stores makes it very difficult to 
estimate iron status precisely. 
Screening for iron deficiency in the neonate and infant has, in 
the past, been focused on the relationship between maternal and 
infant iron status and the prevention of anemia in early child- 
hood. Although these studies do address important aspects of 
iron nutrition, they may fail to identify critical facets of neuro- 
logic dysfunction because anemia is the end-stage state of iron 
deficiency. 
The developing brain can suffer the consequences of iron de- 
ficiency in the absence of anemia. Prioritization of available iron 
to developing red blood cells over other tissues during negative 
iron balance has been reported in developing humans and ani- 
mal models as well as infants born to diabetic mothers and af- 
ter intrauterine hypoxemia and erythropoietin administration 
(264, 275, 276, 349, 350). Brain iron deficiency, independent of 
anemia, is responsible for long-term neurological deficits (179, 
209, 351). Thus, early detection (and prompt treatment) of iron 
deficiency-induced brain dysfunction should be the primary goal 
of screening for early-life iron deficiency (Table 5) (181, 268, 
352). 
A need exists to generate serum biomarkers indexing brain 
dysfunction in the pre-anemic stage of iron deficiency when it 
• Serum iron and TIBC values also rise whereas ZPP/H 
is inversely correlated with gestational age. 
• On the other hand, sTfR levels do not appear to be 
correlated with gestational age (278). 
• Fetal hemoglobin is replaced by adult hemoglobin dur- 
ing the first 6 mo of life. 
• Iron is transferred from RBC containing fetal 
hemoglobin to the storage compartment and then reuti- 
lized for the synthesis of adult hemoglobin. 
• In a study of 573 normal infants and children, a me- 
dian SF concentration of 101 µg/L was reported at birth, 
rising to 356 µg/L at 1 mo and then rapidly falling to 
∼30 µg/L at 6–11 mo (345). 
• A rise in SF from a median value of ∼45 µg/L at 14–16 
wk to >100 µg/L at 39 wk has been observed (346). 
Text Box 29 
Key aspects of iron status during fetal and neonatal periods 
• Transplacental iron transport to the fetus is highest in 
the third trimester, averaging 1.35 mg/kg fetal body weight 
per day (346). 
• Fetal body iron reaches 75 mg/kg (70–80% in 
hemoglobin, 10% in myoglobin and tissue enzymes, and 
10–15% in stores). 
Evidence for biomarkers 
 TABLE 4 Reported biomarker values for umbilical cord blood1 
 
Biomarker 26–28 wk 29–31 wk 32–36 wk 37–41 wk Reference 
SF, µg/L 75 (44–117) — 90 (45–142) 171 (121–259) Sweet et al. (278) 
    131 (90–238) Sweet et al. (347) 
    134 (40–310) Chockalingam et al. (277) 
    101 Siimes et al. (346) 
sTfR, µg/dL 10.3 (7.5–16.5) — 8.2 (5.4–12.5) 8.4 (6.4–10.6) Sweet et al. (347) 
    9.4 (6.7–10.8) Sweet et al. (278) 
ZPP/H, µmol/mol 122 ± 34 103 ± 18 122 ± 34 — Juul et al. (348) 
1Values are medians (ranges) or means ± SDs. SF, serum ferritin; sTfR, serum transferrin receptor; ZPP/H, zinc protoporphyrin/heme ratio.  
 
is still possible to reverse it with iron treatment. Development 
of such tools relies on knowing the relationship between cur- 
rently available biomarkers and brain iron status, or bioindi- 
cators reflecting iron-dependent brain function. Such tools do 
not currently exist (other than perhaps in the neonate) because 
brain iron status is typically unknown in at-risk children. MRI, 
while sensitive enough to measure brain pathology and relate 
it to iron overload (353), is not sensitive or specific enough to 
detect brain iron deficiency. 
The application of various “-omic” approaches (e.g., pro- 
teomic, metabalomic analyses) have enabled identification of 
potential indicators in the cerebrospinal fluid that can index 
brain iron deficiency in nonhuman primates (354, 355), but no 
studies have assessed such potential biomarkers in cerebrospinal 
fluid in humans. Because of the obvious risk and invasive nature 
of such an approach it is unlikely that using lumbar puncture to 
diagnose brain iron deficiency in humans will become a clinical 
tool. 
Given the current inability to directly assess brain iron sta- 
tus in infants and children, attempts have been made to relate 
classical hematologic [e.g., hemoglobin, Hct, mean corpuscular 
volume (MCV)] and nonhematologic (e.g., ferritin, TSAT, ZPP, 
sTfR) indicators to putative brain iron status (as indexed by ab- 
normal neurobehavior). 
To date, two types of approaches have been used to link iron 
to brain function/outcomes: 1) population-based iron biomark- 
ers linked to neurological outcomes; or 2) studies in neonates 
that attempt to more directly link peripheral iron biomarkers to 
brain iron content. Examples of these approaches are included 
in Text Box 30 (262, 276, 283, 284, 296, 343, 349, 356–358). 
 
TABLE 5 Assessment tools for neurological function1 
 
 
Assessment 
 
Modality 
Iron-dependent 
neurologic process 
 
Behavior construct 
 
Other nutrients 
Applicability 
for field use 
 
Comment 
Sensory evoked 
response (ABR, 
VEP) 
Electrophysiology Myelination, synaptic 
efficacy 
Speed of processing Oxygen, iodine 
(infection) 
No Sensitive; rapid; need 
equipment 
Event-related 
potentials 
Electrophysiology Myelination, hippocampal 
integrity, synaptic efficacy 
Speed of processing; 
recognition memory; implicit 
memory 
Glucose, protein, 
oxygen, zinc, iodine 
No Very sensitive, not 
portable 
T2-weighted MRI Neuroimaging Iron content None None No Detects overload, but 
not ID 
Standardized tests 
(e.g., Bayley 
scales) 
Behavior Myelination, synaptic 
efficacy, monoamine status 
Global function (integration 
of effects of brain-wide iron 
deficiency) 
Protein, fat, oxygen, 
glucose, iodine 
Yes Nonspecific; not 
sensitive 
A, not B Behavior Synaptic efficacy; 
monoamines 
Working memory Zinc, iodine Yes Trained tester 
Actigraph Physiology Monoamines Spontaneous motor activity Protein, copper, iodine Yes Trained interpreter 
Social-emotional 
behavior scale 
Behavior; survey Monoamines Frontal lobe Copper, iodine Yes Trained interpreter 
INFANIB Physical exam Myelination Global Oxygen, iodine 
(infection) 
Yes — 
Peabody 
developmental 
motor scale 
Behavior Myelination monoamines Gross and fine motor Protein, fat, oxygen, 
glucose, iodine 
Yes Nonspecific 
Optotrak Behavior Myelination monoamines Motor response Oxygen, iodine No Equipment and 
trained interpreter 
1ABR, auditory brainstem response; ID, iron deficiency; VEP, visual evoked potential.  
 
 ≥ 
 
Text Box 30 
Studies linking population-based biomarker cut-offs to 
neurological outcomes 
• Population cut-offs for hemoglobin, Hct, and MCV 
were used in seminal early papers that demonstrated ab- 
normal brain function as a function of IDA (343, 356). 
• Lozoff et al. (262) chose to define nonanemic iron 
deficiency as 2 abnormal nonhematologic values in the 
context of a normal hemoglobin concentration and related 
nonanemic iron deficiency to poorer neurobehavioral per- 
formance. 
• In none of these studies was it clear whether the re- 
lationship of these peripherally measured biomarkers to 
brain iron is linear or reflects a threshold for adverse out- 
comes. 
• No studies have assessed the positive or negative pre- 
dictive value of specific cut-offs for these markers. 
Studies in neonates: peripheral biomarkers and neuro- 
logical outcomes 
• An autopsy study of nonanemic newborn infants 
demonstrated that a threshold response of brain iron con- 
centration as a function of liver iron concentration oc- 
curred when liver iron was <10% of normal (276), a find- 
ing recently confirmed in the neonatal lamb (349). 
• Calculations were made from a nomogram published 
by Saarinen and Siimes (283) relating SF concentrations 
to liver iron content to predict that the threshold ferritin 
concentration for brain iron deficiency in the neonate was 
35 µg/L (284). 
• This value was tested as a cut-off to determine whether 
it predicted brain function in neonates and was found to 
differentiate those with normal recognition memory from 
those with impaired recognition memory (284). 
• Abnormalities in acute and long-term brain function 
have also been documented in neonates with cord blood 
ferritin concentrations <76 µg/L (i.e., the lowest quartile) 
(296, 357), suggesting that even these neonatal ferritin cut- 
offs are not reliable. The data also serve to emphasize that 
the 5th percentile cut-off for a population biomarker may 
not represent the level at which neurologic dysfunction 
occurs. 
• Recently, ZPP/H > 118 µmol/mol cut-off in cord blood 
was associated with abnormal recognition memory task at 
2 mo (358). 
• No other hematologic or nonhematologic marker 
measured in the peripheral blood or serum has been as- 
sessed with respect to brain iron content. 
• Whether a similar association, either linear or thresh- 
old, with any of the common hematological indexes or iron 
panel measures is present beyond the newborn period has 
yet to determined. 
 
 
Future research should concentrate on matching currently 
available biomarkers of iron status with the time frames for  
the development of iron-dependent neural systems for which 
functional tests are available, e.g. myelination and monoamine- 
driven behaviors. Examples of potentially relevant tests of neu- 
rological function are listed in Table 5. Because prevention of 
brain iron deficiency is the goal, the changes in the screening tool 
ideally should occur before the onset of brain iron deficiency 
and the clinical diagnosis of neurobehavioral effects due to brain 
iron deficiency. Changes in these bioindicators of brain function 
would likely occur well before the onset of anemia. Diagnosis of 
brain iron deficiency can currently only be inferred clinically by 
alterations to behaviors that are dependent on iron deficiency 
(Table 5). Although these behaviors are not specific to iron defi- 
ciency, if they are present within the context of supporting evi- 
dence of IDA, they can be presumed to be due to iron-deficiency 
effects on the brain (Table 5). Myelination affects the speed of 
neurological processing and can be measured through sensory 
evoked responses (typically auditory brain stem responses or vi- 
sual evoked potentials). A continued search for novel biomark- 
ers and alternative approaches to understanding the relationship 
between nutritional iron status during pregnancy in infancy and 
early childhood is also essential. 
 
Effect of iron deficiency on work/exercise capacity. The 
relationship between iron deficiency and work capacity was 
analyzed in depth in two critical reviews that included both 
animal experiments and studies in human volunteers written 
by Haas and Brownlie (359) and McClung and Murray-Kolb 
(360). They evaluated aerobic capacity, endurance, energetic ef- 
ficiency, voluntary activity, and economic productivity. The fol- 
lowing is a brief summary of their conclusions. 
 
Aerobic capacity. Laboratory experiments in animals demon- 
strated that hemoglobin values were inversely correlated with 
aerobic capacity. The severity of the anemia had a direct pro- 
portional effect, that was greater once the hemoglobin fell below 
70 g/L. Laboratory studies in human volunteers yielded similar 
results, demonstrating a strong causal relationship between the 
severity of IDA and aerobic capacity. Iron deficiency without 
anemia did not affect aerobic capacity. Field studies provided 
further support for a causal relationship between IDA and aer- 
obic capacity in manual laborers (359, 360). 
 
Endurance capacity (maximum length of time a given 
workload can be sustained). Studies using the rat as the 
experimental model suggest that although aerobic capacity is 
primarily dependent on hemoglobin concentration, effects on 
endurance are mediated at least in part by reduced oxidative 
capacity due to tissue iron deficiency (361, 362). A small 
number of human experiments were, however, inconsistent and 
failed to provide convincing evidence of an effect of tissue iron 
deficiency on endurance capacity. Haas and Brownlie (359) 
suggest that the discrepancy between animal and human studies 
may well be attributed to experimental design. 
 
Energetic efficiency (amount of physiological energy re- 
quired to perform a specified amount of work). In the lab- 
oratory, energy expenditure is measured by indirect calorimetry 
and work by the use of a treadmill or a cycle ergometer. Field 
studies employ practical surrogate parameters, such as heart 
rate and tasks completed. Haas and Brownlie (359) concluded 
that two of three human laboratory studies demonstrated that 
iron deficiency impairs energetic efficiency even in the absence 
of anemia. 
 
Voluntary activity and economic productivity. A limited 
number of human laboratory experiments, as well as two field 
studies, suggested that iron deficiency with or without anemia 
might have an important influence on human behavior that 
could impact critical social activities such as childcare. Based 
on published models (363–365), food fortification with iron is 
 predicted to have an important beneficial economic influence at 
the population level, but this has yet to be tested in human trials. 
At least one report published after the reviews  of  Haas and 
Brownlie and McClung and Murray-Kolb supports their 
conclusions (366). Most of the studies involved trained ath- 
letes. Iron supplementation of nonanemic iron-deficient women 
(SF < 20 µg/L) improved muscle function (attenuation of the 
rate of decrease in maximal voluntary static quadriceps con- 
tractions) (367). Iron deficiency (sTfR > 8.0 mg/L) without ane- 
mia impaired aerobic adaptation and endurance capacity in un- 
trained women who participated in an aerobic training program 
employing cycle ergometers (368, 369). Iron-depleted (SF < 20 
µg/L) competitive nonanemic female rowers were reported to 
be slower than those with normal iron stores (370). Iron sup- 
plementation improved energetic efficiency (371). 
In summary, IDA has a profound negative effect on work 
capacity. Fortification with iron and other micronutrients may 
provide significant economic benefits for individuals and soci- 
eties (363, 365). 
 
Biomarkers of iron deficiency for  evaluating  effects  on  
work capacity. It is evident that iron deficiency associated with 
anemia may impair physical activity by affecting oxygen deliv- 
ery and oxidative capacity resulting from iron deficiency at the 
tissue level. The reported studies have used the described be- 
low biomarkers that are applied to the evaluation of anemia. 
The principles that have been discussed in evaluating anemia 
should be applicable to exercise capacity. It will be necessary to 
develop specific criteria that ensure both adequate hemoglobin 
levels and tissue iron sufficiency. 
 
Iron deficiency in  relation  to  iodine  utilization  and  thy-  
roid function. Iodine deficiency, like iron deficiency, is a major 
global public health problem and many women and children, 
especially in the developing world, are at risk of both goiter 
and iron-deficiency anemia. Iron deficiency with or without ane- 
mia can have adverse effects on thyroid metabolism and can de- 
crease the production of thyroid hormones. As discussed in the 
BOND iodine review (2), iron deficiency is likely to exacerbate 
iodine-deficiency disorders that include goiter, hypothyroidism, 
impaired mental function, and cretinism. 
The influence of iron deficiency has been evaluated in rela- 
tion to goiter and poor tolerance to cold (a symptom of hy- 
pothyroidism). In iron-deficient populations, it has been shown 
that the efficacy of iodized oil or iodized salt programs to pre- 
vent goiter can be blunted, and that the regulation of body tem- 
perature on cold exposure can be impaired. Zimmermann (372) 
has reviewed in depth the influence of iron status on iodine uti- 
lization and thyroid function. A brief summary follows. 
 
Mechanism of impairment in thyroid function in iron defi- 
ciency. Humans (373) and rats (374) with IDA have decreased 
plasma T3 and T4 concentrations due to decreased levels of 
thyroperoxidase, a heme enzyme that catalyzes the iodination 
of thyroglobulin and the coupling of the iodotyrosine residues 
(93). These are the two initial steps of thyroid hormone syn- 
thesis. Other mechanisms explaining how iron deficiency could 
impair thyroid status have also been proposed. They include al- 
terations to the thyroid hormone feedback system (375), which 
responds to low plasma levels of T3 and T4, lower transforma- 
tion  of  T4  to  T3  in  the  peripheral  tissue  due  to  decreased  51- 
hepatic deiodinase activity (376), and nonspecifically through 
anemia and lower oxygen transport (377). 
Iron deficiency decreases the efficacy of iodine supple- 
mentation. Supplemental iodine is less efficiently utilized for 
thyroid hormone synthesis when a population has a high preva- 
lence of iron deficiency. Zimmermann et al. (378) evaluated the 
response to supplemental iodine in 109 goitrous children aged 
6–12 y in the western Cote d’Ivoire. Fifty-three were not ane- 
mic at the start of the study whereas 56 suffered from IDA 
[hemoglobin (Hb) <110 g/L and SF <12 µg/L or sTfR >8.5 
mg/L and ZPP >40 µmol/mol heme]. Each child received an oral 
daily dose of 200 mg I as iodized oil for 30 wk. The prevalence 
of goiter at 30 wk was 12% in the nonanemic group and 64% 
in those with iron-deficiency anemia. T4 levels were also signif- 
icantly higher in the nonanemic group at 30 wk. This study was 
extended by providing an iron supplement (60 mg Fe as FeSO4 
4 times/wk for 12 wk) to the children who suffered from iron- 
deficiency anemia at baseline. The iron supplement corrected 
the IDA in 50/56 children with IDA and the prevalence of goi- 
ter at 65 wk was reduced to 20% (91). Similarly, in a 9-mo for- 
tification trial in goitrous Moroccan children comparing dual 
fortified salt containing both iodine and iron with iodized salt 
alone (379), a significantly greater reduction in thyroid volume 
and improvement in thyroid function was found in the group 
receiving iron with the iodine. The prevalence of goiter and hy- 
pothyroidism was significantly decreased in the children con- 
suming the dual-fortified salt compared to those receiving the 
iodized salt. These results suggest that a high prevalence of iron 
deficiency in populations with endemic goiter will decrease the 
effectiveness of many national iodized salt programs. 
 
Iron deficiency decreases thermoregulation in response to 
cold exposure. The initial studies on thyroid metabolism in 
iron-deficient rats focused on thermoregulation. Rats with iron 
deficiency anemia were shown to have lower T3 and T4 lev-  
els than controls, and the normal increase in T3 and T4 seen   
in iron-sufficient rats exposed to cold (4°C) was not found in 
rats with IDA  (374). Lower T3 and T4 levels, and lower rec-   
tal temperatures, were also reported in anemic women (373); 
however, when nonanemic and anemic women were subjected 
to a cold stress, involving moving from a bath at 35°C to one    
at 28°C for 100 min, there was no difference in the response   
of thyroid hormones or rectal temperature. Treating the anemic 
women for 12 wk with iron supplements corrected the anemia, 
improved the rectal temperature at 100 min, and partially cor- 
rected the thyroid hormone levels. It is likely therefore that in 
severe cold, individuals with iron deficiency anemia will have 
more difficulty in maintaining body temperature and a reduced 
ability to tolerate cold. 
 
Biomarkers of iron deficiency for evaluating effects on io- 
dine utilization and thyroid function. The reported studies  
used the biomarkers that are applied to the evaluation of ane- 
mia as discussed elsewhere. The limited evidence available at the 
present time suggests that they will be suitable for evaluating the 
effects of iron status on thyroid function. However, further re- 
search is needed to define adequate and optimal iron status for 
normal iodine utilization and thyroid function. 
 
Morbidity related to infectious diseases. As highlighted  in 
Text Box 31, infectious diseases continue to be a major scourge 
of the global community (380). Although a comprehensive dis- 
cussion of all infectious disease is beyond the scope of this re- 
view, it is clear that the current landscape with regard to iron 
and global health is complicated by a number of core issues. 
 ∼ 
 
 
 
While HIV/AIDS, tuberculosis (TB), and malaria account for 
16% of global mortality (381), a significant amount of at- 
tention has been given to the relationships between iron status, 
interventions, and malaria, primarily stimulated by a large ran- 
domized clinical trial of iron supplementation in children (382). 
The core issues are as follows: 1) the need to understand the 
mechanisms to explain increased risk for morbidity and mor- 
tality associated with iron supplementation; 2) how to assess 
nutritional iron status in the context of infection and inflam- 
mation; and 3) the relative risk-benefit associated with various 
intervention options to prevent and treat nutritional iron defi- 
ciency in the context of infections including malaria (383, 384). 
The challenges associated with malaria exemplify some core is- 
sues common to all infections and are illustrative of the key is- 
sues with regard to biomarkers of iron in this context. 
A review of the literature related to iron nutrition and these 
diseases reveals several challenges to our ability to draw con- 
clusions about a specific role of iron nutrition, or to develop 
and implement safe and effective interventions to address iron 
nutrition in these conditions. 
Several recent studies have explored the connection between 
HIV infection, anemia, and nutritional iron status (385–388). 
Kerkhoff et al. (385) assessed iron status, including the mea- 
surement of hepcidin levels, and reported that patients sur- 
veyed suffered predominantly from ACD rather than IDA. Diouf 
et al. (386) reported that diets containing micronutrient- 
fortified lipid-based supplement improved anemia based on 
measurement of hemoglobin; however, they did not include spe- 
cific biomarkers of nutritional iron status. Zinc deficiency was 
highly prevalent in this study cohort but the intervention did 
not improve status despite reaching intake levels comparable to 
DRI. Widen et al. (387) reported that antiretroviral therapy was 
associated with anemia and changes in iron biomarkers (sTfR). 
In a large observational study of HIV-infected adults in Tan- 
zania, Petraro et al. (388) reported a high prevalence of ane- 
mia and identified numerous independent risk factors including 
BMI, CD4 count, and antiretroviral therapy. These authors dis- 
cussed “iron-deficiency anemia,” although the only measures of 
anemia were hemoglobin and MCV, with no other iron-specific 
biomarkers nor any assessment of iron exposure. 
In sum, these results reinforce the challenges of addressing 
iron nutrition in the context of infectious diseases. Fundamen- 
tally, there are several core concerns that can be categorized into 
the following questions: 
1) Our ability to determine whether biomarkers used to as- 
sess iron nutritional status reflect iron nutrition or a phys- 
iological response to the condition(s) in question. How 
does the presence of inflammation (acute or chronic) in 
these conditions affect the selection, use, and interpreta- 
tion of biomarkers used to assess iron status? 
2) Anemia is a common comorbidity of these infections: 
how can we better understand the interactions among dis- 
ease/comorbidities, treatment, and iron status? 
3) If, in fact, evidence indicates nutritional iron deficiency, 
what is the safest and most efficacious intervention to use 
clinically or at scale? 
4) How does the role of public health approaches to address- 
ing iron deficiency at population levels impact on care of 
individuals with infectious diseases? 
There is no question that nutritional iron deficiency is com- 
monly observed in populations with infectious diseases and 
their comorbidities. The core issue is how to assess iron in the 
context of infection, treatment, food insecurity/malnutrition, 
and to develop safe and effective strategies to address these 
complex problems. A concerted effort has begun to develop 
solutions to these issues, particularly the relationships among 
nutrition, disease, and inflammation. These efforts are focused 
on improving approaches to iron status assessment, and more 
specifically, the distinction between nutritional iron status and 
anemia (48, 231). One application of these improved ap- 
proaches would be their use by WHO to develop new guidelines 
for both iron assessment and interventions. 
 
Iron overload. Although much of the focus of this report has 
been on the factors associated with and biomarkers employed 
to assess iron deficiency, the I-EP concluded that iron overload 
was an issue of sufficient public health importance to warrant 
specific coverage. The following section is an overview of the 
current understanding of the causes, public health significance, 
and assessment approaches related to iron overload. 
 
Causes of systemic iron overload. A classification of the 
causes of systemic iron overload is shown in Text Box 32 (389, 
390). The following section deals only with systemic iron over- 
load which may potentially have a nutritional component. Rare 
genetic disorders and conditions that cause localized iron over- 
load are beyond the scope of this review. 
 
 
Text Box 31 
Annual deaths (in millions) 
Disease Deaths 
Respiratory Infections 3.9 
Malaria 1.3–3.0 
HIV/AIDS 2.5 
Diarrheal diseases 1.8 
Tuberculosis 1.7 
Neglected tropical diseases 0.5 
Source: Center for Strategic and International Studies (CSIS) (380). 
 
Text Box 32 
Systemic iron overload [adapted from Bacon et al. (389) 
and Pietrangelo (390)] 
Hereditary hemochromatosis 
• HFE-related hemochromatosis (Type 1). 
• Non-HFE-related: 
-Juvenile hemochromatosis (Types 2A, 2B) 
-TfR related hemochromatosis (Type 3) 
-Ferroportin disease (Types 4A, 4B) 
Secondary iron overload 
Iron-loading anemias 
• Thalassemia syndromes. 
• Sideroblastic anemia. 
• Chronic  hemolytic anemia. 
• Pyruvate kinase deficiency. 
• Pyridoxine-responsive anemia. 
Parenteral iron overload 
• Transfusional iron overload (multiple red blood cell 
transfusions). 
 ∼ 
∼ 
result harmful free radicals may be generated, causing damage 
to lipid membranes, DNA, and various cellular organelles (400). 
In addition, pathogens compete with body cells for iron; avail- 
able iron may lead to increased pathogen virulence. The clinical 
consequences of systemic iron overload that are most conspicu- 
ous in patients with untreated HFE hemochromatosis are listed 
in Text Box 33. 
 
 
 
The ability of the gastrointestinal tract to limit absorption 
even when large quantities of bioavailable iron are ingested is 
remarkable. However, acute iron poisoning may occur in young 
children who accidentally consume adult iron supplements ( 3 
g is lethal in a 2-y-old) (391). On the other hand, there are very 
few reports of chronic iron overload as the result of the con- 
sumption of excessive quantities of iron in adults (392, 393). 
Furthermore, in most cases it would be difficult to exclude other 
factors such as liver disease, alcohol consumption, or an unrec- 
ognized genetic component resulting from a polymorphism af- 
fecting either hepcidin or FPN1 (392). Hepcidin suppression due 
to accelerated erythropoiesis (thalassemias and other hemolytic 
disorders; see Text Box 32) would also have to be considered. 
Despite the frequent inclusion of diet as a potential primary 
cause of chronic systemic iron overload in scholarly articles, 
there is very little observational evidence to support this view, 
with the sole exception of “African iron overload”, discussed 
below. The types of hereditary hemochromatosis are summa- 
rized in Table 6 (390). HFE hemochromatosis is by far the most 
prevalent; 10–15% of Caucasian Americans are carriers of the 
C282Y allele and 1 in 200–250 are homozygous for this autoso- 
mal recessive condition. Another HFE mutation, H63D, occurs 
in 20% individual worldwide (212). However, penetrance is 
low. Clinically significant consequences of iron overload are ob- 
served in only 28% of male and 1% of female C282Y homozy- 
gotes (394, 395). 
One ethnic group merits further consideration. An iron over- 
load syndrome that occurs in South African Bantu men (origi- 
nally called “Bantu siderosis”, also referred to as “African iron 
overload”, “sub-Saharan iron overload”) was first described in 
1929 (396). An excessive iron intake due to the consumption  
of traditional beer brewed in iron drums was considered to be 
the primary etiological factor (100). The beer had an average 
iron concentration of 40 mg/L in a highly bioavailable form. 
The alcohol content was low and many individuals would regu- 
larly drink several liters a day. Fecal analyses demonstrated that 
50–100 mg Fe/d was ingested from beer alone. However, subse- 
quent studies conducted by Gordeuk et al. (397) suggested that 
genetic factors are equally important in the people of south- 
ern and central Africa. The most common phenotype appears 
to be loss of function in SCL40A1 (FPN1) acting in an autoso- 
mal dominant fashion (397, 398). The Q248H allele is the most 
prevalent polymorphism in sub-Saharan Africa and in African 
Americans. However, among African Americans the increased 
risk of iron overload appears to be minimal (399), perhaps be- 
cause the consumption of excessive bioavailable iron is a neces- 
sary cofactor. It is nevertheless important to emphasize that the 
putative genetic component of sub-Saharan iron overload has 
not been identified with certainty at the present time. 
 
Consequences of systemic iron overload. Iron is a highly re- 
active metal. Free iron can alternate between the Fe3+ and Fe2+ 
redox states, resulting in the gain or loss of free electrons. As a 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The clinical manifestations of secondary iron overload re- 
sulting from an iron-loading anemia such as thalassemia major 
include those observed in severely affected patients with hered- 
itary hemochromatosis. Children with untreated β-thalassemia 
also suffer from severe anemia, marked hepatosplenomegaly, 
and skeletal abnormalities due to expansion of the erythroid 
elements in the bone marrow. Intercurrent infections, heart fail- 
ure, and liver cirrhosis are the major causes of death in the first 
two decades of life (401). 
 
Current controversy related to the possible role of iron in 
various conditions 
Iron status and vascular disease. Sullivan (402) postulated in 
1981 that ischemic heart disease occurs less frequently among 
premenopausal women than in men of the similar age because 
of differences in iron status. Interest in the possibility that iron 
had a causative role was stimulated by the observations of Sa- 
lonen et al. (403) who reported that high SF concentrations in 
eastern Finnish men were associated with an increased risk for 
myocardial infarction. Numerous subsequent studies have failed 
to resolve the issue. In most cases iron status was defined by 
SF assays. Vascular disease is known to have an inflammatory 
• Parenteral iron injections. 
Chronic liver disease 
• Porphyria cutanea tarda. 
• Viral hepatitis, especially hepatitis C. 
• Alcoholic liver disease. 
• Nonalcoholic fatty liver disease/nonalcoholic steato- 
hepatitis. 
• Following portacaval shunt.  
Text Box 33 
HFE hemochromatosis: clinical phenotype 
Nonspecific systemic symptoms 
• Fatigue, malaise, lethargy. 
• Weakness, weight loss. 
Liver complications 
• Fibrosis. 
• Cirrhosis. 
• Liver failure, ascites, encephalopathy. 
• Hepatocellular carcinoma. 
Heart complications 
• Congestive cardiac failure due to iron deposition in 
the myocardium. 
• Cardiac arrhythmias. 
Pancreas 
• Diabetes mellitus. 
Other endocrine complications 
• Disruption of the hypothalamic-pituitary axis. 
• Hypogonadism, amenorrhea. 
• Hypothyroidism. 
Joint Problems 
• Arthropathy. 
• Typically pseudogout in the metacarpophalangeal 
joints of the hands. 
• Other joints, especially hips and knees, may also be 
affected. 
Skin 
• Increased pigmentation. 
• Porphyria cutanea tarda. 
 TABLE 6 Hereditary systemic iron-overload disorders1 
Disorder Inheritance Laboratory markers Clinical phenotype 
 
HFE hemochromatosis (type 1) Autosomal recessive TSAT ↑ early Primary hepatocyte iron loading, hepatic fibrosis/cirrhosis, liver cancer 
SF ↑ Cardiomyopathy 
Diabetes mellitus 
Hypogonadism 
Arthropathy 
Skin pigmentation 
Juvenile HJV hemochromatosis (type 2A) Autosomal recessive TSAT ↑ early Similar to HFE hemochromatosis, but early onset and accelerated 
course, endocrine and cardiac disease more prominent than hepatic 
Juvenile HAMP hemochromatosis (type 2B) Autosomal recessive SF ↑ involvement 
TFR2 hemochromatosis (type 3) Autosomal recessive TSAT ↑ early Similar to HFE hemochromatosis 
SF ↑ 
FPN1 loss of function (type 4A) Autosomal dominant SF ↑ Predominant macrophage iron loading in the liver, spleen, and bone 
marrow 
TSAT often normal Later parenchymal iron accumulation with mild liver disease 
May have mild anemia 
FPN1 gain of function (Type 4B) Autosomal dominant TSAT ↑ early Similar to HFE 
  SF ↑  
1FPN1, ferroportin 1; HAMP, gene encoding hepcidin; HFE, human hemochromatosis; HJV, hemojuvelin; SF, serum ferritin; TFR2, transferrin receptor 2; TSAT, percentage 
transferrin saturation; ↑, increase. Adapted with permission from reference 390. 
 
component (404). Raised SF values may therefore merely reflect 
its properties as an acute-phase protein (APP), a conclusion that 
is supported by the absence of a significant association between 
vascular disease and either HFE hemochromatosis or “African 
iron overload.” 
 
Iron and the metabolic syndrome. Diabetes  mellitus  is  one  
of the most common complications of all iron overload states. 
The etiology is complex. Genetic factors, iron deposition in the 
liver, direct damage to the pancreas, and insulin resistance may 
all play a role (405). Patients need appropriate clinical manage- 
ment. The relationship between iron status, and both obesity 
and the metabolic syndrome has been characterized using vari- 
ous iron biomarkers. Increased SF values are commonly encoun- 
tered in the presence of the metabolic syndrome (406). However, 
transferrin saturation is not significantly increased and hepatic 
iron overload, if present, is mild based on MRI (407). Iron is se- 
questered in macrophages. Hepcidin levels are raised and iron 
absorption decreased (408–412). The interaction between iron 
homeostasis and obesity has been reviewed recently (413, 414). 
Hyperferritinemia and hypoferremia is considered to be a con- 
sequence of hepcidin-induced iron sequestration in the reticu- 
loendothelial system and the acute-phase ferritin response to 
inflammation. There is still considerable controversy about the 
potential role iron as a causative factor, but high-intensity blood 
donation which would be expected to markedly reduce the iron 
load was not associated with a decrease in the prevalence of 
the metabolic syndrome (415). Higher SF levels are also asso- 
ciated with type 2 diabetes. Once again, serum iron and trans- 
ferrin saturation are not increased, suggesting that the rise in SF 
is an inflammatory response (416). Nevertheless, the relation- 
ship with iron status and the potential role of iron needs further 
study. 
 
Iron and cancer. The overall risk for hepatocellular carci- 
noma in patients suffering from hemochromatosis is 6–10%.   
It is preceded by the development of liver cirrhosis and is 
responsible for 25–45% of all premature deaths associated 
with hemochromatosis (417). There is some evidence to sug- 
gest that iron status may be related to other  cancers,  but  
more research is needed to  establish  a  causal  role  (418).  
The most convincing evidence suggests a relationship between 
high  red  meat  intake  and  colon  cancer.  However,  if  there   
is a causal relationship, whether the critical factor is iron, 
heme, or some other meat ingredient has not been estab- 
lished. 
 
Iron and infection. With the exception of Lactobacilli and 
Borrelia burgdorferi, all microorganisms require iron to survive 
(419). They compete with their hosts for available iron. The 
body’s ability to withhold iron is considered to be a component 
of the innate immune response (420). Recent studies suggest 
that mild iron deficiency may provide a modest degree of pro- 
tection against falciparum malaria, but more research is needed 
to establish the significance of these observations. On the other 
hand, several investigators have concluded that “African iron 
overload” increases the risk of chronic infectious disorders, par- 
ticularly tuberculosis and HIV disease. These observations deal 
with patients who have significant organ damage, making it dif- 
ficult to be sure of the specific role of iron overload. Moreover, 
SF, which may be confounded by the presence of inflammation, 
has often been used as the critical biomarker (421). Neverthe- 
less, it seems likely that iron toxicity is a contributory factor. 
Similarly, iron overload is considered to be a contributory risk 
factor for bacterial infections which are a major cause of death 
in patients with thalassemia (422). On the other hand, infections 
are not a characteristic complication for most patients suffer- 
ing from HFE hemochromatosis although the virulence of cer- 
tain organisms may be increased; these include Vibrio vulnificus, 
Yersinia enterocolitica, Escherichia coli, and Listeria monocyto- 
genes (423–426). 
 
Biomarkers of iron overload. The diagnosis of  iron  overload 
is made in the clinical setting in patients who exhibit charac- 
teristic symptoms and signs or individuals considered to be    
at risk because of a family history of hemochromatosis or a 
 ≥ 
≥ 
TABLE 7 SF and TSAT levels: 50th and 95th percentile values (95% CI) for SF and 50th and 90th percentile values (95% CI) for TSAT 
for selected age groups for the total US population (NHANES 1999–2002)1 
 
Sex, age (y) SF 50th (µg/L) SF 95th (µg/L) TSAT 50th TSAT 90th 
F 12–19 26.0 (24.0, 27.0) 76.0 (70.0, 85.0) 19.8 (18.4, 20.9) 32.9 (31.0, 36.6) 
F 20–39 32.0 (30.0, 35.0) 126 (110, 146) 21.4 (19.8, 23.3) 38.4 (35.0, 31.1) 
F 40–59 53.0 (46.0, 57.0) 228 (201, 243) 21.5 (20.5, 22.5) 34.8 (32.0, 37.6) 
F ≥60 86.0 (80.0, 93.0) 391 (349, 445) 22.3 (21.1, 23.6) 35.4 (31.8, 37.9) 
M 12–19 42.0 (40.0, 54.0) 142 (125, 154) 25.8 (24.3, 26.9) 42.8 (36.3, 50.4) 
M 20–39 134 (125, 142) 382 (344, 406) 27.1 (25.7, 28.4) 45.9 (43.7, 48.8) 
M 40–59 150 (138, 168) 500 (434, 574) 26.8 (25.4, 28.9) 41.6 (39.8, 43.2) 
M ≥60 134 (125, 147) 552 (493, 623) 25.9 (24.7, 27.3) 41.7 (39.4, 43.8) 
1SF, serum ferritin; TSAT, percentage transferrin saturation. Adapted with permission from reference 429. 
 
hematological disorder that leads to secondary iron overload. 
Stainable bone marrow iron is an important research tool and 
also occasionally employed in the clinical setting. It is, how- 
ever, an invasive procedure and not applicable to population 
surveys or the evaluation of intervention strategies. Moreover, 
it is important to note that  bone  marrow  iron  evaluation  
may be misleading in HFE hemochromatosis where the iron 
excess is present primarily in parenchymal cells, particularly 
hepatocytes. 
SF and  TSAT  are  used  in  combination  by  clinicians  in  
the workup of individuals with clinical findings or a family 
history suggestive of hemochromatosis (389, 427, 428). How- 
ever, screening of the general population is not recommended 
by either the American College of Physicians or the American 
Association for the Study of Liver Disease. 
Investigators whose main focus is nutrition have usually em- 
ployed upper levels for SF as the criterion of iron overload. The 
values chosen have varied, but one commonly quoted source 
gives levels of >200 µg/L for adult males and >150 µg/L for 
adult females as constituting “severe risk for iron overload” 
(218). Based on these criteria, >5% of men in the United States 
over the age of 30 y would be at risk [SF: 382 µg/L (95% CI: 
344, 406  µg/L), 500  µg/L  (95%  CI:  434, 574  µg/L), and  552 
µg/L (95% CI: 493, 574 µg/L) respectively for men aged 20– 
39, 40–59, and 60 y]. Similarly, >5% of apparently healthy 
women over the age of 40 y would be at risk [SF: 228 µg/L 
(95% CI: 201, 243 µg/L) and 391 µg/L (95% CI: 349, 445 µg/L) 
respectively for women aged 40–59 and 60 y] [Table 7 (429)]. 
It is highly unlikely that a sizeable proportion of middle- aged 
and older Americans are at risk for clinically significant iron 
overload. McKinnon et al. (430) reinforced this conclusion 
based on a survey of 1188 adults living in Busselton, Australia 
and also reported a direct correlation with BMI and a significant 
increase in SF levels between 1995 and 2005. They proposed a 
change in reference ranges to accommodate demographic and 
biomedical influences. The North American  Hemochromato- 
sis and Iron Overload Screening (HEIRS) Study also employed 
higher cut-off values (>300 µg/L for men and >200 µg/L for 
women) (431). 
The I-EP has concluded that if the recommendations for 
cutoff levels published in the 2001 UNICEF/UNU/WHO guide 
for program managers (218) are  used,  SF  values  employed  
as the sole  measure  of  iron  status  are  of  limited  to  value  
as a marker of increased iron stores in population  surveys  
and the planning of intervention strategies. It is possible that 
higher SF cutoff levels would improve the evaluation of the  
risk of iron overload in population studies. However, the I-EP 
proposes that an alternative tactic based on  the  approach 
used by clinicians be considered. The first step would be to 
determine the prevalence of a genotype or phenotype (based 
on biomarkers) that is likely to explain the high SF values in  
the target population. The following groups are identified in 
Text Box 34. 
 
 
True iron overload. An increase in TSAT preceding the pro- 
gressive rise in SF is  characteristic  of  the  clinical  pheno-  
type of HFE hemochromatosis, juvenile HJV hemochromato- 
sis, juvenile HAMP hemochromatosis, TFR2 hemochromato- 
sis, and FPN1 gain-of-function ferroportin disease. The one 
exception is FPN1 loss-of-function ferroportin disease, which is 
characteristic of “African iron overload.” TSAT is often normal 
in the face of increased SF. Iron intake does not appear to play  
a significant role in the rate of iron accumulation in the com- 
mon form of iron overload in Caucasians. In the HEIRS study, 
dietary iron intake was analyzed in 213 patients who were ho- 
mozygous for HFE C282Y. No significant relationships between 
SF and dietary heme iron content, dietary nonheme iron con- 
tent, or supplemental iron use were discovered (432). On the 
other hand, as described above, iron intake is considered to be 
an important factor in “African iron overload.” 
Thalassemia syndromes are prevalent in many parts of the 
world, including the Mediterranean region, Africa, and South- 
east Asia. Patients with severe anemia who may or may not    
be transfusion dependent require management by healthcare 
Complex phenotypes: SF ↑, % TSAT ↑, abnormal liver 
enzymes. 
Liver disease 
Phenotype: SF ↑, % TSAT, no trend or ↓. 
Older men and postmenopausal women. 
Phenotype: SF ↑, % TSAT ↓. 
Phenotype: SF↑, % TSAT ↓. 
Obesity/insulin resistance/type 2 diabetes 
Phenotype: SF↑, % TSAT ↑. 
Inflammation 
Infection and inflammation. 
Iron-loading anemias 
Abnormal globin genotype(s) causing thalassemia syn- 
dromes in most cases. 
Phenotype: SF↑,% TSAT↑ (with the exception of FPN1 
loss of function, SF ↑, % TSAT often normal). 
Text Box 34 
True iron overload 
Hereditary Hemochromatosis 
 TABLE 8 Iron absorption in Thai women who are heterozygotes for HbE, α-Thal 1, or B-Thal and in compound heterozygotes for 
HbE/B-Thal1 
 
 
 
Weight, kg 47.8 ± 7.3 53.5 ± 6.3 50.8 ± 8.8 50.4 ± 8.4 45.4 ± 10.0 
Hb 13.0 ± 1.0 12.4 ± 1.2 11.6 ± 1.0 11.1 ± 0.7 6.9 ± 1.4 
SF, µg/L 15 (1–148) 23 (3–112) 28 (1–142) 52 (2–236) 877 (206–4040) 
TSAT 30.7 ± 7.8 34.1 ± 10.2 30.4 ± 6.8 32.5 ± 7.0 77.8 ± 16.6 
% absorption2 8.7 (3.2, 23.4) 7.5 (3.4, 16.7) 5.6 (2.8, 11.3) 4.5 (2.0, 9.7) 10.5 (4.6, 23.9) 
1Values are means ± SDs or means (ranges) unless otherwise indicated. α-Thal, α-thalassemia; B-Thal, β-thalassemia; Hb, hemoglobin; HbE, hemoglobin E; SF,  serum ferritin;      
TSAT, percentage transferrin saturation. Adapted with permission from reference 436. 
2Geometric mean (–SD, +SD). 
professionals. However, the carrier states for these disorders 
that are far more prevalent in the population are of most 
concern to nutritionists. The potential risk for inducing iron 
overload in thalassemia carriers depends on the type of tha- 
lassemia. Consequently, information about the prevalence of 
the various thalassemia syndromes must be taken into account 
when considering fortification or supplementation interven- 
tions. 
Urinary and serum hepcidin levels are markedly decreased 
in β-thalassemia major and β-thalassemia intermedia (433, 
434). They are also suppressed in hemoglobin E β-thalassemia, 
which  is  the  most  common  severe  thalassemia  syndrome  
in Asia and β-thalassemia trait (435). On the other hand, 
Zimmermann et al. (436) measured iron absorption  in  78  
Thai women who were heterozygous for α-thalassemia 1, β- 
thalassemia, hemoglobin E, or were compound heterozygotes 
for hemoglobin E (HbE)/β-thalassemia. Twenty-five women 
with a  normal  globin  genotype  served  as  controls  (Table  
8). SF levels were significantly higher in women with α-1 
thalassemia trait, β-thalassemia trait, and HbE/β-thalassemia. 
The increase was likely to be clinically important only for 
HbE/β-thalassemia. Absorption was appropriately downreg- 
ulated in those with α-1 thalassemia or β-thalassemia  trait, 
but not  in  HbE/β-thalassemia  volunteers.  The  I-EP  differs  
to some extent with the  conclusion  drawn  by  Zimmermann 
et al. (436) (that absorption was not adequately downregu- 
lated), and suggests that a more  plausible  conclusion  would 
be that absorption was appropriately downregulated in α-1 
thalassemia and β-thalassemia heterozygotes, but that the bal- 
ance between stores and absorption was reached at a slightly 
higher level of storage iron in the case of the β-thalassemia 
trait. Nevertheless, the report does support our proposal that 
the potential risk for iron overload in populations where tha- 
lassemia syndromes are prevalent should be based on biomark- 
ers that describe the prevalence of carrier status, particularly for 
β-thalassemia as well as compound heterozygosity. 
 
Inflammation. The inflammatory phenotype is  not  indicative 
of iron overload. It is induced by the combination of two patho- 
logical processes. SF is increased directly, independent of iron 
storage status, because it behaves as an acute-phase reactant. 
The quantitative relationship between SF and iron stores is dis- 
turbed. In addition, the release of iron from stores is downreg- 
ulated, resulting in increased storage iron and, if of sufficient 
severity and duration, anemia. The inflammatory component of 
obesity, insulin resistance and type 2 diabetes, and aging may 
be important contributors to the demographic and biomedical 
variation for which McKinnon et al. (430) recommend reference 
range adjustments. 
The anemia of infection/inflammation, often referred to as 
the “anemia of chronic disease,” is an acquired condition in 
which disordered iron homeostasis, due primarily to increased 
hepcidin secretion, has a central role. Increased SF, and a fall in 
the levels of serum iron, serum transferrin and TSAT are char- 
acteristic laboratory findings (437). 
The relationship between iron status and obesity/insulin re- 
sistance/type 2 diabetes has been discussed previously in the 
section dealing with the consequences of iron overload. The 
preponderance of evidence suggests the increased SF is a man- 
ifestation of the associated subclinical inflammatory state and 
therefore not necessarily indicative of increased risk for the 
consequences of iron overload. 
The phenotype in older men and postmenopausal women   
is also characteristic of a low-grade inflammatory state 
affecting a significant proportion of apparently healthy indi- 
viduals. SF and TSAT  values abstracted from a report by the  
US CDC based on data collected in NHANES 1999–2002 are 
shown in Table 7. It is noteworthy that SF values rise pro- 
gressively in the 95th percentile for men and postmenopausal 
women whereas there is no significant trend in TSAT. At the 
50th percentile there is little, if any, increase in SF. 
 
Liver disease. The assessment of liver disease is complex and 
beyond the scope of this review. Evaluation by health profes- 
sionals is required. However, there is one disorder that could 
affect the design of nutrition interventions. Hepatitis C is preva- 
lent in some countries such as Mongolia. Patients with hepati- 
tis C may accumulate excessive quantities of iron in the liver. 
Some studies have demonstrated that hepcidin production is 
downregulated by the hepatitis C virus (438, 439) and that iron 
removal by phlebotomy (440–442) may be beneficial and im- 
prove the response to treatment with interferon. More research 
is needed. 
In summary, information about the prevalence of genotypes 
that put individuals at risk for iron overload may provide the 
most useful information when considering dietary manipulation 
or supplementation to improve iron status at the population 
level. Careful analysis of the impact of the inflammatory pheno- 
types that lead to increased SF levels in the absence of significant 
iron accumulation will also be essential. 
 
 
Currently available biomarkers 
for evaluating iron nutrition 
Biomarkers of iron nutrition and nutritional iron deficiency may 
be categorized as follows based on the aspects of iron nutrition 
that they address: 
 Normal Hb HbE Trait α-Thal Trait B-Thal Trait HbE/β-Thal 
n 25 26 18 27 9 
Age, y 32.7 ± 7.8 32.1 ± 8.4 32.8 ± 11.3 36.7 ± 9.8 36 ± 10.3 
 
 1) Intake (exposure) and excretion: Several established meth- 
ods for measuring daily iron consumption are described below. 
The greater challenge is the determination of bioavailability. As 
outlined above, the diet always contains more iron than is re- 
quired to meet the requirements of almost everyone. However, 
for myriad reasons discussed previously, the majority of the iron 
is not absorbed. Biomarkers of bioavailability therefore play a 
critical role in determining the adequacy of exposure. Biomark- 
ers of exposure and bioavailability are discussed in the following 
section. 
Iron excretion is not regulated in human beings. Excessive 
iron loss is most commonly the result of diseases that cause 
blood loss, the excretion of heme in the urine as consequence 
of intravascular hemolysis, or bleeding into the lung. Iron ex- 
cretion has been measured experimentally in adults using both 
radio-isotopes (144, 443) and in toddlers and pregnant women 
using stable iron isotopes (444). 
2) Status: Biomarkers of iron status were developed to char- 
acterize the stages of increasingly severe degrees of iron defi- 
ciency that would occur in an individual whose iron intake 
does not meet his or her requirements. As indicated above, 
three stages are generally recognized: storage iron depletion, 
iron-deficient erythropoiesis, and IDA. Currently available 
biomarkers make it possible to categorize the severity of iron 
deficiency in individuals. They are also employed in population 
studies to determine the prevalence of iron deficiency and to 
differentiate between iron-deficiency anemia and anemia due to 
infection and other factors. 
 
Estimation of iron intake 
The only available biomarker for iron exposure is the measure- 
ment of dietary (and supplement) iron intake. The information 
can be used to assess the risk of iron deficiency, and data may 
also be collected in order to compare the average iron intakes of 
different groups or to compare intakes between areas/countries. 
Other reasons for measuring iron intake are to rank individ- 
uals within a group and to assess the individual’s usual  in- 
take, information that is often used in studies of nutritional 
epidemiology. 
Accurate measurement of dietary iron intake is hampered 
by several factors, including the quality of food composition 
data, food fortification practices, supplement use, contami- 
nation iron, and inappropriate choice of methodology.  Text 
Box 35 (445) provides the summary of the  systematic  re-  
view conducted by the EURRECA (European Recommenda- 
tions Aligned) project on dietary intake methodology related to 
micronutrients. 
 
 
 
 
A recent consultation sponsored by EURRECA (445) con- 
cluded that although obtaining an accurate measurement of 
dietary iron intake is challenging, a 7- to 10-d weighed food 
records (i.e., where the respondent is asked to weigh and record 
all foods and beverages at the time of consumption) including 
both weekdays and weekends (when dietary patterns may dif- 
fer) is the “gold standard” for estimating iron intake. 
In recent decades considerable effort has been invested in 
developing FFQs that give a reasonably accurate measure of 
average long-term intakes of nutrients. This information is re- 
quired for nutritional epidemiology where associations between 
diet and various health endpoints are sought. Furthermore, as 
it can take many months for biomarkers of iron status to reach 
a steady state in response to changes in dietary intake, short- 
term (acute) measures of intake may not be appropriate and 
measures of usual intake may be the preferred approach. Sup- 
plemental Table 1 is a summary of selected studies used by the 
I-EP to evaluate the relative utility of available methods for as- 
sessing dietary intake in specific population groups. 
 
 
Conclusions 
The method of choice for determining  iron  intake  depends  
on the question(s) being asked. Key considerations include the 
following: 1) day-to-day and seasonal variability; 2) between- 
subject and within-subject variance; 3) quality of food compo- 
sition tables; 4) skills and experience of fieldworkers and indi- 
viduals tasked with coding food diaries; 5) selection of foods 
and validation of FFQs; 6) respondent burden, compliance; 7) 
changes in dietary patterns initiated by dietary assessment; and 
8) resources available 
Duplicate diets (i.e., when a duplicate portion of all food and 
drink consumed throughout the day is weighed and put aside for 
chemical analysis) are the most accurate method as they avoid 
any errors introduced from food table calculations. However, 
they are generally only used for metabolic balance and other 
small-scale research studies on iron metabolism, as they do not 
necessarily generate representative data. A 7-d weighed record 
is the next most accurate option but requires good compliance 
from the subjects, and significant resources, primarily for field- 
workers to organize data collection and subsequent coding of 
the diaries, so this method is not suitable for large-scale stud- 
ies. If the mean iron intake of a population, rather than that     
of individuals, is required, then FFQs are an acceptable tool. 
They sometimes overestimate (446–448) and sometimes under- 
estimate (447, 449) iron intake, and this is possibly a function of 
the number of food items included since Heath (450) reported 
a less close agreement between diet record and FFQs when us- 
ing 206 compared with 630 food items (451). They should be 
validated and, if necessary, calibrated against another (more 
accurate) method. Portion sizes need to be established, and 
-Short-term intake (DR <7-d) correlation 0.45. 
• Using a weighted DR as the reference method im- 
proves the correlation with FFQ. 
• When the FFQ was compared with the 24-h recall: 
-Long-term intake (DR ≥7-d) correlation 0.49. 
-Long-term intake (7 × 24 h recall) correlation 0.45. 
-Short-term intake (<7d × 24h recall) correlation 0.48. 
 
Text Box 35 
Findings from systematic review on dietary intake method- 
ology conducted by EURRECA (445) 
• The systematic review identified 79 studies that met 
the inclusion/exclusion criteria. 
• FFQ was the most frequently used intake assessment 
method. 
• Dietary record (DR) or 24-h recall were used as refer- 
ence methods. 
• Serum ferritin (biomarker of status, for validating in- 
take data) was used as a reference method in 2 studies. 
• When the FFQ was compared with the DR: 
 tailored for the population group (452). Typical serving sizes 
can be found in reference databases [e.g. UK (453), USA (454), 
Europe (455, 456)] 
 
Translating food consumption data into iron intake 
estimates 
Whenever possible, local or regional food composition 
databases should be used to convert food intake into iron in- 
take. The quality of the data is of overriding importance in that 
it should reflect the average and up-to-date iron content of the 
majority of foods in the diet. In industrialized countries, the con- 
sumption of processed and fortified foods has dramatically in- 
creased over the last 2 decades and this introduces many po- 
tential errors into the calculation of iron intake. The skill of 
food coders is critical as they often need to select codes for 
foods that closely represent any that are not listed in the food 
database, including assumptions about recipes and ingredients. 
Iron-fortified foods do not always contain the quantity of iron 
on the label as an “overage” may be added during processing  
to ensure the concentration in the final product meets the label 
declaration. 
The EuroFIR (European Food Information Resource) Food- 
EXplorer (457) is an innovative interface, which allows its users 
the simultaneous search of more than 25 national food com- 
position databases. Users have access to a wide range of data, 
linking foods and nutrients through harmonized data descrip- 
tion (LanguaL), standardized component and value descrip- 
tion through the use of thesauri (standard vocabularies), and 
associated nutrient value information. The search facility in- 
cludes options to search for food name, food groups, and the 
most commonly used LanguaL food description, as well as the 
powerful and unique ability to compare the component values 
between foods from the several countries. The results can be 
downloaded as a standard Food Data Transport Package. Data 
in the EuroFIR FoodEXplorer includes >25 European coun- 
tries as well as datasets from Australia, Canada and the United 
States, but access is limited to EuroFIR members. Other publica- 
tions/databases include the following: United States (458) and 
Australia/New Zealand (459). 
 
Estimation of iron bioavailability 
As discussed previously, for the purposes of this review, bioavail- 
ability is defined as the extent to which iron is absorbed from 
the diet and used for normal body functions. In nutritional stud- 
ies, it is customarily estimated by using an iron isotope to label 
the test food or iron compound and then determining the per- 
centage of the ingested dose present in the circulating red blood 
cell compartment after 14 d. At this time red blood cell utiliza- 
tion of iron for hemoglobin synthesis is 80% in adults and 90% 
in infants and young children (460). The appropriate correction 
is made to derive an estimate of absorption. The term “relative 
bioavailability” is often applied to iron compounds being eval- 
uated as potential food fortificants or dietary supplements. Cus- 
tomarily, this is a direct comparison between the test substance 
and ferrous sulfate given in the same meal (and ferrous sulfate is 
assumed to have a value of 100%). Adequate bioavailability is 
generally considered to be a vital component of iron nutrition, 
and poor bioavailability a critical contributor to the worldwide 
prevalence of nutritional iron deficiency. The majority of peo- 
ple consume sufficient iron to meet their physiological needs. 
However, absorption is limited because of the effects of dietary 
components, in particular phytates and polyphenols in cereal- 
and legume-based diets. Biomarkers of bioavailability there- 
fore have considerable practical importance for the design of 
intervention strategies aimed at improving iron nutrition. Heme 
iron is virtually always well absorbed. However, most food iron 
is present as non-heme forms. Bioavailability is markedly af- 
fected by meal composition. Several indirect methods for esti- 
mating bioavailability have been developed over the past half 
century and calibrated against human isotopic absorption stud- 
ies (461). 
 
In vitro methods. Dialyzability: Miller et al. (462) demon- 
strated that there was a direct correlation between nonheme 
iron absorption measured by isotopic methods in human volun- 
teers and the meal content of soluble low-molecular-weight iron 
complexes after simulated digestion in vitro. Briefly, mixtures of 
foods are homogenized and exposed at 37°C to pepsin at pH     
2 (simulated gastric digestion). After 2 h, dialysis (6000–8000 
molecular weight cutoff semipermeable membrane) is used to 
adjust the pH to intestinal levels, pancreatin and bile salts are 
added, and digestion continues for another 2 h. Finally the quan- 
tity of iron that diffuses across the membrane is measured. 
The model provides important information about factors 
that affect food iron absorption. However, although it makes it 
possible to screen large numbers of samples rapidly, it has sev- 
eral limitations. Results are based on the assumption that iron 
destined for absorption is always bound to small-molecular- 
weight complexes. There are exceptions to this general rule. The 
results have qualitative value, but are unreliable for determin- 
ing the magnitude of such effects. Furthermore, it has proven 
difficult to achieve uniformity between results for different lab- 
oratories. Therefore this biomarker is no longer widely used as 
a screening test for potential bioavailability, and has been super- 
seded by the Caco-2 cell model. 
Caco-2 cell assays: Caco-2 cells are a commercially available 
immortal cultured cell line that was isolated from an adeno- 
carcinoma in a 72-y-old Caucasian man. The cells proliferate 
rapidly in vitro and can be induced to undergo spontaneous dif- 
ferentiation to develop some of the characteristics of small in- 
testinal enterocytes. Under appropriate culture conditions they 
form a monolayer with tight junctions and brush border mi- 
crovilli that express a number of digestive enzymes as well as 
the known iron transporters. The measurement of in vitro iron 
bioavailability has been refined by exposing monolayer cultures 
to food digestates prepared in a manner similar to that de- 
scribed above for dialysis (463). Large numbers of samples can 
be tested over periods of a few days. Although the results de- 
rived from this biomarker may be more precise and consistent 
than those from dialysis, they also have several limitations. The 
results predict the direction of response for all major nonheme 
iron absorption modifiers, but not necessarily the magnitude. 
Importantly, good quality cell culture facilities and experienced 
operators are essential. The Caco-2 cell method should be con- 
sidered as an initial screen for new potential iron fortification 
products. However, it will always be necessary to test promis- 
ing compounds in human absorption trials. The usefulness of  
in vitro models to predict the bioavailability of iron and zinc is 
reviewed in a consensus statement from the HarvestPlus expert 
consultation (461). 
 
Animal models. Although several animal models have been 
used for studying iron absorption, the only standardized method 
that has seen widespread use is the Association of Official 
Analytical Chemists (AOAC) Rat Hemoglobin  Repletion  As-  
say (464–466). Briefly, weanling rats are fed an iron-deficient 
diet until they develop  IDA  and  are  then  switched  to  the  
test diets. Iron absorption is derived from the increase in red 
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blood cell mass calculated from the change in body weight and 
hemoglobin concentration of the experimental animal. 
The method has most often been used to evaluate iron com- 
pounds being considered as food fortificants and gives a simi- 
lar classification of iron compound bioavailability as in humans 
(467). It should however be noted that the rat does not respond 
to inhibitors and enhancers in the same way as humans and is 
not a good model to measure iron bioavailability from human 
diets (468). 
 
Algorithms. Algorithms have been developed to estimate di- 
etary iron absorption based on dietary data, including the form 
of the iron and the meal content of known enhancers and in- 
hibitors of iron absorption. Monsen et al. (469) were the first to 
suggest this approach. However, they only considered the form 
of the iron (heme or nonheme) and the content of the two ma- 
jor enhancing factors, ascorbic acid and animal tissue (meat, fish 
or poultry). Nevertheless their original models are the basis for 
the bioavailability values employed by the FAO/WHO in cal- 
culating RNIs (78). Since this time several more comprehensive 
algorithms that consider the effect of important inhibitors have 
been published. One of the most comprehensive was developed 
by Hallberg and Hulthen (470). They utilize all the dietary fac- 
tors that have been shown to affect nonheme iron absorption 
in a quantitative model that includes interactions. In addition, 
adjustments are made for iron status, so that bioavailability is 
estimated for an individual with a 40% reference absorption. 
Although beyond the scope of this review, the importance of es- 
timated bioavailability in calculating iron requirements has been 
covered in detail elsewhere (471, 472). Armah et al. (473) pub- 
lished a similar algorithm based on the US diet in 2013. These 
newer algorithms attain greater precision, but the methods still 
have several important shortcomings. It is frequently difficult to 
obtain accurate semiquantitative data for the consumption of 
iron and the major enhancers and inhibitors of absorption, and 
the data upon which they have been based is nonheme iron, so 
assumptions about heme iron intake (and absorption) need to 
be added to the model. Furthermore, results of algorithms devel- 
oped for one population group may not be representative when 
applied in a different setting. Finally, the results tend to under- 
estimate bioavailability and there may be a 3-fold variation in 
estimates using different algorithms (474). Therefore most pro- 
gram planners employ the FAO/WHO absorption levels based 
on a qualitative description of the diet. 
 
Human bioavailability measurements. Studies using radio- 
labeled iron in human volunteers are regarded as the gold stan- 
dard for determining iron bioavailability and estimating absorp- 
tion. Several methods, categorized according to their increasing 
complexity and precision, are available as described below. 
Iron tolerance measurements. The method lacks sensitivity 
and can only be used for high doses ( 10 mg) of iron. The 
plasma iron concentration is measured at intervals (usually six 
samples at hourly intervals) after the ingestion of the iron com- 
pound of interest following an overnight fast. The rise in the 
plasma iron level is used as a measure of absorption by cal- 
culating the area under the curve (100, 475) or applying a 
compartmental model (476). Results are most often expressed 
as relative bioavailability with respect to FeSO4 (or another 
well-absorbed iron compound) by repeating the procedure with 
an equivalent quantity of this iron on a different day. 
Isotopic absorption studies. Data obtained from isotopic 
studies are the basis of our understanding of food and forti- 
fication iron bioavailability. These iron bioavailability studies 
measure the utilization of the absorbed iron for hemoglobin syn- 
thesis and use this to estimate iron absorption. Earlier experi- 
ments utilized radioisotopes, but they have been supplanted by 
stable isotopes to eliminate the potential risk of exposure to ra- 
diation (477). Radioisotopes are added in trace amounts. On the 
other hand, milligram quantities of stable isotopes are required. 
As a consequence, stable isotopic methods are most suited to 
iron fortification studies. When used to investigate dietary fac- 
tors, multiple meals are essential to avoid large increases in iron 
intake. The major limitation of the isotopic approach in general 
is the dependence on assays based on single meals or in some 
cases a limited number of meals on different days (478). Inves- 
tigators may select meals that exaggerate the effects of bioavail- 
ability modifiers. It may therefore be difficult to predict dietary 
bioavailability because the effects of the absorption modifiers 
are often attenuated when the whole diet consumed over ex- 
tended periods of time and the interaction between modifiers 
are considered. 
Field trials. Field trials are costly and time consuming, but 
they provide the most accurate and reliable information about 
the potential impact of proposed fortification or supplementa- 
tion programs. It is essential that they include a control arm 
because the iron status of the target group may change over 
time. This is particularly important for young children. The trial 
period should be 6 mo (60, 479). Iron status biomarkers, in- 
cluding hemoglobin, SF, sTfR, and ZPP, are used to measure the 
change in iron status between baseline and the end of the trial. 
Recent reports suggest that the most accurate estimates can be 
obtained by using the sTfR/SF ratio to calculate body iron in- 
dex (248, 480). If this is done, it is also possible to estimate the 
bioavailability of the iron fortificant or supplement based on 
the change in body iron and the quantity of supplementary iron 
consumed. 
Estimation of dietary bioavailability in a population. 
Bioavailability is a critical factor for estimating recommended 
nutrient intakes for iron and zinc (78). It has, however, proven 
difficult to obtain accurate values at the population level. As 
outlined above, algorithms may be misleading or difficult to ap- 
ply because of incomplete dietary data. The WHO/FAO there- 
fore employed a pragmatic qualitative approach to calculating 
dietary bioavailability by assigning one of three bioavailability 
levels depending on a general description of the diet (5%, 10%, 
or 15%) (78). On the basis of intake data and isotope studies, 
iron bioavailability has been estimated to be in the range of 14– 
18% for mixed diets and 5–12% for vegetarian diets in subjects 
with no iron stores, and these values have been used to generate 
dietary reference values for all population groups (26). Dainty 
et al. (481) recently proposed a new methodology. A full proba- 
bility approach was used to estimate dietary iron bioavailability 
based on calculated requirements, estimated daily intake, and 
the distribution of SF values in the population sample. Subse- 
quently, further refinements were made to the model using data 
from 2 nationally representative studies of adults in the UK and 
Ireland and a trial in elderly people in Norfolk, UK, and an in- 
teractive tool was published (482). An accompanying editorial 
(483) concluded that the model is likely to be widely used in 
populations for whom reliable dietary iron intake and status 
data are available. The method has several potential advantages. 
Results are based on direct observations in the target population 
sample. There is no need to analyze dietary data for enhancing 
and inhibiting factors or heme content: total iron intake is the 
only value that is required. The fortification level necessary to 
achieve a designated SF level can be estimated. There are, how- 
ever, some significant constraints. The iron requirements and 
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dietary intake must be in a steady state for at least a year. The 
method is therefore not suitable for children, pregnant women, 
or immediately after the onset of menopause. Finally, the inves- 
tigators only analyzed data from adults eating a Western diet 
and employed SF as the biomarker for iron storage status. The 
approach should be evaluated in populations traditionally con- 
sidered to be consuming low bioavailability diets. It would also 
be desirable to examine the use of body iron or the sTfR/SF ratio 
instead of SF alone. 
 
Biomarkers of iron status and anemia risk 
Iron stores and storage depletion. The bone marrow is a ma- 
jor iron storage site. All of this iron is available for erythro- 
poiesis. The lack of iron only becomes a limiting factor once 
this supply is exhausted. The absence of stainable bone marrow 
iron is generally regarded as the gold standard for the diagnosis 
of iron deficiency. The invasive nature of the procedure makes 
it unsuitable for most epidemiological studies. It has, however, 
been an invaluable biomarker for the definitive identification of 
iron deficiency in a few well-designed field investigations in set- 
tings where the etiology of anemia is complex. It also remains an 
important option for diagnosing complicated anemias in hospi- 
tal patients (484). 
The source of erythropoiesis in  the  fetus  is  the  liver un- 
til late in the third trimester when there is a liver-bone mar- 
row “switch.” At approximately the same time, a liver-kidney 
“switch” for erythropoietin synthesis occurs. Thus, the interpre- 
tation of stainable iron in the neonate depends on gestational 
age and the timing of the switches. Consequently, due to both 
the changing physiology and the invasiveness of the procedure, 
stainable bone marrow iron is not typically utilized to determine 
neonatal iron status. 
 
Serum ferritin. Although SF is an important biomarker of iron 
status, it represents only a minute fraction of the body’s ferritin 
pool. Most of the ferritin iron is intracellular, with the highest 
concentrations being found in in cells that store iron and can 
also process heme (hepatocytes and specialized macrophages). 
 
Structure and function of ferritin. The iron storage protein 
ferritin has a similar structure in animals and plants. The fer- 
ritin molecule consists of a protein shell with a molecular mass 
of 500 kDa composed of 24 subunits. The protein shell en- 
closes a core of ferric-hydroxy-phosphate that can hold up to 
4500 atoms of iron (485). Ferritin molecules acquire and re- 
lease iron in concert with physiological needs. The mechanism 
of uptake and release of iron is still unclear. It is known that 
iron uptake requires an oxidizing agent and release a reducing 
agent. A range of isoferritins is found in various human tissues 
depending on the specific combinations of the 2 types of subunit, 
H and L (486). H-Rich isoferritins predominate in heart muscle 
and in red and white blood cells, whereas L-rich isoferritins are 
found primarily in liver, spleen, and placenta. 
Ferritin is a soluble protein, but can degrade into insoluble 
hemosiderin. Both ferritin and hemosiderin provide a store of 
iron that is readily available to meet functional requirements. 
Normally most of the iron stored in the body ( 1 g in men and 
less in children and premenopausal women) is stored as ferritin 
but the proportion as hemosiderin increases with iron overload. 
The uptake of iron into ferritin serves a second vital function. 
It prevents oxidative damage to tissues. Free iron could generate 
highly reactive free radicals that could damage DNA, oxidize 
cholesterol, or damage tissue proteins. Ferritin synthesis is in- 
duced by the presence of iron. The initial response is  regulated 
by translation rather than by transcription (487). The transla- 
tional control mechanism involves the 51 IRE of ferritin mRNA. 
The eventual degradation of ferritin remains largely a mystery 
although studies with rat liver cells indicate that the half-life of 
the ferritin molecule is 72 h (487). 
SF is a measure of the amount of iron in body stores if there 
is no concurrent infection or inflammation. When the SF con- 
centration is >15 µg/L, iron stores are present. Values <12– 
15 µg/L are generally considered to be indicative of depleted 
iron stores. The SF measurement is widely available, well stan- 
dardized and, in a subject with anemia, a low SF is diagnostic of 
IDA (488). In otherwise healthy individuals, SF concentration is 
directly proportional to the size of the iron store, with 1 µg/L 
SF corresponding to 8–10 mg storage iron in an adult (488). 
Although SF has been shown to give a larger and more consis- 
tent response to iron interventions than ZPP or sTfR (489), it is 
an APP and is increased independent of iron status by acute or 
chronic inflammation. The SF level is therefore difficult to inter- 
pret in settings where infectious diseases are common. It is also 
unreliable in patients with malignancy, hyperthyroidism, liver 
disease, and heavy alcohol intake (490). 
SF resembles liver or spleen ferritin immunologically and is 
recognized and quantified by monoclonal or polyclonal anti- 
bodies raised against these ferritins. The extent to which SF is 
saturated with iron is variable and can be influenced by phys- 
iological conditions such as inflammation and iron overload. 
Iron saturation of ferritin in normal  serum  was  reported to 
be 24% (491) but it is much less in iron overload. Ferritin 
appears to enter the blood plasma by secretion from hepatocytes 
or macrophages after synthesis on membrane-bound polysomes 
and glycosylation, or via direct release from damaged cell mem- 
branes. The 3 factors controlling SF levels are synthesis, release 
from the cells, and clearance from the plasma. Abnormalities 
occur in synthesis and release, but not in clearance. Many cells 
contain ferritin-binding proteins and injected spleen ferritin is 
rapidly taken up by the liver (492). 
 
Normal ranges of serum ferritin. It was only after the de- 
velopment of sensitive immunoradiometric assays that ferritin 
was detected in the serum or plasma of normal individuals (493, 
494). These early assays have been supplanted by enzyme-linked 
immunoassays using colorimetric and fluorescent substrates or 
by antibodies with chemiluminescent labels. The SF assay is 
available for routine analysis using automated immunoassay an- 
alyzers. 
SF concentrations are normally within the range  15– 
300 µg/L and are lower in children than in adults. Mean values 
in women before menopause are lower than in men, reflecting 
women’s lower iron stores caused by menstruation and child- 
birth. In women after menopause, SF concentration increases 
but remains lower than in men. The changes in SF concentra- 
tion from birth to old age reflect changes in the amount of iron 
stored in the tissues (495). In normal individuals, there is a close 
relationship between the total amount of iron removed by phle- 
botomy and the SF concentration (496). The SF concentration is 
relatively stable in healthy persons and a reduction in the level 
of storage iron is the only known biological cause of low SF 
concentrations. In patients with IDA, a number of studies have 
been used to establish the threshold of 12–15 µg/L as indicative 
of iron deficiency (497) and this cut-off is the cornerstone for 
using SF in clinical practice to identify iron deficiency . Higher 
concentrations of SF may be related to infection, inflammation, 
adiposity, and alcohol consumption (490). 
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Iron supply 
Serum iron, TIBC, percent transferrin saturation. Iron in the 
circulating plasma and extracellular fluid is bound to transfer- 
rin. Serum iron and transferrin saturation values have a circa- 
dian rhythm with most individuals exhibiting a morning peak 
and evening nadir. In the morning, transferrin saturation is 
35% (range 20–55%). The pattern may be reversed in people 
who are awake at night and sleep during the day. When absorp- 
tion and release from stores is insufficient to meet functional re- 
quirements, the serum iron level falls and the transferrin concen- 
tration (customarily expressed as the TIBC) is increased (100). 
The serum iron level, TIBC, and transferrin saturation are there- 
fore all indicators of the adequacy of the iron supply to develop- 
ing red blood cells and other tissues. The iron supply to develop- 
ing erythrocytes is suboptimal when the transferrin saturation 
falls below 15% in iron-deficient, but otherwise healthy, indi- 
viduals (139, 498). However, unlike iron deficiency, in infection 
and inflammation both plasma iron and the TIBC are reduced. 
Transferrin saturation is the biomarker that is employed most 
widely in nutrition studies as an indicator of iron deficiency; it 
is also one of the indicators in the “ferritin model” employed by 
the NHANES surveys in the United States (the “ferritin model” 
comprises three indicators, SF, transferrin saturation, and red 
blood cell protoporphyrin) (499). 
As with adults, serum iron concentrations vary throughout 
the day in newborns, infants, and toddlers. Because of the high 
variation in serum iron and transferrin concentrations, percent 
transferrin saturation is not used as a biomarker of iron status 
in newborns. In the past it was employed once postnatal enteral 
feedings and growth had been established; percent transferrin 
saturation can then be useful in infants with parameters similar 
to those for adults indicating the presence of deficiency. 
 
Erythrocyte protoporphyrin. Ferrochetalase catalyses the ter- 
minal step in heme synthesis, which converts protoporphyrin IX 
into heme by the insertion of ferrous iron. Zinc is an alternative 
metal substrate and ZPP is a normal metabolite that is formed 
in trace amounts during normal heme biosynthesis (500, 501). 
Erythrocyte ZPP is not increased with simple iron depletion, the 
stage of iron deficiency when iron delivery to the erythroid mar- 
row is preserved. When the iron supply can no longer meet ery- 
thropoietic requirements, erythrocyte ZPP rises progressively, 
providing an index of the severity of the functional iron defi- 
ciency. 
Using results of bone marrow examinations as the criteria 
for stages of iron deficiency, erythrocyte ZPP has been shown 
to provide a sensitive and specific measure of uncomplicated 
functional iron deficiency (iron-deficient erythropoiesis and 
IDA) (502). ZPP levels are established while red  blood  cells 
are maturing and then remain unaltered for the mature red 
blood cells lifespan ( 3–4 mo). Consequently, red blood  cell 
ZPP is a measure the average iron availability to the ery-  
throid marrow during the preceding 3–4 mo. While increased 
erythrocyte protoporphyrin is an early indicator of iron de- 
ficiency, the result is not specific. Levels are also  increased 
with chronic lead poisoning, the anemia of inflammation, β-
thalassemia trait, α-thalassemia trait, hemoglobin E  dis- ease, 
and some sickle cell carriers (503–505) and other less widely 
discussed xenobiotic compounds (e.g., lead and other metals, 
hexachlorobenzene, halogenated aromatic hydrocar- bons, 
pesticides, sulfides, and dihydropyridines) that disrupt heme 
synthesis (506). Nevertheless, values >150 µmol/mol heme 
are highly suggestive of iron deficiency, usually with anemia, 
rather than thalassemia (504). Other cut-off values to 
distinguish between functional iron deficiency and thalassemia 
or hemoglobinopathy carrier status have been proposed (502). 
ZPP levels have been assessed in studies of preterm infants as 
a marker of potential iron deficiency (348, 507). Standards for 
preterm and term newborns have not been formally established. 
A value >80 µmol/mol heme has been used as an indicator of 
iron deficiency in multiple studies of toddlers (262). 
 
Reticulocyte hemoglobin and proportion of hypochromic 
circulating red blood cells. Reticulocyte hemoglobin content 
(reported as CHr, Ret-He, RHE, RHCc by  different  hematol-  
ogy analyzers), the proportion of hypochromic red blood cells, 
the ratio of microcytic to hypochromic red blood cells, as well 
as various parameters of reticulocyte volume can be measured 
by modern hematology analyzers (508, 509). These measures 
may be helpful in the evaluation of anemia in the clinical set- 
ting. For example, CHr is considered an optional approach to 
establish iron status in young children with anemia (510, 511). 
This group of methods has also been applied extensively to the 
management of iron status and the prediction of responsiveness 
to intravenous iron and erythropoiesis-stimulating agents in pa- 
tients with chronic kidney disease (512). However, their appli- 
cation to the evaluation of nutritional anemia, particularly in 
limited-resource countries, is constrained by the cost of purchas- 
ing and maintaining the necessary analytical equipment. 
 
Serum transferrin receptor. Kohgo et al. (513) were the first  
to identify TfR1 in the plasma by immunoassay. It is a single 
polypeptide chain with a molecular mass of 85 kDa, being a 
truncated fragment of the TfR1 monomer produced from cleav- 
age by a serine protease (514). It circulates in the plasma bound 
to transferrin and is usually called the soluble or sTfR. It can 
also be called the plasma transferrin receptor. sTfR concentra- 
tion is closely linked to cellular iron demands and the erythroid 
proliferation rate (515). When intracellular iron supply is re- 
duced, cell surface TfR1 expression is upregulated in order to 
acquire more iron. It is downregulated when there is sufficient 
iron. Parallel changes in the concentration of sTfR occur. 
The main source of serum sTfR is bone marrow erythroid 
precursors (516). Once iron stores are exhausted, soluble TfR 
values rise progressively as hemoglobin concentrations fall in 
adults undergoing phlebotomy (517). By calculating the induced 
iron deficit, Skikne et al. (517) demonstrated that the sTfR level 
provides a quantitative estimate of the size of the induced iron 
deficit in iron-deficient adults. sTfR concentrations have also 
been shown to correlate with the severity of iron deficiency    
in young children (518) and with the evaluation of iron sta-   
tus based on stainable bone marrow iron (519–521). How- 
ever, sTfR concentrations are also affected by the rate of ery- 
thopoiesis (515, 522, 523). When iron supply is not limiting, 
the sTfR level can be used to monitor bone marrow erythropoi- 
etic activity (524). 
When sTfR was measured in 12 nonanemic women aged 
23–30 y on 15 consecutive days under standardized conditions 
the day-to-day variation was 8.1%, and there were no signifi- 
cant differences across the menstrual cycle. The conclusion of 
this study was that one blood sample was sufficient to measure 
sTfR (525). Although not typically used in newborns, infants, 
and toddlers, the developmental trajectory of plasma TfR has 
been studied (526, 527). Serum TfR increases during the first 4 
mo of life and then remains relatively stable during the first year 
in breastfed infants (528). 
A number of lifestyle and environmental factors have been 
reported to affect sTfR. Lower sTfR values were observed 
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among smokers in a cross-sectional study (529). Although high 
consumption of alcohol is associated with liver damage and 
changes in iron metabolism, sTfR values in alcoholics were re- 
ported to be independent of weekly alcohol intake, age, dura- 
tion of consumption, length of abstinence, time of last drink, 
and liver function tests (530). sTfR and sTfR/log ferritin in-  
dex were unaffected by oral contraceptive use (531). In a study 
examining iron status and nutrient intake in 28 highly active 
(>12 h purposeful physical activity per week) and 28 sedentary 
young women it was reported that although the active women 
had higher iron and similar heme iron intakes, they had higher 
sTfR, sTfR/log ferritin index and lower ferritin concentrations 
than the sedentary women (532). It is not possible to draw con- 
clusions about the etiology of the raised sTfR from this study 
but other published literature in the field indicates that high lev- 
els of physical activity are associated with lower iron status. In a 
cross-sectional study that compared the iron status of 234 obese 
adults with that of 172 nonobese adults attending an outpatient 
clinic, the obese patients had a higher prevalence of iron defi- 
ciency defined by sTfR and serum iron but not by ferritin (533). 
The authors suggest that the hypoferraemia of obesity is due  
to both true iron deficiency and inflammatory-mediated func- 
tional iron deficiency. By measuring serum hepcidin in obese 
premenopausal women, Tussing-Humphreys et al. (534) were 
able to investigate the reason for iron depletion in obesity. They 
postulated that hepcidin is expressed in response to obesity- 
related inflammation rather than changes in iron status, and 
concluded that the iron deficiency of obesity is a true body iron 
deficit rather than maldistribution of iron due to inflammation. 
These observations suggest that sTfR is an accurate biomarker 
of iron status in obese and overweight individuals. Finally, a sys- 
tematic review of the relationship between obesity and hypofer- 
raemia (535) included 25 studies of which 10 examined iron 
status in free-living obese individuals and 15 reported baseline 
iron biomarkers from bariatric surgery candidates. Nonobese 
subjects were used as controls in only 40% of the studies and 
sTfR was measured in only a few of the more recent studies. 
When reported, sTfR was slightly (and hepcidin was markedly) 
elevated in the obese subjects, but it was not possible to draw 
definitive conclusions due to insufficient data. 
A large (n 221) cross-sectional study demonstrated that 
men with altered glucose tolerance had significantly increased 
sTfR and ferritin values compared with normal controls (536). 
There was a negative correlation between SF and sTfR. Insulin 
sensitivity and glucose tolerance status were negatively corre- 
lated with sTfR. 
sTfR concentrations are affected by erythropoietic rate. 
When iron supply is not limiting, sTfR levels are proportional 
to bone marrow erythropoietic activity (524). The evaluation 
of suspected IDA in the clinical setting must include informa- 
tion on conditions that impact erythropoiesis. The prevalence 
of some thalassemia traits may complicate the interpretation  
of sTfR levels in population surveys. sTfR concentrations are 
raised in carriers of α0- and β-thalassemia trait. Nevertheless, 
sTfR may still be informative if diagnostic criteria are adjusted 
to differentiate between iron deficiency and thalassemia traits 
(537–539). 
 
sTfR/SF ratio. The sTfR/SF ratio has been shown to be more 
reliable than either parameter alone for the identification of iron 
deficiency (540). The sTfR/SF ratio proved to be the best pre- 
dictor of absent bone marrow iron in a large population of 
schoolchildren with severe anemia and a wide variety of dis- 
eases including bacteremia, hookworm infection, HIV disease, 
and vitamin A and B12 deficiencies (541). However, the practical 
utility of the sTfR/SF ratio for detecting iron deficiency in the 
presence of inflammation is still unclear. The sTfR/SF ratio has 
also been shown to be the most sensitive indicator of a change 
in iron status following iron supplementation (542). 
 
Iron-deficiency anemia: hemoglobin, Hct, MCV, mean cor- 
puscular hemoglobin, mean corpuscular hemoglobin con- 
centration, RDW. The circulating red blood  cells  represent 
the largest and most accessible functional compartment for 
iron. The measurement of hemoglobin is both an important 
screening tool for detection of iron deficiency and an impor- 
tant criterion for determining severity.  The  Hct  or  packed  
cell volume was fairly widely employed in the  past.  How-  
ever, it provides no additional information if hemoglobin val- 
ues are available. The sensitivity of hemoglobin as a screen-  
ing test for iron deficiency is low because there is consid- 
erable overlap in the in the hemoglobin concentrations of 
healthy individuals and those with mild or moderate iron de- 
ficiency. Specificity is also poor since other  causes  of  ane-  
mia are prevalent in Africa, Asia, the Mediterranean  region, 
and to some extent South America. The most important are 
other nutritional deficiencies, particularly vitamin A deficiency, 
infectious diseases (particularly malaria, HIV disease, and tu- 
berculosis), and inherited red blood cell disorders (particularly 
the thalassemia syndromes and hemoglobin E disease). 
Changes  in  the  red  blood  cell  indexes  [reduced   MCV 
and mean corpuscular hemoglobin (MCH) and  increased  
RDW] are characteristic, but relatively late indicators of iron-
deficient erythropoiesis.  Reliable  results  are  provided by 
automated instrumentation. However, they  lack  speci- ficity. 
Several algorithms that allow iron deficiency to be 
distinguished from other causes of microcytic hypochromic ane- 
mia have been published (543, 544). They have not, however, 
gained widespread acceptance. Measurement of reticulocyte in- 
dexes, including the hemoglobin content of reticulocytes (CHr) 
and the reticulocyte hemoglobin equivalent (Ret He) provide 
earlier indicators of functional iron deficiency, but require spe- 
cific models of hematology analyzer and are generally not used 
in field studies. 
Hemoglobin concentrations are higher in newborn infants 
(130–180 g/L) than in older infants, toddlers, and children 
(>110 g/L) (545). A newborn with a hemoglobin concentration 
<130 g/L is considered anemic, although the etiology of anemia 
is much more likely to be due to blood loss or hemolysis than 
to iron deficiency. Iron-deficiency anemia at birth is extremely 
rare because of the active transport of iron from mother to fe- 
tus even in the face of significant maternal deficiency (177). In- 
fants undergo a “physiologic anemia” in the first 6–8 wk. By 
6 mo of age, hemoglobin norms are the same as older children 
and adults (>110 g/L). The MCV is higher in newborn infants 
due to the presence of fetal hemoglobin. Thus, the utilization 
of low MCV as an indicator of iron deficiency is problematic. 
The RDW is also elevated in neonates as the relatively larger red 
blood cells containing fetal hemoglobin (t1/2 60 days) are re- 
placed by smaller cells containing hemoglobin A. Standards for 
hemoglobin, Hct, MCV, MCH concentration, and RDW after 6 
mo of age have been published by the CDC (234, 546). 
 
Implications related to inflammation for the interpretation 
of biomarkers of iron status. The evaluation of iron status 
in countries where infectious disorders, particularly recurrent 
childhood infections, parasitic illnesses, HIV disease, and tuber- 
culosis, are prevalent is complicated by the behavior of SF as an 
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acute-phase protein. Low-grade inflammation is also common 
in older people in all countries, confounding the use of SF as a 
biomarker of iron status. On the other hand, sTfR concentra- 
tions are less influenced by inflammation than SF (547), making 
it potentially a more robust measure of iron deficiency than SF 
in individuals suffering from infectious and inflammatory dis- 
orders, the ACD, and in the elderly (540, 548–551). However, 
some prevalent infectious disorders, particularly malaria, may 
be associated with increased sTfR levels because of changes in 
eythropoietic rate (552). 
The systemic response to infection or tissue damage is a series 
of events known as the acute-phase response (APR). The local 
reaction is inflammation. The systemic APR may be induced by 
infection, inflammatory disorders (e.g., obesity, diabetes, malig- 
nancy) as well as physical trauma. At the metabolic level, the 
APR comprises the increased production (positive) or reduction 
(negative) of a numerous APPs prior to the full activation of  
the immune response. The main purpose of the APR is to pre- 
vent damage to the tissues by removing harmful molecules and 
pathogens. The changes in the levels of APPs reflect changes in 
their production by hepatocytes, which in turn are regulated by 
cytokines such as IL-1, IL-6, and tumor necrosis factor α acting 
in a complex network (553). The implications of the APR and 
inflammatory response to nutrition and vice versa was the focus 
of a collaboration between NICHD and BMGF called Inflam- 
mation and Nutrition Science for Program/Policy and Interpre- 
tation for Research Evidence (INSPIRE) (128). 
For the purposes of this review, it is important to acknowl- 
edge that biomarkers used to assess iron nutrition, particularly 
SF (increased in inflammation) and transferrin (decreased in in- 
flammation), are APPs influenced by the APR, which thus af- 
fects their selection, use, and interpretation. The case of SF of- 
fers an opportunity to explore the current efforts to address this 
challenge. The patterns by which APP rise and fall with inflam- 
mation have been studied and evaluated with the aim of using 
concentrations of other relevant markers of inflammation to ac- 
count for the influence of inflammation on SF values to yield a 
value that would reflect only nutritional iron status. The timing 
of the increase, the extent of the rise and the period over which 
the concentrations of different APPs are elevated varies consid- 
erably depending on the specific APP and the type of infection 
or inflammatory disorder (128, 554, 555). 
Northrop-Clewes (554) reviewed several studies to 
compare the responses reported for SF and inflammatory 
markers, including α-1-acid glycoprotein (AGP), CRP, α1- 
antichymotrypsin (ACT), haptoglobin, and fibrinogen, to 
infection or trauma (556). SF increased from its initial value by 
an average of   2.5-fold, peaked at 4 d and was still elevated at  
6 d. AGP had a similar pattern to SF and increased on average 
2-fold, peaked between 2 and 4  d and was still elevated at 6 
d. On the other hand, both CRP and ACT rise and fall more 
rapidly than  SF.  The  average  increase  in  CRP  was  3-fold,  
the peak value occurred at day 2. After 6 d the CRP was 
approaching baseline. ACT increased 2-fold,  peaked  at  2  d 
and had decreased somewhat at day 6, but less so than CRP. 
Haptoglobin and fibrinogen were still rising at day 6. 
The potential of using SF to quantify iron deficiency in pop- 
ulations with widespread infections and inflammation has been 
the focus of considerable recent effort. A partnership between 
the WHO and CDC has convened a working group to ad- 
dress the use of SF as a biomarker for population surveillance. 
Those deliberations are being informed by collaboration be- 
tween NICHD, CDC, Bill & Melinda Gates Foundation, and  
the Global Alliance for Improved Nutrition (GAIN) called the 
Biomarkers Reflecting Inflammation and Nutritional Determi- 
nants of Anemia (BRINDA) Project. Both projects have been 
informed by the INSPIRE Project. INSPIRE included an effort  
to identify potential approaches to account for the impact of the 
APR/inflammation on selection and interpretation of biomark- 
ers. 
Text Box 36 (294, 490, 557–559)outlines the primary ap- 
proaches that were identified by the INSPIRE consultancy and 
are now being evaluated by both BRINDA and the WHO/CDC 
efforts. 
 
 
These projects involve both systematic reviews of the rele- 
vant extant literature and de novo analyses of existing datasets 
to explore the biomarker/inflammation relationship. The Text 
Box 37 (560–565) summarizes some of the key findings of the 
BRINDA project specific to the intersection of iron biomarkers 
and inflammation. 
 
 
Text Box 36 
Potential approaches to account for inflammation 
• Ignore inflammation 
Comment: the redistribution of the biomarker of inter- 
est without a real change in the total body content of the 
micronutrient results in a distorted measurement of the mi- 
cronutrient status. 
• Exclusion of the sample with elevated biomarkers of 
inflammation 
Comment: not useful in areas of high infection burden 
and other acute and chronic inflammatory disorders, e.g., 
parts of sub-Saharan Africa. as this approach could sub- 
stantially decrease sample size and could lead to an atypi- 
cal residual sample which would bias the results especially 
if subjects with iron deficiency are more susceptible to in- 
fection. 
• Change cut-off values 
Comment: as the rise and fall of ferritin in response to 
infections and inflammation is variable and time depen- 
dent, the sensitivity of diagnosis would be expected to be 
low (490). 
• Standardization (to calculate the prevalence of mi- 
cronutrient deficiency in those with and without inflamma- 
tion, then calculate a weighted prevalence estimate using a 
“standard” prevalence estimate of inflammation). 
Comment: too many uncertainties regarding preva- 
lence and type of inflammation and differences in 
biomarker/APP response: temporal, direction (up or 
down), and magnitude. 
• Correction factor approach, e.g., Thurnham et al. 
(557) 
Concerns: differences in inflammatory response in 
terms of developmental biology (infants compared with 
adults, pregnancy, etc.), temporal changes in context of 
acute compared with chronic infection (APP selection; CRP 
compared with AGP), and differences in relationships of 
nutrient biomarkers to inflammatory markers (294, 558, 
559). 
• Statistical options/regression modeling 
Comment: current focus of both WHO and BRINDA 
projects. 
  
 
Text Box 37 
Summary of BRINDA Aims and Key Findings (560–565) 
Aim 1: Identify risk factors of inflammation as defined 
by the positive APPs): CRP and AGP 
• Inflammation as indicated by elevated CRP and AGP is 
common in population-based nutrition surveys of women 
of reproductive age (WRA) and preschool children (PSC). 
• Factors associated with elevated CRP differ from those 
associated with AGP. 
-A consistent positive relationship was observed be- 
tween CRP and obesity among WRA 
-A consistent positive relationship was observed be- 
tween AGP and stunting in PSC 
• Variability in the factors associated with CRP or AGP 
suggest the need to measure these APPs directly to under- 
stand inflammation in populations. 
• Elevated CRP or AGP could not be predicted by so- 
ciodemographic covariates 
Aim 2: Assess the relationships between inflammation 
and biomarkers of iron status and compare adjustment 
approaches in pursuit of more accurate assessment of mi- 
cronutrient status of populations 
Ferritin 
• The association with CRP/AGP was consistent in al- 
most all data sets, and in both PSC and WRA. 
• The strength of correlation ranged widely between 
countries and tended to be stronger in children than in 
women. 
• No clear cutoff (threshold) for CRP or AGP at which 
there was a change in the relationship between inflamma- 
tion and ferritin was found. 
BRINDA conclusion 
• The regression correction is proposed as an improve- 
ment to the correction factor approach to account for the 
full range and severity of inflammation. 
• Adjusting for malaria in addition to CRP  and  AGP  
did not significantly change the estimated prevalence of de- 
pleted iron stores. 
sTfR: 
• Association with AGP was stronger and more consis- 
tent than association with CRP in both PSC and WRA. 
BRINDA conclusion 
• The regression correction approach should be used to 
adjust TfR for AGP to account for the full range and sever- 
ity of inflammation. 
• The effect of adjusting the prevalence of iron-deficient 
erythropoiesis (i.e., elevated TfR) for CRP was minimal 
and inconsistent across surveys and therefore not recom- 
mended. 
• In most countries, adjusting for malaria in addition to 
AGP did not significantly change the estimated prevalence 
of iron-deficient erythropoiesis. 
Body iron index 
• There was a slight positive association with CRP and 
AGP in both PSC and WRA. 
BRINDA recommendation 
• Body iron index is affected by inflammation and 
should be adjusted when estimating the prevalence of 
 
 
 
 
 
 
 
 
 
 
 
 
 
Analytical Considerations 
The physiologic aspects of the biomarkers of iron deficiency 
were described in the previous section. This section provides an 
overview of the analytical aspects, of the tools and methods used 
to ensure the quality of the measurement, and of preanalytical 
considerations that are relevant to sample collection, processing, 
and storage because they may affect the measurement results for 
these biomarkers. In addition to the presence of stainable iron 
in the bone marrow, iron status biomarkers can be categorized 
into hematological (red blood cell parameters) and biochemical 
indicators (mainly serum-based parameters, but also erythro- 
cyte protoporphyrin). Most analytical methods that measure 
these biomarkers are well established and widely used in clini- 
cal practice, program evaluation, and research settings. They are 
relatively simple analytical techniques compared to techniques 
used to measure other nutrients in biological samples, yet there 
are remaining issues with regards to assay comparability and 
standardization. This section summarizes the advantages and 
disadvantages of common analytical methods used to measure 
whole-blood-based (Table 9) and serum-based (Table 10) iron 
status indicators. 
 
Stainable bone marrow iron 
The Prussian blue stain (potassium ferrocyanide) is used to stain 
bone marrow aspirates or biopsies. Most of the stainable iron  
is hemosiderin located in macrophages. Roughly half of the 
nucleated erythroid precursors also contain small cytoplasmic 
iron granules (sideroblasts). The amount and distribution of the 
stainable iron provides a semiquantitative estimate of the size of 
body iron stores (566). The evaluation of bone marrow requires 
an experienced observer and careful attention to detail. Absent 
bone marrow iron may be reported in aspirates that contain in- 
sufficient bone marrow stroma for adequate evaluation (567). 
Iron contamination may occur if acid-washed glassware and 
slides are not used. Iron may be leached out of biopsy specimens 
during decalcification. Finally patients who have received some 
types of parenteral iron such as iron dextran that are processed 
in macrophages may have stainable bone marrow iron despite 
being iron deficient because the iron is in a form that is not 
easily mobilized (568). In malarial regions, hemozoin (malarial 
pigment) in the bone marrow may be misidentified as storage 
iron (521). 
 
low  body  iron  index,   particularly   in   children   living  
in areas with a high prevalence of inflammation and 
infections. 
• Malaria does not appear to have an additional effect 
on body iron index that is independent of inflammation. 
Aim 3: To assess factors associated with anemia 
amongst PSC and WRA, and to estimate the proportion 
of anemia associated with iron deficiency 
• In both PSC and WRA, the proportion of anemia as- 
sociated with iron deficiency depended on the underlying 
prevalence of infection/inflammation. 
• The proportion of anemic individuals with concomi- 
tant iron deficiency varied by  the  burden  of  infections  
in the country and ranged  from  30%  to  58%  in  PSC  
and from 35% to 71% in WRA. Inflammation was as- 
sociated with anemia in countries with high infection 
burdens. 
 TABLE 9 Advantages and disadvantages of the main methods used to measure whole-blood-based iron status indicators1 
Indicator Method Advantages Disadvantages 
 
Hemoglobin HemoCue • Battery-operated, hand-held instrument • Requires freshly collected blood 
• Point of contact result can be reported to the participant • Capillary blood sampling technique needs to be “standardized” to avoid considerable variability 
• Requires one drop of blood 
• Can be performed from a finger stick 
• Inexpensive 
• Suited for low-resource settings 
 
Automated flow cytometry • Fully automated instrument • Restricted to laboratory setting 
• Available in most hospitals • Usually requires venous blood from which the analyzer aspirates a small amount of specimen through a small-bore tube 
• Good precision • Instrumentation requires regular maintenance and periodic technical service 
• Different blood cells can be counted; results can provide 
insight on general health status 
Hematocrit or 
packed cell 
volume 
 
 
 
 
 
 
 
 
Erythrocyte 
Microcentrifuge • Simple and inexpensive • Requires freshly collected blood 
 
• Instrument is portable • Requires stable power supply 
• Requires <100 µL blood • Poor reproducibility 
• Suitable for low-resource settings • Blood may spill into centrifuge if capillaries are not properly sealed or if they break 
 
Automated flow cytometry • Fully automated instrument • Restricted to laboratory setting 
• Available in most hospitals • Usually requires venous blood from which the analyzer aspirates a small amount of specimen through a small-bore tube 
• Good precision • Instrumentation requires regular maintenance and periodic technical service 
• Different blood cells can be counted; results can provide 
insight on general health status 
Hematofluorometer (ZPP, ZPP/H) • Simple instrumentation • Requires freshly collected blood 
protoporphyrin • Can be used in the field, if set up in one location (do not 
place in direct sunlight or in a draft) 
• Needs stable power supply (voltage regulator) 
 
 
 
 
 
Chemical extraction with 
conventional fluorometry (free 
erythrocyte protoporphyrin) 
• Point of contact result can be reported to the participant • Moderate precision 
• Requires one drop of blood • Fluorescent interferences possible 
• Can be performed from a finger stick • Technique is important (oxygenate blood sample if not freshly collected) 
• Inexpensive • Instrument requires readjustment after moving (optics get misaligned easily) 
• Calibration has to be done at the factory 
 
• Older or frozen EDTA anticoagulated blood can be used • Manual multistep assay 
• Dried blood spots can be used • Requires chemical fume hood due to the use of ethyl acetate/acidic acid and diluted hydrochloric acid; fumes are irritating 
• Requires only 20-µL specimen per test • Moderate precision (need for duplicates) 
• Requires relatively inexpensive fluorometer • Requires complete hemolysis of cells (either through freezing or dilution of fresh whole blood 1:5 with saline) 
• Can be done with washed erythrocytes (when using fresh 
blood) to remove potential fluorescent interferences 
 
 
 
 
1Hct, hematocrit; ZPP, zinc protoporphyrin; ZPP/H, zinc protoporphyrin/heme ratio. 
• External fluorescent contamination possible (from wooden applicator sticks, glassware with soap residues, some hand 
lotions) 
• Nondisposable actinic glassware needs to be washed with 10% (v/v) hydrochloric acid and thoroughly rinsed with 
deionized water, because concentrated acids quench fluorescence 
• Work under subdued light conditions, particularly when handling calibrators 
• Requires Hct to correct for packed cells 
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 TABLE 10 Advantages and disadvantages of the main methods used to measure serum-based iron status indicators1 
Indicator Method Advantages Disadvantages 
Serum iron, TIBC, 
or UIBC 
Colorimetric assay • Requires relatively inexpensive photometric instrument • Manual multistep assay 
• Relatively inexpensive • Requires fairly high sample volume (≥500 µL) 
• Rigorous elimination of iron contamination 
• Moderate precision 
 
Clinical chemistry 
analyzer (colorimetric) 
 
 
 
 
Atomic absorption 
spectrophotometry 
 
Serum transferrin Immunoassay on 
analyzer 
• High sample throughput • Typically requires sample volume of ≥150 µL 
• Quick turnaround time to first result • No control over lot-to-lot variability or assay recalibration/reformulation 
• Available in commercial kit form for several instrument platforms • Moderately expensive instrumentation 
• Minimum operator involvement • Instrumentation requires regular maintenance and periodic technical service 
• Good precision 
• Relatively low reagent cost 
 
• Relatively simple processing • Relatively expensive instrumentation 
• Quick analysis time • Instrumentation requires regular maintenance and periodic technical service 
• Good precision 
• High sample throughput • Typically requires sample volume of ≥150 µL 
• Quick turnaround time to first result • No control over lot-to-lot variability or assay recalibration/reformulation 
• Available in commercial kit form for several instrument platforms • Moderately expensive instrumentation 
• Minimum operator involvement • Instrumentation requires regular maintenance and periodic technical service 
• Good precision 
 
Serum ferritin ELISA assay • Requires small to moderate sample volume (50–100 µL) • Manual assay; several pipeting steps; adherence to strict timing 
• Requires relatively inexpensive microplate reader (450 ± 10 nm filter) • Plate washer is recommended; insufficient washing may result in poor precision 
• Available in commercial kit form from several manufacturers • Moderate precision (duplicates recommended) 
• Reagent cost can be moderately high 
 
Immunoassay on 
analyzer 
• High sample throughput • Typically requires sample volume of ≥150 µL 
• Quick turnaround time to first result • No control over lot-to-lot variability or assay recalibration/reformulation 
• Available in commercial kit form for several instrument platforms • Moderately expensive instrumentation 
• Minimum operator involvement • Instrumentation requires regular maintenance and periodic technical service 
• Good precision 
• Relatively low reagent cost 
 
Serum soluble 
transferrin 
receptor 
ELISA assay • Requires small sample volume (≤50 µL) 
• Requires relatively inexpensive microplate reader (450 ± 10 nm filter 
plus second filter for 550–650 nm) 
• Available in commercial kit form from few manufacturers 
 
• Manual assay; several pipetting steps; adherence to strict timing 
• Plate washer is recommended; insufficient washing may result in poor precision 
• Moderate precision (duplicates recommended) 
• Reagent cost can be moderately high 
 
Immunoassay on 
analyzer 
 
 
 
1TIBC, total iron-binding capacity; UIBC, unsaturated iron-binding capacity. 
• High sample throughput • Typically requires sample volume of ≥150 µL 
• Quick turnaround time to first result • No control over lot-to-lot variability or assay recalibration/reformulation 
• Available in commercial kit form for several instrument platforms • Moderately expensive instrumentation 
• Minimum operator involvement • Instrumentation requires regular maintenance and periodic technical service 
• Good precision • Moderately high reagent cost 
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Hematological parameters 
Hb. Hb measurements, used to assess anemia in an  individ- 
ual or in populations, are well standardized and provide good 
precision (Tables 9 and 11). The accepted  reference  method 
for the determination of Hb in human blood is the photomet- 
ric determination of hemiglobincyanide (cyanmethemoglobin) 
(569). This method reliably measures all Hb variants except 
sulfhemoglobin. Red blood cells are lysed and potassium fer- 
ricyanide, which oxidizes Hb to methemoglobin, is added. 
Methemoglobin combines with potassium cyanide to form 
cyanmethemoglobin. The brown color is measured spectropho- 
tometrically. The end point of the reaction is stable and the 
reaction is linear to 20 g/dL. However, reagents for cyan- 
methemoglobin are light sensitive and poisonous. This method 
is the benchmark against which all other methods are evalu- 
ated. It is the basis for Hb measurements on most automated 
cell counter analyzers and for hand-held “screening” devices. In 
this field-appropriate technology, whole blood is collected into 
a disposable cuvette containing reagent in dried form for Hb 
measurements and cyanmethemoglobin or azidemethemoglobin 
is measured with a simple, portable, dedicated photometer. 
The HemoCue is one such portable device that has been 
used worldwide to assess anemia rates in various populations. 
For tips on how to use the HemoCue instrument, how to col- 
lect a valid specimen, and how to avoid common mistakes, the 
reader is referred to the Micronutrient Survey Toolkit (570) and 
a manual published by Helen Keller International (571). Differ- 
ent HemoCue models are available (B-Hb, Hb-201, and Hb- 
301); the two newer models (Hb-201 and Hb-301) no longer 
require the use of a control cuvette due to an internal self-test. 
The Hb-301 additionally offers an extended temperature range 
(10–40°C) for the storage of cuvettes compared to the previous 
models (15–300C). This latest model measures absorbance of 
whole blood at an Hb/BbO2 isobestic point with turbidity com- 
pensation and does not require hemolysis of the sample. The 
instrument is factory calibrated against the reference method 
from the International Council for Standardization in Haema- 
tology (ICSH), needs no further calibration, and has no active 
reagents in the cuvette. Using venous blood from adult volunteer 
donors, good comparability of the B-Hb and Hb-201 models 
was demonstrated (572), but systematic differences between the 
Hb-301 (2.6% higher) and Hb-201 models were found (573). 
The exposure of cuvettes for all three models to elevated tem- 
perature (37°C) for up to 3 wk had only minimal effects (<1%) 
on Hb results (572). However, exposing the Hb-201 cuvettes to 
moisture and elevated temperature caused them to fail within 
minutes, whereas the Hb-301 cuvettes withstood those condi- 
tions for 3 wk (573). The largest source of error with this tech- 
nique is the use of improperly collected capillary samples. This 
issue is discussed in the preanalytical factors section. 
 
Hematocrit. The Hct does not offer new or additional informa- 
tion about anemia beyond Hb and unless the value is needed as 
a measure of packed cells to normalize other blood-based mea- 
surements, measuring the Hct in the field is probably not worth 
the effort. Field assays are often unreliable because of difficul- 
ties encountered in calibrating portable centrifuges. Automated 
cell counter analyzers provide calculated Hct results as part of 
the complete blood count profile (Table 9). 
 
Other red blood cell parameters. The MCV,  MCH, and  
RDW are also part of the complete blood count profile ob- 
tained from automated cell counter analyzers, but are no longer 
commonly used in the diagnosis of iron deficiency. As indicated 
1044S Lynch et al. 
above, measurement of reticulocyte indexes (CHr and Ret He) 
require specific models of hematology analyzers and are gener- 
ally not used in field studies. 
 
Biochemical indicators 
Erythrocyte protoporphyrin. Porphyrin compounds fluoresce 
in the red portion of the spectrum when excited by light at a 
wavelength corresponding to their Soret absorption maximum. 
ZPP can be measured directly by either reflective fluorescence in 
a hematofluorometer or after extraction of the zinc moiety using 
ethyl acetate and hydrochloric acid. The free erythrocyte proto- 
porphyrin (FEP) is measured by conventional fluorometry at an 
excitation/emission wavelength of 405/620 nm (Table 9). Both 
FEP and ZPP should be interchangeable with the term “erythro- 
cyte protoporphyrin” (EP). The 1996 National Committee for 
Clinical Laboratory Standardization (NCCLS) EP testing guide- 
line (574) and an article by John Beard (575) discussed these two 
analytical approaches in detail as well as the variety of reporting 
units and equations used to convert units. The main advantage 
of the chemical extraction method is that it does not require 
freshly collected blood. However, the procedure is complex and 
requires chemicals that pose safety hazards. These may be some 
of the reasons why it is no longer widely used. 
The simpler hematofluorometer method has been employed 
more often in the recent past, particularly to screen for elevated 
EP values as a result of iron deficiency or lead poisoning in chil- 
dren. This method has several advantages for field studies: the 
instrument provides a direct estimate of the ZPP/H, only a drop 
of capillary or venous blood is required, the volume of the sam- 
ple need not be measured, and neither processing nor anticoag- 
ulation is required. The excitation light at 415 nm is focused on 
the bottom of a drop of blood on a horizontal glass slide at an 
angle of 37° to the vertical. The light emitted from the sample 
at 596 nm is collected below the sample and is proportional to 
the ZPP/H. Calibration standards are supplied by the manufac- 
turer. While this direct approach is attractive for studies in low- 
resource settings, two factors limit its use. Most importantly, the 
instrument requires frequent recalibration to ensure appropri- 
ate alignment of the filters and mirrors if it is transported under 
unfavorable conditions. It has to be shipped back to the manu- 
facturer for this to be done. A secondary concern is interference 
by non-porphyrin fluorescent compounds, such as bilirubin, ri- 
boflavin, and certain medications, that may be present in the 
plasma. The accuracy of the estimate can be improved by using 
saline-washed erythrocytes. Continued problems with calibra- 
tion, sources of bias, and discrepancies in results between the 
major manufacturers of these instruments have complicated the 
use and interpretation of ZPP/H assays. 
 
Serum iron, TIBC, and transferrin saturation.  The  serum  
iron pool represents the amount of ferric iron (Fe3+) that is in 
transit through the circulation bound to transferrin. Three as- 
say results are customarily reported together, namely the serum 
iron (SI), the transferrin concentration, usually reported as the 
quantity of iron that can be bound to transferrin (TIBC), and the 
TSAT ( SI 100/TIBC) (575). The utility of SI and TSAT as 
screening tools for iron deficiency is, however, limited by the cir- 
cadian variation, the confounding effects of infectious diseases, 
and many other clinical disorders. 
Analytical methods for SI are either  based  on  colorimet- 
ric principles (manual assay or using automated analyzer) or 
direct assay by atomic absorption spectrophotometry (100, 
576) (Tables  10  and  11)  (577–579).  The  former  approach  
is available in most clinical laboratories, whereas the latter 
 ∼ 
TABLE 11 Available reference materials and proficiency testing programs for iron status indicators1 
Indicator Reference materials Selected list of PT8 programs 
Hemoglobin NIBSC IS 98/708 (dilute solution of hemiglobincyanide produced from bovine blood; 
49.8 µmol/L [803.3 mg/L]; consensus value) 
CAP Hematology and Clinical Microscopy Survey 
 
Serum iron NIST SRM 937 (iron metal); NIST SRM 3126A (iron standard solution) CAP Chemistry Survey and Cal V/L Survey; UK NEQAS 
 
Serum ferritin NIBSC RM 94/572 (human plasma, freeze-dried; recombinant; 6.3 µg/ampoule; 
consensus value) 
 
CAP Chemistry Survey and Cal V/L Survey; UK NEQAS 
Serum soluble transferrin 
receptor 
NIBSC RR 07/202 (human serum, freeze-dried; recombinant; 21.7 mg/L and 303 
nmol/L [free sTfR monomer]; gravimetric/spectrophotometric value assignment) 
CAP Soluble Transferrin Receptor Survey 
 
1Reference materials found online (577, 578). Cal V/L, Calibration Verification and Linearity Survey; CAP, College of American Pathologists; IS, international standard; NIST, National 
Institute of Standards and Technology; PT, proficiency testing; RM, reference material; RR, round robin; SRM, standard reference material; sTfR, serum transferrin receptor; UK 
NEQAS, United Kingdom National External Quality Assessment Service. Adapted with permission from reference 579. 
 
approach is mostly available in research laboratories. Both ap- 
proaches are well-established procedures that have been avail- 
able for decades. In 1998 the NCCLS approved standards for 
the determination of serum iron, TIBC, and TSAT and provided 
a detailed description of the colorimetric manual laboratory 
procedures (580). While rigorous elimination of iron contam- 
ination has been a critical concern for the manual colorimetric 
assay, this has not been a problem with the use of automated 
analyzers. 
The concentration of serum transferrin can be measured ei- 
ther directly by immunologic methods or by the use of the TIBC 
as a proxy measure of transferrin (100, 576). The TIBC assay   
is identical to the SI assay, but applies an additional step (satu- 
ration of iron-binding sites of the transferrin molecule with ex- 
cess iron) followed by the removal of the unbound iron. Most 
clinical analyzers actually measure the unsaturated iron bind- 
ing capacity (UIBC) because it is more easily automated; the 
TIBC concentration is then calculated by summing SI and UIBC 
concentrations. This works well for the detection of iron deple- 
tion when SI concentrations are low and UIBC concentrations 
are high; however, in the presence of iron overload the mea- 
surement of very low UIBC concentrations may result in rela- 
tively high method imprecision. In an interlaboratory compar- 
ison study, Blanck et al. (581) found no significant differences 
in SI, TIBC, or UIBC results among methods [and low within- 
method variation for SI (CV <3%)] regardless of the chromogen 
used to form the color complex with iron (ferine or ferrozine) 
and whether the automated methods were corrected for copper 
and protein. 
 
Serum ferritin. The measurement of SF is a well-established 
routine procedure carried out by clinical laboratories (Tables 10 
and 11). To allow for high sample throughput, most laboratories 
use fully automated immunoassays for which several manufac- 
turers produce commercial kits for various analyzer platforms. 
If a laboratory does not have access to a clinical analyzer, a man- 
ual ELISA can be used (492, 582). Commercial kits from several 
manufacturers are available for this type of assay. While proce- 
dures for the analysis of ferritin in plasma or serum (583, 584) 
spotted onto filter paper have been published, they have been 
only rarely utilized. Procedures for the storage and transport of 
dried plasma or serum spots are more convenient than those 
for frozen samples; however, a centrifuge (and electrical power) 
is still needed. While ferritin can be measured in dried blood 
spots, its usefulness is diminished by the release of much higher 
ferritin concentrations from hemolyzed erythrocytes (585). 
Worwood (490) discusses potential pitfalls in the analysis of  
SF, including different isoferritin forms, the “high-dose hook” 
effect, interference by non-ferritin proteins, and antibodies to 
some animal proteins. None of them seem to cause notewor- 
thy issues with current assays. Generally, ferritin assays compare 
reasonably well across methods, with a CV of 10–15% (586); 
however, an improvement in comparability would be desirable. 
Agreement among laboratories performing the same method is 
good (CV <10%) (586). 
 
Serum transferrin receptor. Immunoradiometric assays and 
ELISAs were initially developed  for  the  measurement  of 
sTfR. They were later followed by latex-enhanced immunoas- 
says (nephelometry and turbidimetry) and more recently by 
fluoroimmunoassays and immunofluorometric assays (530) 
(Tables 10 and 11). While microplate ELISA assays have been 
employed for >20 y, commercial kits that can be used on fully 
automated clinical analyzers have only been available more re- 
cently (587, 588). The usefulness of commercial assays has been 
severely limited by several factors. The various assays express re- 
sults in different units (mg/L and nmol/L). There is poor agree- 
ment between different kits. An international reference stan- 
dard has been available since 2010 but its use has been limited 
due to commutability questions. The poor comparability across 
assays (589) is likely to be due to manufacturers using differ- 
ent calibrators (TfR isolated from human placenta, not com- 
plexed to transferrin; sTfR extracted from serum either in free 
form or complexed with transferrin), different antibodies (mon- 
oclonal or polyclonal), and even different reporting units (mg/L 
and nmol/L) (530). Standards derived from placental TfR have 
produced higher TfR assay values than standards isolated from 
serum (590). This lack of commutability, and the relatively high 
reagent cost, are some of the reasons why sTfR measurements 
have not been widely adopted in clinical practice. Methods for 
sTfR measurement using dried blood spots have been reported 
(585, 591). 
 
Measuring several iron status indicators in one assay. Er- 
hardt et al. (592) have developed an inexpensive and sensitive 
sandwich ELISA assay that allows the combined measurement 
of ferritin, sTfR, CRP, and retinol binding protein in 50 µL of 
serum or plasma. It is a convenient option for evaluating iron 
and vitamin A status and, at the same time, accounting for the 
effect of infection or inflammation. The current assay also in- 
cludes the measurement of AGP, a sensitive acute-phase reac- 
tant that captures the response to inflammation over a longer 
time period (4–5 d) compared to CRP (1–2 d). This assay has 
been successfully applied to numerous micronutrient surveys in 
low-resource settings where the specimen volume was insuffi- 
cient to conduct several conventional assays. The assay has the 
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TABLE 12 Cutoff values for erythrocyte protoporphyrin, serum ferritin, and transferrin 
saturation by stages of iron status and by population group (218) 
 
 
 
Erythrocyte protoporphyrin 
 
Population group 
 
 
<5 y of age ≥5 y of age 
Iron overload Normal Normal 
Normal iron status Normal Normal 
Iron depletion Normal Normal 
Iron deficiency with or without anemia >70 g/dL RBC >80 µg/dL RBC 
>2.6 µg/g hemoglobin >3.0 µg/g hemoglobin 
>61 mmol/mol heme >70 mmol/mol heme 
Serum ferritin, µg/L 
Severe risk of iron overload No cutoff >200 (adult males) 
>150 (adult females) 
Depleted iron stores in the presence of infection <30 No cutoff 
Depleted iron stores <12 <15 
Transferrin saturation, % 
Iron overload >60–70 
Iron deficiency anemia <16 
 
following shortcomings: 1) the interassay variability is generally 
higher than that of commercial fully automated assays, necessi- 
tating the use of a daily “adjustment factor” derived from the 
analysis of a material with a known value; 2) the assay has not 
yet been reliably transferred to laboratories in low-resource set- 
tings; and 3) some of the antibodies used in the assay are no 
longer commercially available. However, given that this assay  
is a desirable and promising platform for future applications, 
the CDC is evaluating modifications of the assay to incorpo- 
rate currently commercially available antibodies and improve 
its ruggedness in the hopes that it will allow successful tech- 
nology transfer to low-resource settings. PATH in collaboration 
with Quansys Biosciences have recently developed a commer- 
cially available multiplex ELISA assay for simultaneous quan- 
tification of iron (serum or plasma ferritin and sTfR), vitamin 
A, and inflammation status markers (593). The reagent costs 
for this assay are lower than purchasing separate commercial 
kits for each indicator and processing time and specimen vol- 
ume are reduced. However, the performance of this assay re- 
quires the following further improvements: 1) to the calibra- 
tion system by using purified or recombinant antigen cocktails 
instead of a commercially available control that does not pro- 
vide optimal concentration ranges for each indicator; 2) to the 
precision—currently the interassay CV for ferritin is 9.3–14.1% 
and for sTfR 7.3 –13.5%; and 3) to the correlation of this assay 
with conventional ELISA assays—satisfactory correlation was 
obtained for ferritin (r  0.951), but the correlation was too   
low for sTfR (r   0.606). Furthermore, this assay will have to   
be compared to established methods for which the performance 
with reference materials is known and acceptable. 
 
Interpretation of data and cutoff values 
(Tables 12 and Table 13) 
There are three stages in the development of iron-deficiency ane- 
mia: iron depletion, where the amount of storage iron is re- 
duced (low SF); iron-deficient erythropoiesis, which represents 
restricted iron supply to the bone marrow and thereby mild tis- 
sue deficiency (transferrin saturation is reduced, sTfR and EP are 
increased); and finally IDA, where iron-containing functional 
compounds including Hb are underproduced (low Hb). In situ- 
ations of chronic disease, anemia can develop without an initial 
iron deficiency, so-called ACD. In the presence of iron overload, 
indicators of storage and transport iron are elevated (high SF 
and transferrin saturation). 
A recent WHO Vitamin and Mineral Nutrition Information 
System (VMNIS) document provides a summary of cutoff val- 
ues for Hb for the diagnosis of anemia and assessment of sever- 
ity by population group (236). This document also provides ad- 
justments for altitude and smokers. The older WHO guide for 
program managers provides cutoff values for Hct for the same 
population groups as well as for EP and ferritin for children 
<5 y of age and persons    5 y of age and for TSAT (218). Be- 
cause of large assay differences in the measurement of sTfR 
(589), the manufacturer’s assay-dependent cutoff values have 
been used. The Ramco enzyme immunoassay, the first com- 
mercially available sTfR kit assay, reported a normal range in 
healthy volunteers of 2.9–8.3 mg/L (594). Mei et al. (595) de- 
rived cutoff values (97.5th percentile in a defined healthy refer- 
ence population) for two vulnerable US population groups using 
data from NHANES 2003–2010 as 6.0 mg/L for children 1–5 y 
and 5.3 mg/L for nonpregnant women 15–49 y. The NHANES 
data were produced using the Roche Tina-quant sTfR assay, 
which yields values that are on average 30% lower than those 
from the Ramco assay (587). 
Since the inception of NHANES in 1971, special focus was 
dedicated to monitoring the iron status of the US population 
(596). Each NHANES has included a battery of  hematologic 
and biochemical indicators of iron status (597). Since NHANES 
II (1976–80), models that employed multiple biochemical iron 
status indicators have been used to define iron deficiency in the 
population (598). In 1980, the ferritin model, also known as the 
three-indicator model, was developed and applied to NHANES 
III (1988–94) as well as to the first few years of the continu- 
ous NHANES survey beginning in 1999. In this model, partic- 
ipants who had two out of three abnormal iron status indica- 
tors (SF, transferrin saturation, and erythrocyte protoporphyrin) 
were categorized as iron deficient. Reference data for various 
hematological and biochemical iron status indicators measured 
in persons 1 y and older during NHANES III have been re- 
ported as part of a National Center for  Health  Statistics Se- 
ries 11 report (599). Reference data for biochemical indicators 
measured in persons 1 y from NHANES 1999–2002 were in- 
cluded in the CDC’s National Report on Biochemical Indicators 
of Diet and Nutrition in the US Population 1999–2002 [the First 
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TABLE 13 Relationships between biomarkers and iron status 
 
 
Iron status 
Sustainable bone 
marrow iron 
Serum 
ferritin 
Transferrin 
saturation 
Erythrocyte 
protoporphyrin 
Serum transferrin 
receptor 
 
Hemoglobin 
Iron-deficiency anemia Absent Low Low High High Low 
Iron-deficient erythropoiesis Absent Low Low High High Normal 
Iron depletion Absent Low Normal Normal Normal Normal 
Normal iron status Normal Normal Normal Normal Normal Normal 
Iron overload Normal or increased High High Normal Normal Normal 
 
 
Nutrition Report (429)]. Starting in 2003, NHANES limited the 
population of interest to children (1–5 y) and women of child- 
bearing age (12–49 y). Furthermore, the measurement of serum 
sTfR was introduced, which allows the evaluation of iron status 
by the body iron model (248). Reference data for ferritin, sTfR, 
and body iron for children and women of childbearing age were 
reported as part of the CDC’s Second Nutrition Report (600). 
While SF is the most sensitive index of iron status as long   
as residual iron stores are available, this biomarker does not 
reflect the severity of the depletion as it progresses; sTfR con- 
centrations, on the other hand, continue to rise with increasing 
functional iron deficiency. Because of the reciprocal changes in 
ferritin and sTfR, the ratio of sTfR/SF is a valuable measure     
of the extent of iron deficiency (517). At least three different 
approaches have been used to calculate this ratio. With each 
approach, cutoff values to interpret the ratio are different. Fur- 
thermore, the ratios are derived from different sTfR assays and 
there is confusion in the scientific community as to what assay 
data can be used with which ratio. 
 
sTfR index. The sTfR index is calculated as the ratio of 
sTfR/log SF and was introduced by Punnonen et al. (601) as     
a parameter for the identification of persons with depleted iron 
stores. A subsequent review article presented cutoff values for 
the sTfR index (mg/L) to distinguish between ACD (<1) and 
IDA (>2) or both conditions (>2) (602). A recent prospective 
multicenter clinical trial compared the diagnostic accuracy of 
sTfR and the sTfR index for differential diagnosis of ACD and 
IDA using the automated Access Beckman Coulter instrument 
(540). The authors found that the sTfR index was superior to 
sTfR and use of all three parameters in combination more than 
doubled the detection of IDA from 41% (SF alone) to 92% (fer- 
ritin, sTfR, and sTfR index). The cutoff value for IDA or a com- 
bination of IDA and ACD was >1.03 mg/L. The authors claim 
that the sTfR index has higher sensitivity/specificity than the 
sTfR/ferritin ratio. The interpretation of the sTfR index is as- 
say dependent. The proposed cutoff values for the sTfR index 
derived from the Access Beckman Coulter instrument can only 
be used by other methods if those methods generate compara- 
ble sTfR and ferritin results to results generated by the Access 
Beckman Coulter instrument. 
 
Body iron index. The logarithm of the ratio of sTfR/SF is lin- 
early related to body iron stores expressed as mg per kg body 
weight, as derived from a phlebotomy study (14 healthy adults 
aged 24–46 y, 6 men and 8 women) in which iron status and iron 
deficit were assessed. The formula for this relationship [using 
both sTfR (Ramco-related assay) and SF in µg/L] is as follows: 
body iron (mg/kg) –[log(sTfR/SF) – 2.8229]/0.1207 (248).  
The investigators who developed this methodology coined the 
term “body iron” and it has gained widespread acceptance in 
the literature (517). However, for many readers it is confusing 
because “body iron” is not a measure of the quantity of iron     
in the individual’s body. It provides a quantitative estimate of 
the size of the body iron store when iron is present in the store 
(values >0 mg/kg) or the size of the functional iron deficit that 
would need to be corrected before iron could again be accu- 
mulated in the store in an individual who is iron deficient (val- 
ues 0 mg/kg). Some investigators have proposed that the term 
“body iron index” might be more appropriate. The I-EP has de- 
cided to use this term. Other terms, such as “total body iron” 
and “total body iron stores,” have also been frequently used in 
the literature and TBI is often used as an abbreviation. 
Advantages of the body iron index estimate include the fol- 
lowing. It is conceptually easy to interpret. The results provide 
a distribution of quantitative estimates for individuals in a pop- 
ulation sample and do not depend on dichotomous assignments 
based on cutoff values. It is possible to estimate the quantita- 
tive impact and bioavailability of a fortification or supplemen- 
tation intervention based on the change in body iron stores 
and the cumulative consumption of supplemental or fortifica- 
tion iron. Finally, the method has been adopted for NHANES 
surveys that will provide a useful database for the comparative 
evaluation of future surveys. The major limitation is that the 
body iron stores equation derived from the phlebotomy study 
has only been validated using the in-house ELISA sTfR assay 
developed by Flowers et al. (516), which is putatively equiva- 
lent to the Ramco sTfR assay. To enable the use of body iron in- 
dex in NHANES, the CDC established the relationship between 
the Roche assay used in NHANES and the Flowers assay in a 
method comparison study: Flowers sTfR 1.5 Roche sTfR 
0.35 mg/L (587). The CDC also showed that the Roche and 
Ramco sTfR assays compare similarly to the Roche and Flow- 
ers assays, which indirectly demonstrates the equivalence of the 
Flowers and Ramco sTfR assays (587). Data from other sTfR 
assays that produce different results from either the Ramco or 
the Roche assay cannot be directly used on the body iron index 
equation. It is generally assumed that a body iron index value of 
0 should be the criterion for defining iron deficiency. However, 
consideration should be given to revising this definition for the 
following reasons: 
 
— An optimal iron supply may depend on the presence of a 
small amount of storage iron, i.e., the immediate return of 
iron derived from hemoglobin processing in macrophages 
may not be quantitatively complete. 
— Cogswell et al. (247) used NHANES 2003–2006 data to 
compare the estimated prevalence of iron deficiency in US 
women aged 12–49 y based on calculated body iron index 
with that derived for the ferritin model. The estimated preva- 
lences of iron deficiency based on the ferritin model were 
15.6% and 15.7% for women aged 12–19 and 20–49 y re- 
spectively. However, only 9.3% and 9.2% of women respec- 
tively had body iron index values <0. Had they employed 
 ∼ 
a higher cutoff, say 2 mg/kg, the prevalence values for the 
body iron index and ferritin models would have been com- 
parable. Examination of their figure describing the relation- 
ship between anemia prevalence and the distribution of body 
iron index values provides some support for this suggestion. 
Approximately 20% of women with a body iron index of     
0 are anemic. However, anemia prevalence approaches zero 
at body iron index values > 2 mg/kg, suggesting the iron 
deficiency is the most important cause of anemia in this pop- 
ulation and that a small iron store is necessary for optimal 
erythropoiesis. 
 
“Simple” ratio of sTfR to ferritin. In a phlebotomy  study, 
Skikne et al. (517) also calculated the ratio of TfR to ferritin 
(µg/µg). The ratio increased from <100  in  those  with  am- 
ple iron stores to >2000 in those with significant functional 
iron deficiency. A rise >500 occurred when stores were fully 
depleted (iron stores of 0 mg/kg). This approach has been 
adopted by several investigators (245, 603, 604). The advan- 
tage of this measure is that the calculation is simpler than for 
body iron. As with the other two measures, the interpretation 
of this ratio is again assay dependent because the cutoff value 
for depleted stores has been established with the Ramco assay. 
 
Laboratory infrastructure 
While two of the iron status indicators, Hb and ZPP, can be mea- 
sured quickly and inexpensively in the field, the fieldwork can be 
expedited and errors minimized if a venous whole blood sam- 
ple is collected during the day, stored on cold packs in a shipper, 
and all the laboratory work is conducted at the end of the day 
in a centralized laboratory using a minimum number of instru- 
ments and fewer analysts. While one team can centrifuge the 
red-top tubes to obtain serum for biochemical measurements, 
the other team can conduct Hb and ZPP measurements as re- 
quired. Sixty samples collected during the day by three or four 
teams can be processed in 2–3 h with two well-trained and or- 
ganized assistants. It is therefore important to have at least one 
back-up HemoCue instrument for every three field teams and 
one back-up hematofluorometer, should the primary machine 
fail or not work properly. 
All other biomarkers require at the minimum a midlevel lab- 
oratory infrastructure that guarantees uninterrupted electrical 
power supply for a freezer, refrigerator, and the operation of 
analytical instrumentation, including a water purification sys- 
tem that provides deionized water. Protection of specimens from 
direct sunlight and artificial light is highly recommended for 
EP testing. Manual ELISA assays require several pieces of in- 
strumentation, but they are comparatively less expensive than a 
clinical analyzer. They comprise a microplate reader; microplate 
washer (recommended); a vortexer; a balance accurate to at 
least two, preferably three decimal points (0.001 g); and various 
adjustable air displacement pipettes including an eight-channel 
pipettor and a repeater pipettor. The throughput of the ELISA 
assay can be greatly enhanced by the use of a liquid handler to 
automate the various pipetting steps including the dilution of 
serum samples. A barcode scanner can speed up sample log-in 
and avoid transcription errors. 
Automated analyzers are relatively expensive and most ana- 
lyzers operate on a closed-channel basis, allowing only reagents 
from one particular manufacturer to be used. Furthermore, the 
laboratory is limited to conducting regular simple instrument 
maintenance, while a certified service engineer takes care of re- 
pairs and more complex maintenance, often as part of an an- 
nual service agreement. Calibrators and reagents are typically 
purchased from the manufacturer in a ready-to-use form. They 
require minimal handling. 
 
 
Quality assessment 
Overview. Quality assessment (QA) helps to ensure accurate 
and high-quality laboratory results through full staff participa- 
tion by avoiding mistakes, ensuring consistent performance and 
data integrity, and offering opportunities for training. The basic 
components of a QA system include the following: 1) internal 
quality control (QC) through the use of bench and blind QC 
samples; 2) external QA via participation in proficiency test- 
ing (PT) programs; 3) equipment monitoring and maintenance; 
4) documentation of policies and procedures; 5) proper staff 
training; and 6) laboratory audits. However, methods must be 
validated (for accuracy, precision, sensitivity, and ruggedness) 
and verified periodically (verification of assay calibration, veri- 
fication of pipette and instrument accuracy) before the quality 
and consistency can be monitored. For a more detailed descrip- 
tion of each QA system component, an example of a minimum 
QA system for a low-resource setting as well as instructions for 
the preparation, characterization and use of QC materials, the 
reader is referred to the Survey Toolkit for Nutritional Assess- 
ment, Laboratory and Field section, Quality Control and Qual- 
ity Assurance subsection, developed by the CDC and hosted by 
the Micronutrient Initiative (570). 
While commercial kits typically supply QC materials and 
manufacturers will require information on how the assay is 
performing with the commercial QC material if involved in 
troubleshooting, the user should keep in mind that frequent  
lot changes on the commercial QC material may prevent an 
assessment of assay shifts over time. The only way to know 
whether an assay fluctuates or shifts over time is to analyze 
well-characterized materials in every assay or at least period- 
ically. In-house preparation of large batches of QC pools has 
two advantages. It is more cost efficient and it facilitates close 
monitoring of assay performance. It is advisable to prepare two 
(normal and abnormal) or three (low, medium, and high) levels 
of QC pools, characterize them over the course of 20 individual 
analytical runs to establish target values and assay-associated 
variability, and then include them in every analytical run to- 
gether with the unknown samples to judge whether the run is 
within the pre-established control limits. 
Participation in PT programs is recommended for good 
laboratory practice to allow external verification of results. 
Such participation is a requirement for the laboratory to be     
in compliance with certain laboratory certifications. However, 
PT programs have their limitations. Most PT programs use 
method means to  evaluate  laboratories,  making  it  difficult  
to identify methods with unsatisfactory performance or even 
monitor method shifts over time due to the lack of a stable 
reference point. Because PT programs require large sample vol- 
umes, must test a range of concentrations, and because it is dif- 
ficult and expensive to distribute actual pooled human serum 
on a regular basis, PT samples are often modified (e.g., adding 
preservatives or other additives, supplementing materials with 
nonnative forms of analyte, using animal plasma or outdated 
human plasma from blood banks), potentially changing their 
behavior in the assay compared to fresh-frozen samples. This 
may lead to commutability problems with PT materials (605). 
Noncommutability is when an assay responds differently to pro- 
cessed samples compared to native, nonprocessed samples. As 
a result, information gained from the PT program may not be 
used to adjust assays. 
 ± 
≤ 
≥ 
∼ 
∼ 
∼ 
∼ 
Biomarker-specific issues. The availability of an accepted 
ICSH reference method for Hb measurements (569) and corre- 
sponding ICSH reference material since the 1970s (606) made 
it possible to calibrate most hemoglobinometers and automated 
blood cell counters throughout the world. The reference mate- 
rial is available through the UK National Institute of Biologi-  
cal Standards and Control (NIBSC) as the WHO International 
Standard 98/708 and through the European Community Bu- 
reau of Reference as CRM 522 (Table 11). The ICSH also rec- 
ommended a reference method and a simpler “surrogate ref- 
erence” method for the measurement of Hct or packed cell vol- 
ume, both of which are fully traceable to the ICSH reference Hb 
method. 
While no formal standardization programs exist for SF or 
iron/TIBC, most methods for these biomarkers produce reason- 
ably comparable results and the assays display generally good 
accuracy, precision, and linearity. This is likely to be due to the 
inclusion of these analytes in many PT programs, some of which 
are available from State Department of Health PT programs 
(e.g., New York State Department of Health Wadsworth Cen- 
ter), and the availability of international reference materials for 
many years (Table 11). Thorpe (607) has reviewed the devel- 
opment, role, and availability of international biological refer- 
ence materials for the diagnosis of iron deficiency and anemia. 
The author discusses the difficulties in standardizing immuno- 
based methods due to the heterogeneity of the antibodies used 
in the assays, the technical difficulties in producing a standard 
preparation that is identical to the circulating serum form, and 
the absence of physicochemical reference methods to establish 
“true” concentrations. These issues were addressed in a study 
conducted by Blackmore et al. (586) to assess the traceability 
of various ferritin assays to the three WHO international stan- 
dards developed over the years. While four out of five methods 
recovered all three international standards within acceptable 
limits (100% 10%), one method significantly over-recovered 
each of the internal standards (124–155%), despite giving SF 
results that were comparable to the other methods for five na- 
tive serum samples. This may be explained by the antibodies 
employed in each of the assays having different epitope speci- 
ficities or properties. 
No reference material has been available for sTfR assays 
until recently. Several years ago the WHO commissioned the 
production of a reference standard and because of the diffi- 
culties in purifying sufficient quantities of sTfR, efforts were 
focused on employing recombinant sTfR, which has a slightly 
shorter molecular structure than serum sTfR. This WHO Ref- 
erence Reagent (07/202) was evaluated by five manufacturers 
of commercial kits. Although the dose-response plots demon- 
strated acceptable parallelism with commercial in-house stan- 
dards and serum samples, there was poor agreement with the 
measured values for sTfR in the kits, even between kits ex- 
pressing sTfR concentrations in the same units. In 2009, the 
NIBSC made available this WHO Reference Reagent with a 
value assigned based on a theoretical extinction coefficient and 
the molecular weight (21.74 mg/L or 303  nmol/L)  (589). If 
the commutability of this material can be confirmed in an on- 
going commutability study, it could be used  by  manufactur- 
ers or researchers as a calibrator for immunoassays. While a 
full standardization of manufacturer assays may take several 
years, intermittent steps of assay harmonization through a set of 
well-characterized reference samples may allow users to “cali- 
brate” their assays to a common basis and therefore produce 
comparable results across laboratories, instruments, and as- 
says. 
Preanalytical factors 
Overview. Because each method, analyte, and laboratory may 
have specific sample handling requirements, it is best to discuss 
details with the laboratory that will perform the analyses at the 
time of study planning. In general, the iron status biomarkers are 
quite stable. If the blood sample cannot be centrifuged within 
1–2 h of collection, it should be kept cold and protected from 
light, but freezing should be avoided to prevent hemolysis (vacu- 
tainers should not be in direct contact with frozen cold packs). 
Frozen serum samples should be shipped on dry ice to avoid 
thawing. For long-term storage, serum samples should be kept 
frozen at ≤−40°C. 
Biomarker-specific issues. Preanalytical factors influencing 
whole-blood-based indicators of iron status are summarized in 
Table 14 (290, 608–611). Because the within-person biologi- 
cal variation of Hb  and  Hct  is  very  low  (<3%), one  sample 
is considered sufficient to estimate the biomarker concentration 
with 95% confidence and 20% accuracy (608). As Hb measure- 
ments only require small sample volumes, the use of capillary 
blood samples is common. However, this can lead to inaccurate 
or variable results if the capillary sample is not collected prop- 
erly (e.g. “milking” the finger; use of the first drop of blood). 
Using 33 paired venous and capillary blood samples collected 
into a microtainer, Whitehead et al. (573) found no significant 
differences in mean Hb concentrations. Pooled capillary blood 
produced comparable results to the second and third, but not 
the fourth drop of blood (3.3% lower) (573). Others have also 
reported that pooled capillary blood samples can be reliably 
used, whereas single drop measurements, as recommended by 
the manufacturer, may result in slightly different results (609). 
Delays in Hb measurement (Hb-201 HemoCue® model) for up 
to 3  d did not affect values ( 2%) if the venous or capillary 
blood was kept cold (610). However, blood could only be stored 
for 1 d at 20–23°C prior to Hb measurement with the Hb-301 
model (573). 
The three main serum-based iron status indicators have dif- 
ferent preanalytical requirements, particularly when it  comes 
to variables related to the subject (Table 15) (240, 608, 611– 
614). Data from several thousand US adults participating in 
NHANES 2003–06 showed no difference in SF, sTfR, or body 
iron index whether samples were collected from fasted ( 8  h 
after the last meal) or nonfasted (<3 h after the last meal) in- 
dividuals (615). On the other hand, fasting is usually recom- 
mended for the measurement of serum iron, particularly in the 
clinical setting. Moreover day-to-day ( 30%) and diurnal vari- 
ations (10–20%) within a person are quite large (575, 611). 
Fasting may be less important in  population  studies  and  in 
fact NHANES has not used fasted serum samples to measure 
serum iron. Dale et al. (616) have examined diurnal variation   
of serum iron, iron-binding capacity, and ferritin concentrations 
and found that although significant differences among mean 
values for the collection times were noted, no consistent diurnal 
variation was seen and the between-day variation was similar to 
the within-day variation. The authors concluded that the prac- 
tice of restricting iron specimen collection to a specific time of 
day does not improve the reliability of the test result. 
Serum sTfR has a relatively small within-person variation 
(CVw 12%). One sample is generally considered sufficient to 
estimate the biomarker concentration with 95% confidence and 
20% accuracy (240). The CVw for SF is largely dependent on the 
population group ( 10–15% for males or elderly women, 25% 
for young women) (240, 608). A higher number of sam- ples has 
therefore been recommended for SF [3 for males, 4 
  
 
 
 
 
 
TABLE 14 Preanalytical factors influencing whole-blood-based indicators of iron status 
 
Variables  Hemoglobin  Hematocrit Erythrocyte protoporphyrin 
Subject      
Fasting Not required  Not required  Not required 
Biological variation      
Within-person 2.8% (608)  1.8% (608)  9.8% (611) 
Between-person 
Number of samples required1 
 
1 (608) 
  
1 (608) 
 32.9% (611) 
Sample collection 
Venous vs. capillary blood Comparable, particularly if pooled capillary sample from 
microtainer is used (609, 610) 
Avoid “milking” of finger 
 
Generally venous blood is used Comparable (288); partially clotted samples may not give accurate 
results 
Influence of anticoagulants Anticoagulants other than EDTA are not customary Anticoagulants other than EDTA are not customary Anticoagulants other than EDTA are not customary 
Sample processing 
General requirements Use freshly collected EDTA whole blood Use freshly collected EDTA whole blood Use freshly collected EDTA whole blood; protect sample from 
light; avoid hemolysis if measured by hematofluorometer; avoid 
contamination with fluorescent interferences 
Measure hematocrit to correct for packed cells 
Delayed processing Whole blood can be kept refrigerated for a few days if 
measurement cannot be done immediately (avoid freezing to keep 
RBC intact) (610) 
Whole blood can be kept refrigerated for a few days if 
measurement cannot be done immediately (avoid freezing to keep 
RBC intact) (610) 
Whole blood can be kept refrigerated for a few days or it can be 
frozen if fluorometric extraction assay is used 
Sample storage 
Storage stability Not applicable Not applicable Stable for up to 10 d if protected from light and refrigerated; 
stable for years at ≤–200C 
Freeze-thaw stability Not applicable Not applicable Excellent stability 
1Number of samples required to estimate biomarker concentrations with 95% confidence and 20% accuracy. 
  
 
 
 
 
TABLE 15 Preanalytical factors influencing serum-based indicators of iron status 
Variables Serum iron/TIBC1 Serum ferritin Serum soluble transferrin receptor 
 
Subject 
Fasting Recommended (in clinical setting) due to diurnal variation Not required Not required 
Biological variation 
Within-person 31.9%/9.0% for general US population (611); 26.1%/3.8% 
for elderly women (608) 
20.8% for general US population (611); ∼13% for males, ∼26% for 
young women, ∼18% on average (240); 9.7% for elderly women (608) 
11.8% for young adults (240); 10.9% for elderly women (608) 
Between-person 41.9%/16.1% for general US population (611) 89.8% for general US population (611) 
Number of of samples required2 7/1 for elderly women (608) 3 for males, 4 for young women (240); 1 for elderly women (608) 1 for males, 1 or 2 for young women (240); 2 for elderly women (608) 
Sample collection 
Venous vs. capillary blood Capillary blood generally does not provide sufficient sample 
volume 
Comparable, but higher variability with capillary samples (240) Comparable, but higher variability with venous samples (240) 
Influence of anticoagulants Serum preferred over plasma (might contain fibrinogen 
clots) 
Serum preferred over plasma (might contain fibrinogen clots); EDTA 
plasma produces comparable results (240) 
Serum preferred over plasma (might contain fibrinogen clots); EDTA 
plasma produces comparable results (240) 
Sample processing 
General requirements Prompt processing and freezing of serum desirable Prompt processing and freezing of serum desirable Prompt processing and freezing of serum desirable 
Delayed processing Prepare serum within 1 d, but no later than within 2–3 d of 
blood collection; keep blood refrigerated 
 
 
 
 
 
Sample storage 
Prepare serum within 1 d, but no later than within 2–3 d of blood 
collection; keep blood refrigerated 
Storage of unprocessed whole blood at room temperature <96 h is 
acceptable [∼3% increase, but not significant (612)] 
Storage of unprocessed whole blood at elevated temperature 
(32–37°C) is acceptable if ≤6h (614), but unacceptable if ≥1d 
(∼10% increase) (613) 
Prepare serum within 1 d, but no later than within 2–3 d of blood 
collection; keep blood refrigerated 
Storage of unprocessed whole blood at elevated temperature (37°C) is 
unacceptable [∼5% increase after 1 d (613)] 
Storage stability Stable for days if refrigerated; stable for years at ≤–20°C Stable for up to 14 d if refrigerated (613); stable for years at ≤–20°C Stable for up to 14 d if refrigerated (613); stable for years at ≤–20°C 
Freeze-thaw stability Stable for at least 3 cycles (613) Stable for at least 3 cycles (613) Stable for at least 3 cycles (613) 
1TIBC, total iron-binding capacity. 
2Number of samples required to estimate biomarker concentrations with 95% confidence and 20% accuracy.  
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for young women (240)] and serum iron [7 for elderly women 
(608)] to account for the larger CVw for these two analytes. 
However, pragmatic considerations frequently limit the number 
of samples that can be collected in population-based surveys and 
intervention studies. 
It has been recommended that the method imprecision 
should be less than one-half of the CVw. Although this can be 
achieved with currently available methods for SF and iron, it is 
only achievable for sTfR with fully automated assays on clini- 
cal analyzers. Manually conducted ELISA assays typically have 
a method CV of 10% (492, 581, 587). Serum-based iron sta-  
tus indicators generally have good storage stability and can also 
withstand some delays in whole-blood processing as long as the 
sample is refrigerated (612, 613). 
One preanalytical variable that has large influence on iron 
status indicators in general and SF (being a positive APP) in 
particular is the confounding effect of infection and inflamma- 
tion. Using NHANES 2003–06 data from women aged 20–49 y, 
Haynes et al. (615) found that SF concentrations were 24% 
higher in women with elevated CRP concentrations ( 5 mg/L). 
On the other hand sTfR concentrations were only slightly higher 
(4%). Body iron index also showed a positive association with 
inflammation, but the difference in body iron index between 
women with and without inflammation was smaller than for 
ferritin (12%). 
 
 
Future directions and new biomarkers 
Throughout this report the I-EP has identified critical research 
gaps and directions for research. These are highlighted in Text 
Box 38. The I-EP also wants to acknowledge the potential of 
several new biomarkers. 
 
Research carried out over the past half century has provided 
a clear understanding of the relationships between uncompli- 
cated nutritional iron deficiency and anemia. Iron status can  
be determined with a high degree of accuracy and biomarkers 
that are suitable for field use are affordable and freely avail- 
able. However, this approach is less satisfactory in populations 
where anemia is caused by an infection or an infection and iron 
deficiency combined. Furthermore, the concepts developed for 
predicting the risk for iron-deficiency anemia have not been 
shown to be predictive of some other putative critical func- 
tional consequences of iron deficiency, particularly pregnancy 
outcome and cognitive, motor and emotional development in 
infancy. There is clearly a need to search for alternative ap- 
proaches as well as other biomarkers. The measurement of 
plasma (serum) hepcidin is the most promising option at the 
present time (617). 
 
 
Novel red blood cell indexes 
Modern hematology analyzers provide a variety of red blood 
cell parameters that are of potential use, including the follow- 
ing: 1) the proportion of hypochromic red blood cells; 2) the 
ratio of microcytic to hypochromic red blood cells; 3) the imma- 
ture reticulocyte fraction; 4) the reticulocyte mean hemoglobin 
content (as CHr, Ret-He, RHE, or RHCc by different manufac- 
turers); and 5) the mean reticulocyte volume (as MCVr, MCVR, 
MVR, or MRV by different manufacturers). 
None of these potential biomarkers have been studied sys- 
tematically for the evaluation of nutritional anemia. Moreover, 
their use is complicated by the lack of standardization, in part 
because of the different techniques used by the various manu- 
facturers (509). They have, however, gained acceptance for the 
management of anemia and iron status in patients with chronic 
kidney disease (512). In addition, the measurement of reticulo- 
cyte hemoglobin concentration has been included in the Ameri- 
can Academy of Pediatrics guidelines for the evaluation of ane- 
mia in childhood (267). 
 
Text Box 38 
Future directions and research priorities 
• Improved understanding of the relationship between 
iron status and physiology as impacted by both life stage 
and factors such as inflammation and infection. 
• Improved understanding of the relationship between 
maternal iron status during pregnancy and birth outcome 
including cognitive and motor development in the infant. 
To address this need the I-EP highlighted the following 
areas: 
-Assessment tools to distinguish between physiological 
response and nutritional need. 
-Need to match currently available biomarkers of iron 
status with the time frames for the development of iron- 
dependent neural systems for which functional tests are 
available, e.g. myelination, monoamine-driven behav- 
iors. 
-Need for bioindicators reflecting relevant functional 
outcomes (e.g., neurological, cognitive, and behavioral 
development) that can be used along with appropriate 
iron biomarkers. 
• Advance our understanding of the effect of genotype 
on risk of iron deficiency. 
• Enhanced understanding of the nature and health im- 
plications of nutrient-nutrient interactions (iron-zinc, vita- 
min A etc.). 
• Better understanding of the specific role and how best 
to assess iron status in various infectious diseases (malaria, 
HIV, TB, diarrheal disease) and noncommunicable diseases 
(e.g., cancer). 
• Approaches for the assessment of iron overload: 
-Giving consideration to the context  of  inflamma-  
tion and life stage as the interpretation of currently 
designated upper limits of the most commonly used 
biomarker (SF) is impacted by both, particularly in 
older men and postmenopausal women. 
-Better tools to assess iron overload for population 
screening. 
-Because iron overload resulting solely from excessive 
iron consumption is rare in the absence of an identifi- 
able hepcidin or ferroportin abnormality, an alternative 
approach to address risk of iron overload was proposed 
by the I-EP and needs to be evaluated. It is based on de- 
termining the prevalence of one or more iron-loading 
genotypes that affect the hepcidin/ferroportin axis in 
the population under consideration either directly or 
because of their effect on erythropoietic rate. 
 Hepcidin 
As described elsewhere, hepcidin plays a central role in control- 
ling iron absorption and systemic iron supply to all cells. The 
functional form of the peptide can be measured in both plasma 
and urine. Hepcidin synthesis rises in response to increasing liver 
iron stores and serum iron concentration. It is therefore an im- 
portant indicator of iron status. 
Similar to  SF,  levels  are  also  increased  by  inflammation. 
A second factor may confound the relationship with iron 
status. Hepcidin is suppressed in the presence of increased 
erythropoietic activity, putatively by a recently identified protein 
that is produced by erythroblasts, erythroferrone (124). Plasma 
hepcidin levels are also influenced by many other factors (618). 
The response of hepcidin to increased erythropoiesis is an 
important concern with potentially significant public health 
implications. Jones et al. (435) reported suppressed hepcidin 
levels and increased iron accumulation in 62 of 69 Sri Lankan 
patients with HbE β-thalassemia with a moderate or severe 
phenotype. Sri Lankan school children with β-thalassemia trait 
also had mildly decreased hepcidin levels. As a consequence, 
the potential exists for public health interventions (e.g., iron 
fortification of food, iron supplementation) intended to im- 
prove iron status particularly in such groups as women, infants, 
and school-aged children, to increase risk of iron overload in 
populations with high prevalence of HbE β-thalassemia (the 
most common severe thalassemia syndrome in Asia). More 
information is needed to determine whether programs that rely 
on hepcidin levels to monitor iron status will both provide a 
more reliable assessment of iron status than currently available 
biomarkers (SF) and avoid the risk of contributing to iron 
overload in populations where thalassemia syndromes and 
thalassemia carrier status are prevalent. 
Hepcidin has been measured in various settings. Plasma con- 
centrations during the first trimester of pregnancy are within the 
references range for nonpregnant women (226, 255, 619). Dur- 
ing the second trimester serum hepcidin concentrations fall to 
very low levels and remain low in the third trimester (172, 226, 
255). The mechanisms underlying hepcidin suppression during 
pregnancy are unknown, but they do not seem to be related to 
maternal iron status (256, 620, 621). 
Cord blood hepcidin levels may be predictive of anemia and 
malaria in Tanzanian children (622) and Pasricha et al. (623) 
have suggested that hepcidin levels may prove to be a valuable 
tool for identifying IDA  in African children. Finally they may   
be useful in detecting the rare genetic disorder that leads to iron 
deficiency which is unresponsive to oral iron (IRIDA) (624). 
The application of hepcidin assays to the evaluation of nu- 
tritional iron status is further complicated by differences in 
methodology and the lack of assay commutability and stan- 
dardization, making comparisons between studies difficult. Ref- 
erence intervals are method dependent. However, considerable 
progress has recently been made toward the development of a 
reference material that will improve the equivalences between 
different hepcidin assay procedures (625). 
Based on the current status of our understanding of hepcidin 
biology and assessment, the I-EP concluded that it is unclear 
whether hepcidin assays provide any advantage over SF and the 
other currently available methods for assessing nutritional iron 
status. 
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